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 Summary 
BEACH (Bettering the Evaluation and Care of Health) is a continuous national study of general 
practice activity in which ever-changing random samples of about 1,000 individual general 
practitioners (GPs) participate each year. Each GP records details of 100 consecutive encounters with 
consenting patients. BEACH began in April 1998 and closed in June 2016 after 18 years of continuous 
data collection. Since BEACH began it has measured and reported major changes in Australian 
general practice including the changes in GP and practice characteristics, patients at encounters, 
reasons for encounters, problems managed and the management provided. 
From June 2006 to June 2015, the population of Australia rose by 17%, from 20.6 million to 
24.1 million, and the proportion aged 65 years and over rose by 33% (from 2.7 to 3.6 million). At least 
one GP consultation was claimed by 83% of the population in 2006–07 and this increased to 87% in 
2015–16. The number of Medicare-claimed GP consultation items (excluding practice nurse items) 
grew by 38% from 103.4 million to 143.0 million. The average number of GP visits per capita rose from 
5.0 to 6.0, and the average for those who visited at least once rose from 6.0 to 6.9 visits.  
Administrative statistics provide information about the frequencies and costs of visits claimed for GP 
services and some prescribed pharmaceuticals. BEACH gives us an understanding of changes in the 
content of encounters and the services and treatments GPs provide.  
This book presents results of each of 10 years of BEACH data to identify changes over the decade 
2006–07 to 2015–16. The report is based on details of almost 1 million GP–patient encounters from 
9,721 participating GPs. Estimates are given of the national effect of change in GP activity through 
extrapolation of the BEACH results to the total Medicare GP consultations claimed in the first and last 
year of the decade. 
Released in parallel with this report is a more detailed report of results for 2015–16 in the BEACH 
program, General practice activity in Australia 2015–16.1 This companion report contains a feature 
chapter investigating changes in the care of middle aged people aged 45–64 years in general practice 
over 16 years, 2000–01 to 2015–16 (see Chapter 14).  
The GP participants and their practices (Chapter 4) 
Reflecting changes in the recognised GP workforce, females made up an increasing proportion of GP 
participants (34% in 2006–07 to 45% in 2015–16), as did the proportion aged 55 years and over (from 
35% to 45%). Average hours in patient care decreased from 38 to 37 hours per week, with a decrease 
from 40% to 28% of GPs working more than 40 hours. 
The proportion of GP participants who graduated from their primary medical degree in Australia 
decreased from 74% to 61%. GP participants holding Fellowship of the Royal Australian College of 
General Practitioners increased from 46% to 63%. 
The move toward larger practices continued, with decreased proportions of participants working in 
practices of 2–4 individual GPs (36% to 24%), while the proportion in practices of 10 or more GPs 
almost doubled, from 16% to 29%. The proportion using deputising services for some or all of their 
after-hours patient care increased from 48% to 57%. 
  
 x 
The encounters (Chapter 5) 
As a proportion of all Medicare Benefits Schedule (MBS)/Department of Veterans’ Affairs (DVA)-
claimable recorded consultations, short surgery consultations, chronic disease management items, 
health assessments, and GP mental health care, all increased significantly while standard surgery 
consultations decreased significantly. 
Over the decade, the mean length of consultations for all MBS/DVA-claimable encounters significantly 
increased from 14.1 minutes to 14.9 minutes, and the median length increased from 12 to 13 minutes.  
The patients at encounters (Chapter 6) 
There was no significant change in the proportion of encounters with male or female patients. As a 
proportion of all encounters, those with patients aged 15–24 years decreased from 9.1% to 7.9%, 
while those with patients aged 65–74 years increased from 12.7% to 14.7%. Extrapolated, this 
suggests that nationally there were approximately 8 million more encounters with patients aged 65–74 
years in 2015–16 than a decade earlier. This increase is likely due to the wave of ‘baby boomers’ 
entering this age group, and the overall increase in average number of GP visits per capita over this 
decade. The proportion of encounters that were with Repatriation Health Card holders decreased from 
3% to 2%, probably due to declining numbers of veterans and their partners. 
A patient providing just one reason for encounter was most common in all years of the decade. The 
proportion of encounters where two patient reasons for encounter (RFEs) were recorded increased 
from 28% to 30%. RFEs related to infections significantly decreased, while those describing processes 
of care increased, particularly requests for ‘medications, treatments and therapeutics’ and test results. 
There was a large increase in requests for administrative procedures.  
Problems managed at encounters (Chapter 7) 
In 2015–16, GPs managed 154 problems per 100 encounters, significantly more than a decade earlier 
(149 per 100). The combination of the increased number of problems managed at encounters and the 
increased number of GP visits, suggests that GPs managed 67 million more problems at patient 
encounters in Australia in 2015–16 than in 2006–07. 
Across the decade, the most frequently managed problems were hypertension, check-up and upper 
respiratory tract infection. Significant increases occurred in management rates of general check-up, 
depression, back complaint, prescription, anxiety, test result, administrative procedure, vitamin/ 
nutritional deficiency, and abnormal test result. The last of these is likely to be due to the increasing 
number of tests per order, which increases the chance an abnormal result will be reported, and 
consequently managed. 
There were significant decreases in management rates of hypertension, oral contraception, ischaemic 
heart disease, cardiovascular check-up and fracture. 
The management rate of chronic conditions in 2015–16 did not differ from the rate in 2006–07. Those 
most commonly managed were non-gestational hypertension, depressive disorder, non-gestational 
diabetes, chronic arthritis, and lipid disorder. There were increased management rates of depressive 
disorder, chronic back pain, and unspecified chronic pain. Extrapolation of these findings to all MBS-
claimed GP consultation items suggests that compared with a decade earlier, in 2015–16 there were: 
• 21 million more chronic problem management occasions in general practice, even without a 
change in their management rate per 100 encounters by GPs 
• 2.2 million more GP management occasions of depressive disorder, 670,000 more of 
hypothyroidism/myxoedema, 400,000 more of chronic back pain, and 400,000 more of 
unspecified chronic pain. 
 xi 
Overview of changes in management of problems (Chapters 8–12) 
All management actions are reported as both rates per 100 encounters and per 100 problems 
managed. The former is used to extrapolate the national effect of an increase while the latter is used 
to describe changes in how GPs actually manage the problems they treat. Even without a change in 
rates of clinical actions the total number of these actions undertaken nationally will still increase due to 
the increased number of problems managed combined with the increased visit rate. 
The changes in management actions (as rates per 100 problems managed) are summarised below.  
• Medications prescribed/supplied/advised did not change significantly (from 68 to 66 per 100 
problems). However, there were some notable changes: 
– Prescribed medications decreased significantly from 56 to 53. However, due to the increased 
attendance rate, we estimated there were 31 million more prescriptions given nationally in 
2015–16 than a decade earlier. 
– The rate of GP-supplied medications was not significantly different in 2006–07 compared with 
2015–16 (6.0 to 5.9) but this rate varied widely through the decade.  
– The rate of advised over-the-counter (OTC) medications did not change over the decade. 
• Clinical treatments were provided at a significantly higher rate in 2015–16 (25 per 100 problems 
managed) than in 2006–07 (20 per 100). Combined with the increased number of problems 
managed per encounter, the rate of clinical treatments increased from 30 to 39 per 100 
encounters, suggesting about 25 million more were provided nationally in 2015–16 than in  
2006–07. 
• Procedures undertaken significantly increased, from 10 to 11 per 100 problems managed, and 
combined with the increased number of problems managed, rose from 15 to 18 per 100 
encounters. The extrapolated effect was about 10 million more procedures nationally in 2015–16. 
• Referrals to medical specialists rose from 5 to 6 per 100 problems managed, and those referred 
to allied health services increased from 2 to 4. This increase, combined with more problems 
managed per encounter and more encounters overall, suggests about 10 million more GP 
referrals were made nationally in 2015–16 than in 2006–07, which included about 5 million more 
to medical specialists and 5 million more to allied health services. 
• Pathology tests/test batteries ordered increased by 8%, from 29 tests/batteries to 31 per 100 
problems managed. Tests ordered per 100 encounters increased from 42 to 48, which suggests 
about 24 million more tests/batteries were ordered nationally in 2015–16. 
• Imaging tests ordered increased from 6 to 7 per 100 problems. Total imaging orders per 100 
encounters increased significantly from 9 to 11, suggesting nationally there were 6 million more 
imaging tests ordered in 2015–16 than in 2006–07. 
Medications (Chapter 9)  
Notable changes in medications prescribed/advised/supplied (described as rates per 100 problems 
managed) in 2015–16 compared with 2006–07, are summarised below. 
• Drug types prescribed less often included: antibacterials for systemic use, agents acting on the 
renin-angiotensin system, drugs for obstructive airway disease, anti-inflammatory and 
antirheumatic medications, sex hormones and modulators of the genital system, beta blocking 
agents, calcium channel blockers, ophthalmologicals and diuretics. Individual drugs prescribed 
less often included amoxicillin, plain paracetamol and paracetamol/codeine combination products, 
temazepam, roxithromycin, and ibersartan. 
• Drug types prescribed more often included psychoanaleptics, digestive drugs for acid-related 
disorders, systemic corticosteroids and antiepileptic drugs. Individual drugs prescribed more often 
included esomeprazole, oxycodone, rosuvastatin, pantoprazole, prednisolone, 
oxycodone/naloxone, and pregabalin. 
 xii 
• Five repeats were recorded for a greater proportion of prescriptions, while the proportion of 
medications with one repeat or three to four repeats significantly decreased. 
• Nine of the top 10 GP-supplied medications were vaccines, and rates of most childhood vaccines 
increased. There was a significant increase in GP supply of vitamin B12. 
• The overall rate of advice for OTC medications did not change but there was a significant rise in 
the advised purchase of ibuprofen and vitamin D3 (cholecalciferol). 
Other (non-pharmacological) treatments (Chapter 10) 
Clinical treatments  
• General advice and education was the most frequently recorded clinical treatment throughout the 
decade, provided at a rate of 4.1 per 100 problems managed in 2015–16. There was no 
significant change in the rate between 2006–07 and 2015–16. 
• There were significant increases in the rate GPs provided advice/education about medication and 
treatment, counselling/advice about lifestyle and about health/body. The rate of GP-provided 
administrative procedures/documentation almost doubled.  
Procedures 
The most frequently recorded group of procedures throughout the decade was excision/removal 
tissue/biopsy/destruction/debridement/cauterisation. There was an increase in the rate of procedures 
undertaken, which was partially caused by a four-fold in international normalised ratio (INR) tests, and 
significant increases in preventive procedures/high risk medication, and local injection/infiltrations. 
Referrals (Chapter 11)  
The likelihood that a problem managed at encounter would be referred, increased from 8% to 10% 
over the decade. The rate of referral to medical specialists rose from 5 per 100 problems managed in 
2006–07 to 6 per 100 in 2015–16. The rate of referral to allied health services increased from 2 to 4 
per 100 problems managed. Referrals to psychologists rose almost three-fold and those to podiatrists/ 
chiropodists doubled. Referrals to physiotherapists and dietitians/nutritionists also increased. 
Tests and investigations (Chapter 12) 
Pathology test orders  
• There was no change in the proportion of problems for which pathology was ordered (13% in 
2006–07 and 14% in 2015–16) but there was an 8% increase in the number of tests/batteries 
ordered, due to GPs ordering more tests per problem once the decision to order had been made. 
• There was no change in the proportion of encounters at which pathology was ordered (17% in 
2006–07 and 18% in 2015–16), but increased GP visit rates meant that pathology was ordered at 
about 8 million more encounters nationally in 2015–16 than 10 years earlier. The rate of ordering 
increased from 42 to 48 tests per 100 encounters, suggesting there were 24 million more tests 
ordered nationally in 2015–16 than a decade earlier. 
Imaging orders 
• The likelihood of GPs ordering imaging at an encounter rose from 8% to 9%, suggesting orders 
were placed at 5 million more encounters nationally in 2015–16 than a decade earlier.  
• There was a move away from ordering diagnostic radiology toward ultrasound imaging. 
Ultrasounds were the most commonly ordered imaging test, and orders increased from 3 to 5 
orders per 100 encounters, a national increase of about 4 million ultrasound orders. The rates of 
computerised tomography and magnetic resonance imaging, while accounting for a lower 
proportion of total orders, also increased over the decade. 
 xiii 
Substudies of patient risk factors (Chapter 13)  
Body mass index 
• Adults (n = 30,000–32,000 per year): Prevalence of obesity in sampled adult patients (aged 18+ 
years) increased significantly from 24% in 2006–07 to 29% in 2015–16. The prevalence of 
overweight (35%) did not change and there was a marginal decrease in the prevalence of 
underweight (from 3% to 2%). Prevalence of normal weight decreased significantly from 39% to 
35%. 
• Children (n = 3,000–4,000 per year): There was no change in the prevalence of obesity, 
overweight, or underweight among sampled children (aged 2–17 years) over the decade.  
Smoking (n = 31,000–34,000 per year): Among sampled adults (aged 18+ years), there was a 
significant decrease in prevalence of current daily smoking and occasional smoking from 16% and 3% 
respectively in 2006–07, to 13% and 2% in 2015–16.  
Alcohol consumption (n = 30,000–34,000 per year): Among sampled adults (aged 18+ years), 
prevalence of at-risk levels of alcohol consumption declined from 27% in 2006–07 to 23% in 2015–16, 
and there was an increase in non-drinkers from 28% to 33%.  
Risk profile in adults (n = 29,000–32,000 per year): There was a significant increase in the 
proportion of sampled adults with one risk factor, from 50% to 54%, in parallel with significant 
decreases in the proportion with two (from 20% to 19%), and three risk factors (from 4% to 3%).  
Attending population prevalence estimates: We estimate the prevalence of risk factors for patients 
who attend a GP at least once in the surveyed year by applying statistical adjustment for adult 
population attendance rates by age–sex. This adjustment is available for data collected from 2007–08 
to 2015–16. Over this time, in the population who attended general practice at least once, the 
prevalence of: 
• obesity increased from 23% to 28% 
• daily smoking decreased from 19% to 16% 
• at-risk alcohol consumption decreased from 29% to 25%. 
Among those who attended a GP at least once, patients with only one risk factor increased from 48% 
to 52%, and there was a corresponding decrease in the proportion of patients with two (22% to 20%) 
and three risk factors (5% to 4%). 
  
 
  
 1 Introduction 
This report is the 41st and last book in the General practice series from the Bettering the Evaluation of 
Care and Health (BEACH) program. It includes summary results from the most recent 10 years of the 
program, from 2006–07 to 2015–16 inclusive. Released in parallel with this report is a more detailed 
report of results for 2015–16 in the BEACH program, General practice activity in Australia 2015–16,1 
available at <purl.library.usyd.edu.au/sup/9781743325131>. 
BEACH was a continuous national study of general practice activity in which ever-changing random 
samples of about 1,000 general practitioners (GPs) participated each year. Each participating GP 
recorded details of 100 consecutive GP–patient encounters with consenting patients. The final BEACH 
database includes records for almost 1.8 million GP–patient encounters from 17,707 GP participants, 
representing 10,798 individual GPs. This book investigates results from each of the past 10 years of 
data to identify changes that have occurred over the decade 2006–07 to 2015–16. This report is 
based on information for 972,100 GP–patient encounters provided by 9,721 participating GPs. 
After 18 years of continuous data collection, the BEACH program closed in June 2016. It began in 
April 1998 and was the culmination of about 20 years of research and development work at the 
University of Sydney. Initially the program was conducted by the Family Medicine Research Centre 
(FMRC), University of Sydney, in collaboration with the Australian Institute of Health and Welfare 
(AIHW), under the AIHW Act, but from April 2011, it was conducted by the FMRC alone. BEACH was 
supported financially by government and private industry (see Acknowledgments). 
Researchers and the public can continue to access reports from the BEACH data set (see 
Section 1.2). A discussion of principles for consideration in future general practice data collection is 
included in the Preface of General practice activity 2015–16.1 
The structure of this report follows the pattern of past annual BEACH reports. Ten years of results are 
provided about the GPs, the patients and the problems managed, followed by an overview of 
management, and specific chapters for each type of management action. Changes in prevalence of 
some patient risk factors are also presented. 
Each chapter contains an overview of the section (including definitions where relevant) and a brief 
description of the major findings, followed by the results tables. In the tables, statistically significant 
changes between 2006–07 and 2015–16 are marked. The national effect of significant change can be 
estimated by extrapolating the BEACH results to all GP Medicare-claimed encounters. The method 
adopted for extrapolation of the effect of a change is described in Section 2.9. Examples of 
extrapolation of a measured change are also provided in each of Chapters 5 to 12 inclusive. The 
reader can apply this method to any significant change in the BEACH data presented in terms of rate 
per 100 encounters, to gain an estimate of the size of the national effect of this change. 
In this report, changes over time in, for example, GP management actions for a specific problem, or 
changes in the problems managed for a selected group of patients, are not generally investigated. 
However, such analyses can be requested (see Section 1.2). 
1.1 Background 
GPs are usually the first port of call in the Australian healthcare system. Payment for GP visits is 
largely on a fee-for-service system, there being no compulsory patient lists or registration. People are 
free to see multiple practitioners and visit multiple practices of their choice. There is a universal 
medical insurance scheme (managed by Medicare Australia), which covers all or most of an 
individual’s costs for a GP visit.  
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Changes in demographics, health expenditure and provision of general practice services over the 
decade are outlined below. 
Population changes 
The Australian population increased by 17% between June 2006 (20.6 million) and June 2015 
(24.1 million).2 Over the same period: 
• the proportion of the population aged 65 years and over increased by 33%, from 2.7 million 
people to 3.6 million2  
• the number of Australians aged 85 years and over increased by 48% from 319,000 people to 
472,000.2 
Australia’s population is projected to change significantly over the coming decades. A greater 
proportion of the population will be aged 65 and over, increasing from 15% of the total population 
today, to about 23% over the next 40 years.3 
This is projected to have significant implications for health and aged care service demand.3 As life 
expectancy continues to improve, people are living longer with disease, so a greater part of the GP 
workload will involve management of older patients with multiple chronic conditions. 
Health expenditure 
• In 2013–14, Australia’s health expenditure was $154.6 billion,4 $60.5 billion (78%) more than in 
2005–06 ($86.9 billion).5 
• The average amount spent per capita was $6,639 in 2013–14, increasing from $4,268 in  
2005–06.4,5 
• Health expenditure as a proportion of gross domestic product (GDP) increased, from 8.7% in 
2005–06 to 9.8% in 2013–14.4,5  
• In 2005–06, governments funded more than two-thirds (67.8%) of health costs, compared with 
60.8% in 2013–14.4,5  
General practice services 
• Expenditure on general practice services (total non-referred attendances including 
GP/vocationally recognised GP, Enhanced Primary Care, practice nurse items, and other items) 
increased from $4.0 billion in the 2006–07 financial year to $6.8 billion in 2014–15.6 
• Changes in the number of practising GPs in Australia over the last decade are difficult to calculate 
due to the varying methods used to count GPs. According to reports from the AIHW, in 2005 there 
were 22,589 primary care practitioners in Australia (including but not limited to GPs),7 while in 
2014 there were 26,885 medical practitioners self-identifying as GPs, making up 110.6 full-time 
equivalents (FTE, based on a 40-hour week) per 100,000 population.8 
• In the April 2015 to March 2016 year, 86.9% of the Australian population claimed at least one GP 
service from Medicare (personal communication, Australian Government Department of Health 
[DoH], May 2016). In the same period, Medicare paid rebates for about 143.0 million claimed 
general practice service items (total non-referred attendances excluding practice nurse items),9 at 
an average of about 6.0 GP visits per head of population or 6.9 visits per person who visited at 
least once. This equates to about 2.8 million GP–patient encounters per week. 
• A decade earlier, in the 2006–07 financial year, 82.7% of the population claimed at least one GP 
service from Medicare, and total Medicare claims for GP–patient encounters numbered 
103.4 million, an average attendance of 5.0 visits per head of population or 6.0 visits per 
attendee.6 
Medicare statistics provide information about the frequencies and costs of visits claimed from 
Medicare for GP services. BEACH has given us an understanding of the content of GP–patient 
encounters and the services and treatments that GPs provide. The BEACH program aimed to: 
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• provide a reliable and valid data collection process for general practice that is responsive to the 
ever-changing needs of information users 
• establish an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and their relationship with service activity. 
Users of BEACH data might wish to consolidate information from multiple sources. Readers need to 
be aware of how the BEACH data differ from those drawn from other sources. A summary of 
differences between the BEACH data sets and those in national administrative data sets and studies 
is available in General practice activity in Australia 2015–16 (Sections 1.2 and 1.3).1  
1.2 Access to BEACH data 
Public domain 
This annual publication provides a comprehensive view of general practice activity in Australia. The 
BEACH program has generated many papers on a wide variety of topics in journals and professional 
magazines. All published material from BEACH is available through: 
<sydney.edu.au/medicine/fmrc/publications>. 
Throughout the 18 years of the program, a section at the bottom of each encounter form has been 
used to investigate aspects of patient health or healthcare delivery not covered by general practice 
consultation-based information. These substudies are referred to as SAND (Supplementary Analysis 
of Nominated Data). The SAND methods are described in Section 2.6. Abstracts of results and the 
research tools used in all SAND substudies have been published. Those from: 
• April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia10 
• April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts and 
research tools 1999–200611 
• August 2006 to March 2015 were published in each of the BEACH annual reports12-20 
• April 2015 to March 2016 are included in Chapter 15 of General practice activity in Australia  
2015–16.1 
Abstracts of results for all SAND substudies are also available on the FMRC website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts> where you can search by topic. 
Purchasing reports 
Following closure of the BEACH program, individuals and organisations will continue to be able to 
purchase standard reports or other ad hoc analyses. Charges are outlined at 
<sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. Contact details are provided at the 
front of this publication.  
Analysis of the BEACH data is a complex task. The FMRC designed standard reports that cover most 
aspects of a subject under investigation. Examples of a problem-based standard report, a group report 
and a pharmacological-based standard report for a single year’s data, are available at 
<sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. Customised data analyses can be 
done where the specific research question is not adequately answered through standard reports.  
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 2 Methods 
In summary: 
• each year, BEACH involved a new random sample of about 1,000 GPs 
• each GP recorded details of about 100 doctor–patient encounters of all types  
• the GP sample was a rolling (ever-changing) sample, with about 20 GPs participating in any one 
week, 50 weeks a year (with two weeks break over Christmas) 
• each GP could be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD) Program triennium (that is, once in each 3-year period) 
• the encounter information was recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also completed a questionnaire about themselves and their practice (Appendix 2). 
2.1 Sampling methods 
The source population included all vocationally registered GPs and all general practice registrars who 
claimed a minimum of 375 Medicare general practice items of service in the most recently available  
3-month Medicare data period (which equates to 1,500 such claims in a year). This ensured inclusion 
of the majority of part-time GPs, while excluding those who are not in private practice but claim for a 
few consultations a year. 
The Medicare statistics section of the Australian Government DoH updated the sample frame quarterly 
from the Medicare claims data. They then removed from the sample frame any GPs already randomly 
sampled in the current triennium, and drew a new sample from those remaining in the sample frame. 
This ensured the timely addition of new entries to the profession, and timely exclusion of those GPs 
who have stopped practising, have already participated or been approached in the current triennium. 
2.2 Recruitment methods 
The randomly selected GPs were approached by letter, posted to the address provided by the DoH. 
• Over the following 10 days, the telephone numbers generated from the Medicare data were 
checked using the electronic white and yellow pages. This was necessary because many of the 
telephone numbers provided from the Medicare data were incorrect. 
• The GPs were then telephoned in the order they were approached and, referring to the approach 
letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicated that the selected GP had moved 
elsewhere, but was still in practice. Where a new address and/or telephone number could be 
obtained, these GPs were followed up at their new address. 
• GPs who agreed to participate were set an agreed recording date several weeks ahead. 
• A research pack was sent to each participant before the planned start date. 
• Each GP received a telephone reminder early in the agreed recording period – this also provided 
the GP with an opportunity to ask questions about the recording process. 
• GPs could use a ‘freecall’ (1800) number to ring the research team with any questions during their 
recording period. 
• Non-returns were followed up by regular telephone calls for 3 months. 
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• Participating GPs earned clinical audit points towards their QI & CPD requirements through the 
Royal Australian College of General Practitioners (RACGP) and/or the Australian College of Rural 
and Remote Medicine (ACRRM). As part of this QI process, each GP received an analysis of his 
or her results compared with those of nine other de-identified GPs who recorded at about the 
same time. Comparisons with the national average and with targets relating to the National Health 
Priority Areas were also provided. In addition, GPs received some educational material related to 
the identification and management of patients who smoke or consume alcohol at hazardous 
levels. Additional points could be earned if the participant chose to do a follow-up audit of smoking 
and alcohol consumption among a sample of patients about 6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2015–16 was obtained from the Human Ethics Committee of the 
University of Sydney.  
Although the data collected by the GPs were not sufficient to identify an individual patient, informed 
consent for GP recording of the encounter details was required from each patient. GPs were 
instructed to ensure that all patients presenting during their recording period were provided with a 
Patient Information Card (Appendix 3), and to ask the patient if they were happy for their data to be 
included in the study. If the patient refused, details of the encounter were not recorded. This was in 
accordance with the ethics requirements for the BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and patient 
health status. An example of the form used to collect the encounter data and the data on patient 
health status is included in Appendix 1. The GP characteristics questionnaire is provided in 
Appendix 2. The GP characteristics and encounter data collected are summarised below. Patient 
health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care hours 
worked per week, country of graduation, general practice registrar status, Fellow of the RACGP 
status, Fellow of the ACRRM status, use of computers at work for clinical purposes, work 
undertaken in other clinical settings, number of practice locations worked in a regular week. 
• Practice characteristics: postcode of major practice, number of individual and number of full-
time equivalent (FTE) GPs working in the practice, number of individual and number of FTE 
practice nurses working in the practice, usual after-hours care arrangements, other health services 
located at the major practice. 
Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box options), up to 
three Medicare Benefits Schedule (MBS)/Department of Veterans’ Affairs (DVA) item numbers 
(where applicable), and other payment source (where applicable) (tick box options). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) were 
provided for Commonwealth concession card holders, holders of a Repatriation Health Card (from 
DVA), non-English-speaking background (patient self-reported that a language other than English 
is the primary language at home), Aboriginal person (self-identification), and Torres Strait Islander 
person (self-identification). Space is provided for up to three patient reasons for encounter (RFEs) 
(see Glossary). 
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• The problems managed at encounter (at least one and up to four). Tick boxes were provided to 
denote the status of each problem as new or continuing for the patient. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter (OTC) purchase 
including brand name, form (where required), strength, regimen, status (new or continuing 
medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and education, and 
procedures undertaken, and whether the recorded other treatment was provided by a practice 
nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, and 
hospital admissions 
– investigations, including pathology tests, imaging, and other investigations ordered.  
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to the encounter, the GP and the patient characteristics 
• all types of management are directly related to the problem being managed  
• RFEs have only an indirect relationship with problems managed, as a patient may have described 
one RFE (such as ‘repeat prescriptions’) that relates to multiple problems managed, or several 
RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single problem managed (such as upper 
respiratory tract infection) (see Section 6.3). 
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The encounter 
 date 
 direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
 indirect (e.g. telephone) 
Patient substudies (SAND) 
 risk factors 
— body mass 
— smoking status 
— alcohol consumption  
 other topics 
Management of each problem 
Medications (up to four per problem) 
 prescribed 
 over-the-counter advised 
 provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
 procedural treatments 
 clinical treatments (e.g. advice, 
counselling) 
 practice nurse involvement 
 
Other management 
 referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
 pathology tests ordered (up to five) 
 imaging ordered (up to three) 
GP characteristics 
 age and sex 
 years in general practice 
 country of graduation 
 direct patient care hours/week 
 FRACGP status (yes/no) 
 FACRRM status (yes/no) 
 currently a registrar (yes/no) 
 clinical use of computers  
 
Practice characteristics 
 practice size (no. & FTE GPs) 
 practice nurse(s) (no. & FTE) 
 after-hours arrangements 
 postcode  
 presence of other health services 
Problems managed 
 diagnosis/problem label 
 problem status (new/old) 
 work-related problem status 
The patient 
 age and sex 
 practice status (new/old) 
 Commonwealth concession 
card status 
 Repatriation Health Card 
status 
 postcode of residence 
 NESB/Indigenous status 
 reasons for encounter 
Note: FRACGP – Fellow of the Royal Australian College of General 
Practitioners; FACRRM – Fellow of the Australian College of 
Rural and Remote Medicine; FTE – full-time equivalent;  
DVA – Department of Veterans’ Affairs; NESB – non-English-
speaking background; SAND – Supplementary Analysis of 
Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data 
A section at the bottom of each recording form investigated aspects of patient health or health care 
delivery in general practice not covered by the consultation-based data. These substudies are referred 
to as SAND (Supplementary Analysis of Nominated Data). 
• Each year, the 12-month data period was divided into 10 blocks, each of 5 weeks, with three 
substudies per block. The research team aimed to include data from about 100 GPs in each block.  
• Each GP’s pack of 100 forms was made up of 40 forms that ask for the start and finish times of 
the encounter, and included questions about patient risk factors: patient height and weight (used 
to calculate body mass index, BMI), alcohol intake and smoking status (patient self-report). The 
methods and results of topics in the SAND substudies for alcohol consumption, smoking status 
and BMI are reported in Chapter 13. The start and finish times collected on these encounters are 
used to calculate the length of consultation. The length of consultation for Medicare-claimable 
encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack were divided into two blocks of 30, so each SAND block 
included about 3,000 records. Some topics were repeated to increase sample size. Different 
questions were asked of the patient in each block and these varied throughout the year. 
• The order of SAND sections was rotated in the GP recording pack, so that 40 patient risk factor 
forms may appear first, second or third in the pad. Rotation of ordering ensures there was no 
order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to March 2016 
have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia10 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200611 
• conducted between August 2006 and March 2015 have been published in each of the general 
practice activity annual reports12-20 
• conducted in the 2015–16 BEACH year are provided in Chapter 15 of the companion report, 
General practice activity in Australia 2015–16.1  
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
2.7 Statistical methods 
The analysis of the 2015–16 BEACH data was conducted with Statistical Analysis System (SAS) 
version 9.3.21  
BEACH has a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
correlation between observations within clusters. Procedures in SAS version 9.3 were used to 
calculate the intracluster correlation, and adjust the confidence intervals accordingly.21  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex distribution of 
the participating GPs and those in the sample frame from which the samples were drawn; and for the 
varying activity level of each GP (measured by number of claims each has made in the previous 
12 months from Medicare Australia). Each year, the age–sex distribution of patients at the sampled 
encounters has excellent precision when compared with the age–sex distribution of patients at all 
Medicare-claimed services of this type.  
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The encounter is the primary unit of inference. Proportions are used only when describing the 
distribution of an event that can arise only once at a consultation (for example, patient or GP age and 
sex), or to describe the distribution of events within a class of events (for example, problem A as a 
percentage of total problems). Due to rounding, proportions may not always add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the consultation (for 
example, RFEs, problems managed or medications). Rates per 100 problems are also used when a 
management event can occur more than once per problem managed.  
Statistical significance is tested by chi-square statistic for GP characteristics, but significance of 
differences in/for rates is judged by non-overlapping confidence intervals of the results being 
compared. The magnitude of this difference can be described as at least p < 0.05. Assessment using 
non-overlapping confidence intervals (CIs) is a conservative measure of significance,22-24 particularly 
when differences are assessed by comparing results from independent random samples, as is the 
case when changes over time are investigated using BEACH data. Due to the number of comparisons 
made in this and the companion publication, we believe this more conservative approach is warranted. 
• Changes over time in the frequency of events are judged significant (that is, a real change has 
occurred) if the two sets of CIs do not overlap. For example, Result A: 11.5 per 100 encounters 
(95% CI: 11.3–11.7) is significantly less than Result B: 11.9 per 100 encounters  
(95% CI: 11.8–12.0). 
• If the two sets of CIs butt together, the difference is regarded as marginal. For example,  
Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is marginally lower than Result B:  
11.9 (95% CI: 11.7–12.1). 
• If the two sets of 95% confidence intervals overlap, then no change was measured. 
• Differences discussed in this report are statistically significant unless otherwise stated. 
2.8 Changes over time 
For each of the 10 years from 2006–07 to 2015–16, patient RFEs and problems managed are 
reported as rates per 100 encounters. In earlier years, rates per 100 encounters were used when 
measuring changes in each of the management actions (prescriptions, other treatments, referrals, 
pathology and imaging). However, there has been a significant increase in the number of problems 
managed per encounter (see Chapter 7). This means that at each encounter, there is an increased 
chance of a management action occurring, without any change in the management practise of GPs. 
All management actions are therefore reported in two ways — as rates per 100 problems managed 
(used as the primary measure of change in GP behaviour) and as rates per 100 encounters (used as 
the basis of extrapolation).  
Data presented in this report are comparable for each result across all data years wherever possible. 
However, as in any long-term research program, changes occur over the years. Where methodological 
changes have occurred, the data have either: 
• been recalculated across all years using the new method (for example, body mass index was 
recalculated due to a change in the World Health Organization’s [WHO] body mass index 
groupings) 
• been regrouped for comparability. Where this occurs, it is noted in the footnotes of the table. An 
example is the combined presentation of home visits and institutional visits in Chapter 5 because 
the MBS now has only one item number for both. In previously published data it was possible to 
differentiate the two 
• been omitted from this report (if recalculation or grouping was not possible). Where data are 
omitted, this is noted as not applicable (N/A) or not available (NAv), as appropriate. 
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Each table includes the most frequent events occurring in 2015–16, and the comparative results for 
each of the earlier years. In addition, each table includes data for events that were more frequent in 
past year(s), but were no longer the most frequent in 2015–16. In general, results are presented in 
decreasing 2015–16 order of frequency. 
The direction and type of change between 2006–07 and 2015–16 is indicated for each result in the far 
right column of the tables: 
• / indicates a statistically significant change (increase or decrease) in 2015–16 when compared 
with the first year of data reported 
• / indicates a marginally significant change in 2015–16 when compared with the first year of 
data reported 
• — indicates there was no significant change in 2015–16 when compared with the first year of data 
reported 
• § indicates a noteworthy change during the decade. 
2.9 Extrapolated national estimates 
Extrapolations can be used to estimate the number of occurrences of a selected event at GP–patient 
encounters in Australia at a single time point, or to estimate the total national effect of a measured 
change. 
Where the results demonstrate a significant change over time, the estimated national change across 
total GP Medicare services from 2006–07 to 2015–16 can be calculated using the method detailed 
below. Note that extrapolations are always based on rate per 100 encounters rather than rate per 100 
problems, because there is no independent measure of the number of problems managed in 
Australian general practice. In contrast, the number of national encounters can be drawn from 
Medicare claims data.  
Examples of extrapolated national change are given in each chapter in the report from Chapter 5 to 
Chapter 12 inclusive. 
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2006–07 by 100, and then multiply by 
the total number of general practitioner service items claimed through Medicare in 2006–07 
(rounded to the nearest 100,000). As shown in Table 2.1, this was 103.4 million. This provides the 
estimated national number of events in 2006–07 
• repeat the process using data from 2015–16. 
The difference between the two estimates gives the estimated national change in the frequency of that 
event between 2006–07 and 2015–16. Estimated national number of events is rounded to the nearest 
100,000 if more than one million, and to the nearest 10,000 if below one million. It is possible to use 
this method to calculate the national effect of any significant change in a single result over any two 
time points.  
• Change is expressed as the estimated increase or decrease over the study period in the number 
of general practice contacts for that event (for example, an increase or decrease in the number of 
GP management contacts with problem X); or an increase or decrease in the number of times a 
particular management action (for example, a selected medication type) was prescribed in 
Australia in 2015–16, when compared with (usually) 2006–07. 
  
10
  
Extrapolations can also be made using data from a single time point to estimate the number of 
occasions that an event occurs in general practice encounters nationally in a specific year. When 
extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and multiply by the total number 
of general practitioner consultations claimed through Medicare that year (rounded to the nearest 
100,000) to give the estimated national number of events in that year. 
Table 2.1 provides the total (rounded) number of general practice professional service items claimed 
from Medicare in each financial year from 2006–07 to 2015–16.  
Table 2.1: Rounded number of general practice professional services claimed from Medicare Australia 
each financial year, 2006–07 to 2015–16 (millions) 
 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15 2015–16(a) 
Rounded number of 
Medicare GP items 
of service claimed 
103.4 109.5 113.0 116.6 119.2 123.9 128.7 134.2 139.4 143.0 
(a) Medicare data for the 2015–16 year included data from the April 2015 to March 2016 quarters because the 2015–16 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare Statistics.6,9  
 
Examples of extrapolation 
Example 1: Change in the number of clinical treatments performed nationally (with 95% 
confidence intervals) 
GPs’ use of clinical treatments (such as counselling and advice) increased by 30%, from 29.6 
tests/batteries (95% CI: 27.7–31.5) per 100 encounters in 2006–07 to 38.6 (95% CI: 36.1–41.0) in 
2015–16. 
The calculation used to extrapolate the effect of this change across Australia is:  
• In 2006–07 (29.6/100) x 103.4 million = 30.6 million clinical treatments performed nationally  
Lower confidence interval: 27.7/100 x 103.4 million = possibly as few as 28.6 million 
Upper confidence interval: 31.5/100 x 103.4 million = possibly as many as 32.6 million 
• In 2015–16, (38.6/100) x 143.0 million = 55.2 million clinical treatments performed 
Lower confidence interval: 36.1/100 x 143.0 million = possibly as few as 51.6 million 
Upper confidence interval: 41.0/100 x 143.0 million = possibly as many as 58.6 million. 
This suggests there were 24.6 million (55.2 million minus 30.6 million) more GP performed clinical 
treatments in Australia in 2015–16 than in 2006–07.  
This is the result of both the increase in the clinical treatments performed by GPs at encounters and 
the increased number of GP visits over the decade across Australia. 
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Example 2: National change in the number of GP–patient encounters at which diabetes was 
managed (with 95% confidence intervals)  
The management rate of diabetes did not change between 2006–07 (3.6 per 100 encounters, 95% CI: 
3.4–3.9) and 2015–16 (4.0 per 100, 95% CI: 3.8–4.3).  
For 2006–07, our best estimate for the total national encounters involving management of diabetes is: 
3.7 million [(3.6/100) x 103.4 million], but we are 95% confident that the true number lies between 
3.5 million [(3.4/100) x 103.4 million] and 4.0 million [(3.9/100) x 103.4 million]. 
For 2015–16, our best estimate for the total national encounters involving management of diabetes is: 
5.7 million [(4.0/100) x 143.0 million], but we are 95% confident that the true number lies between 
5.4 million [(3.8/100) x 143.0 million] and 6.1 million [(4.3/100) x 143.0 million]. 
Therefore, we estimate that even though the management rate of diabetes in an average 100 
encounters did not change, the huge increase in the number of attendances nationally in 2015–16 
(compared with 2006–07) led to an estimated additional 2.0 million GP–patient encounters across the 
country at which GPs managed diabetes, compared with a decade earlier.  
Considerations and limitations in extrapolations 
The extrapolations to the total number of events occurring nationally in any one year are only 
estimates. They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the extrapolations 
are made to Medicare-claimed GP consultations, not to the total number of GP–patient encounters 
per year – an additional 5% of BEACH encounters annually include encounters paid by sources 
other than Medicare, such as DVA, state governments, workers compensation insurance, and 
employers 
• an underestimate of activities of relatively low frequency with a skewed distribution across 
individual GPs.  
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than one million, and to the 
nearest 10,000 if below one million. However, the rounding has been applied to all years, so the effect 
on measures of change will be very small. Therefore, the extrapolation still provides an indication of 
the size of the effect of measured change nationally. 
Extrapolations are based on the unit of the encounter because the number of national encounters is 
quantifiable using Medicare claims data. However, the reader should be aware that where an event 
can occur more than once per encounter (for example, GPs can record up to two referrals per 
encounter), the extrapolation represents the number of occurrences of that event nationally (for 
example, the number of referrals nationally), rather than the number of encounters nationally where at 
least one event (for example, a referral) occurred. 
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2.10 Classification of data 
The following data elements are classified according to the International Classification of Primary Care 
– Version 2 (ICPC-2), of the World Organization of Family Doctors (Wonca):25 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in primary care. 
It is accepted by the WHO in the WHO Family of International Classifications,26 and is the declared 
national standard in Australia for reporting of health data from general practice and patient 
self-reported health information.27  
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic code) and 
seven components on the other (numeric codes) (Figure 2.2). Chapters are based on body systems, 
with additional chapters for psychological and social problems. Component 1 includes symptoms and 
complaints. Component 7 covers diagnoses – it can also be expanded to provide data about 
infections, injuries, neoplasms, congenital anomalies and ‘other’ diagnoses. 
Component 2 (diagnostic, screening and prevention) is often applied in describing the problem 
managed (for example, check-up, immunisation). Components 3 to 6 cover other processes of care, 
including referrals, other (non-pharmacological) treatments and orders for pathology and imaging. The 
components are standard and independent throughout all chapters. The updated component 
groupings of ICPC-2 codes, released by the Wonca International Classification Committee in 200428 
have been used in this report. 
The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have been 
selected for inclusion on the basis of their relative frequency in primary care settings, or because of 
their relative importance in describing the health of the community. ICPC has about 1,370 rubrics and 
these are sufficient for meaningful analyses. However, reliability of data entry, using ICPC-2 alone, 
requires a thorough knowledge of the classification for correct classification of a concept to be 
ensured. 
In 1995, recognising a need for a coding and classification system for general practice electronic 
health records, the FMRC (then the Family Medicine Research Unit, FMRU) developed an extended 
clinical terminology classified according to the ICPC, now called ICPC-2 PLUS.29 This is an interface 
terminology, developed from all the terms used by GPs in studies such as The Australian Morbidity 
and Treatment Survey 1990–91 (113,468 encounters),30 A comparison of country and metropolitan 
general practice 1990–91 (51,277 encounters),31 The Morbidity and Therapeutic Index 1992–1998 (a 
clinical audit tool that was available to GPs; approximately 400,000 encounters), and BEACH  
1998–2016 (about 1.8 million encounters). Together, these make up about 2.4 million encounter 
records, involving about 3.5 million free text descriptions of problems managed and a further 
3.5 million descriptions of patient reasons for encounter. These terms are classified according to 
ICPC-2 to ensure data can be compared internationally. Readers interested in seeing how coding 
works can download the ICPC-2 PLUS Demonstrator at <sydney.edu.au/health-sciences/ncch/icpc-2-
plus/demonstrator.shtml>.  
When the free-text data are received from the GPs, trained secondary coders (who are undergraduate 
students), code the data in specific terms using ICPC-2 PLUS. This ensures high coder reliability and 
automatic classification of the concept, and allows us to ‘ungroup’ such ICPC-2 rubrics as ‘other 
diseases of the circulatory system’ and select a specific disease from the terms within it. 
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 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
Presentation of data classified in ICPC-2 
Statistical reporting is usually at the level of the ICPC-2 classification (for example, acute otitis 
media/myringitis is ICPC-2 code H71). However, there are some exceptions where data are grouped 
either above the ICPC-2 level or across the ICPC-2 level. These grouped morbidity, pathology and 
imaging codes are defined in Appendix 4 available at: <hdl.handle.net/2123/15482>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in recording 
the management of hypertension, they may simply record the problem as ‘hypertension’. In ICPC-2, 
‘unspecified hypertension’ is classified as ‘uncomplicated hypertension’ (code K86). There is another 
code for ‘complicated hypertension’ (K87). In some cases, the GP may simply have failed to specify 
that the patient had hypertension with complications. The research team therefore feels that for 
national data reporting, it is more reliable to group the codes K86 and K87 and label this 
‘Hypertension*’ – the asterisk indicating that multiple ICPC-2 codes (as in this example), or ICPC-2 
PLUS codes (see below), are included. Appendix 4, Table A4.1 lists the codes included in these 
groups.  
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. For 
example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, such as L92 
– shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of shoulder, rotator cuff 
syndrome). When reporting osteoarthritis in this publication, all the more specific osteoarthritis ICPC-2 
PLUS terms classified within all the appropriate ICPC-2 codes are grouped. This group is labelled 
‘Osteoarthritis*’ – the asterisk again indicating multiple codes, but in this case they are PLUS codes 
rather than ICPC-2 codes. Appendix 4, Table A4.1 lists the codes included in these groups. 
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Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life.  
To identify chronic conditions, a chronic condition list32 classified according to ICPC-2 was applied to 
the BEACH data set. Chronic and non-chronic conditions (for example, diabetes and gestational 
diabetes) are often grouped together when reporting (for example, diabetes – all*). When reporting 
chronic morbidity, only problems regarded as chronic have been included in the analysis. Where the 
group used for the chronic analysis differs from that used in other analyses in this report, they are 
marked with a double asterisk. Codes included in the chronic groups are listed in Appendix 4, 
Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 classifies 
pathology and imaging tests very broadly (for example, a test of cardiac enzymes is classified in  
K34 – Blood test associated with the circulatory system; a computerised tomography (CT) scan of the 
lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal system). In 
Australia, the MBS classifies pathology and imaging tests in groups that are relatively well recognised. 
The team therefore regrouped all pathology and imaging ICPC-2 PLUS codes into MBS standard 
groups. This allows comparison of data between data sources. For groups marked with an asterisk, 
inclusions are listed in Appendix 4, Tables A4.7 and A4.8. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP, or advised for over-the-counter purchase, 
are coded and classified according to an in-house classification, the Coding Atlas for Pharmaceutical 
Substances (CAPS).  
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as medication 
class, medication group, generic name/composition, and brand name. 
The generic name of a medication is its non-proprietary name, which describes the pharmaceutical 
substance(s) or active pharmaceutical ingredient(s). 
When strength and regimen are combined with the CAPS code, we can derive the prescribed daily 
dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)33 classification, which is the 
Australian standard for classifying medications at the generic level.27 The ATC has a hierarchical 
structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
CAPS is now in the care of the National Centre for Classification in Health. Further information about 
CAPS is available from <sydney.edu.au/health-sciences/ncch/caps.shtml>.  
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Use of the pharmaceutical classifications in reporting 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme or the 
ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately allocated 
a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic may initially enter the classification at any level (1 to 5), not always at the 
generic level. Reclassification to lower ATC levels may occur later. Therefore, the ATC uses a top-
down approach. 
When analysing medications across time, a generic medication that is initially classified to a higher 
ATC level will not be identifiable in that data period and may result in under-enumeration of that drug 
during earlier data collection periods. 
There are some differences in the labels applied to generic medications in the two classifications. For 
example, the medication combination of paracetamol and codeine is labelled as ‘Paracetamol/codeine’ 
in CAPS and as ‘Codeine combinations excluding psycholeptics’ in the ATC. 
2.11 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key words or 
word fragments, and selecting the required term or label from a pick list. This was then automatically 
coded and classified by the computer. To ensure reliability of data entry we used computer-aided error 
checks (‘locks’) at the data entry stage, and a physical check of samples of data entered versus those 
on the original recording form. Further logical data checks were conducted through SAS regularly. 
2.12 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published elsewhere.34 This 
section summarises some aspects of reliability and validity of active data collection from general 
practice that should be considered by the reader.  
In the development of a database such as BEACH, data gathering moves through specific stages: GP 
sample selection, cluster sampling around each GP, GP data recording, secondary coding and data entry. 
At each stage the data can be invalidated by the application of inappropriate methods. The methods 
adopted to ensure maximum reliability of coding and data entry have been described above. The 
statistical techniques adopted to ensure valid analysis and reporting of recorded data are described in 
Section 2.7. Previous work has demonstrated the extent to which a random sample of GPs recording 
information about a cluster of patients represents all GPs and all patients attending GPs,35 the degree to 
which GP-reported patient RFEs and problems managed accurately reflect those recalled by the patient,36 
and reliability of secondary coding of RFEs37 and problems managed.30 The validity of ICPC as a tool with 
which to classify the data has also been investigated in earlier work.38 
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 3 The samples 
For annual response rates and measures of representativeness of individual annual GP samples, 
please see the annual report for each year in question (available at: 
<sydney.edu.au/medicine/fmrc/publications/books/GP-series>). 
More detailed descriptive analyses of the final sample in 2015–16 can be found in Chapter 3 of 
General practice activity in Australia 2015–16.1  
Table 3.1 shows the number of encounter records contained in each year of the BEACH program 
since April 2006, and the size of the database for those 10 years for each variable (weighted), upon 
which all comparisons over time described in this report are based. 
Table 3.1: Annual summary of data sets, 2006–07 to 2015–16 (final weighted data) 
Variable 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15 2015–16 
Total 10 
years 
General 
practitioners 
930 953 1,011 988 958 984 978 959 995 965 9,721 
Encounters 91,805 95,898 96,688 101,349 95,839 99,030 98,564 95,879 98,728 97,398 971,178 
Reasons for 
encounter 
138,434 146,696 151,282 157,071 149,005 153,218 152,278 148,880 151,636 149,084 1,497,584 
Problems 
managed 
136,333 145,078 149,462 155,373 146,141 152,286 152,517 151,675 153,133 150,279 1,492,277 
Medications 93,193 98,439 102,737 108,001 100,817 106,007 101,065 98,394 101,776 99,398 1,009,827 
Other 
treatments 
41,011 49,130 49,048 53,243 50,235 53,395 53,163 54,104 50,204 54,744 508,277 
Referrals & 
admissions 11,230 12,017 13,251 13,481 13,526 14,382 14,561 15,012 15,697 15,671 
138,828 
Pathology 38,963 41,375 44,066 45,594 43,313 46,544 46,398 47,035 46,435 46,315 446,038 
Imaging 8,229 9,143 9,469 9,877 9,370 9,978 10,163 10,460 11,314 10,733 98,736 
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 4 The participating GPs 
4.1 Characteristics of the participating GPs 
In BEACH, each GP participant completed a profile questionnaire about themselves and the major 
practice at which they work (see Appendix 2). Over the 10 years, the questions were altered 
occasionally to improve the quality and clarity of the data collected, or to investigate topics not 
previously surveyed as they became relevant. Therefore, for some characteristics we have data over 
the full 10-year period, and for others, over shorter periods. 
In this chapter, statistical significance of change is tested with the 2 (chi-square) statistic, with a 
decision level of α < 0.05. More detailed analyses of the participating GPs in 2015–16 can be found in 
Chapter 4 in General practice activity in Australia 2015–16.1  
Over the period 2006–07 to 2015–16, some trends emerged in the characteristics of GP BEACH 
participants (Table 4.1). The most noticeable changes are listed below and some are presented in 
Figure 4.1. 
• The feminisation of the general practice workforce is reflected in the growing proportion of GP 
participants who are female. The proportion of female participants increased from 34.1% in  
2006–07 to 44.9% in 2015–16. This change reflects change in the sex distribution of all 
recognised GPs claiming more than 375 general practice Medicare items of service in the 
previous quarter (35.3% in 2006–0712 and 42.7% in 2015–16), as provided each year by DoH from 
Medicare claims data. In Table 4.1, there was a ‘spike’ in the proportion of female GPs among the 
participating sample in 2009–10. As previously reported, this was the result of female GPs being 
over-represented in the sample provided by the (then) Department of Health and Ageing (DoHA) 
when compared with the national sample frame (as may occasionally happen in the random 
sampling process).15  
• From 2006–07 to 2015–16, there was a significant change in the age distribution of participants, 
with a decrease in the proportion aged 45–54 years (from 35.6% to 24.6%), and an increase in the 
proportion aged 55 years and over (from 35.0% to 45.3%). Again, these changes reflect the 
changes in the practising GP population (as defined for BEACH from Medicare claims data), in 
which the proportion aged 45–54 years decreased from 35.6%12 to 24.6%, and the proportion 
aged 55 years and over increased from 31.5%12 to 45.3%. In BEACH, the mean age of GP 
participants in 2006–07 was 50.7 years (median 50 years), while in 2015–16, it was 52.0 years 
(median 53 years). 
• There was a significant increase in the proportion of GPs working 21–40 hours per week in direct 
patient care (from 47.9% in 2006–07 to 61.8% in 2015–16), and a significant decrease in the 
proportion working 41–60 hours (36.9% in 2006–07 to 25.8% in 2015–16), the dramatic change 
occurring in 2009–10 (from 40.2% in 2008–09 to 30.8% in 2009–10). The proportion working more 
than 60 hours per week in direct patient care also steadily decreased (from 2.9% to 2.0% over the 
decade). When the last two results are combined, there was a decrease from 39.5% of 
participants working more than 40 hours per week in direct patient care in 2006–07 to 27.8% 
working these hours in 2015–16. There was a significant decrease in the mean number of hours 
spent in direct patient care, from 38.4 hours in 2006–07 to 36.7 hours in 2015–16. This has 
implications for workforce planning. 
• The proportion of GPs who had graduated from their primary medical degree in Australia 
significantly decreased, from 73.6% in 2006–07 to 60.8% in 2015–16. 
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• The proportion of GP participants holding Fellowship of the RACGP (FRACGP) significantly 
increased, from 46.3% in 2006–07 to 62.6% in 2015–16. Since 1995, FRACGP has been 
mandatory for new clinicians entering general practice, so this change would largely reflect the 
inclusion of new GPs into practice who hold FRACGP. 
• The proportion of participating GPs currently in training programs increased in recent years, 
peaking in 2012–13 at 6.1%, but showing a significant increase over the decade from 2.9% in 
2006–07 to 4.8% in 2015–16. 
4.2 Characteristics of participants’ major practice 
From 2006–07 to 2015–16, some trends emerged in the characteristics of the GP participants’ major 
practices (Table 4.2). The most noticeable changes over the 10 years are listed below.  
• The proportion of participants in smaller practices of 2–4 GPs decreased significantly, from 35.7% 
in 2006–07 to 24.3% in 2015–16. The proportion working in practices of 10 or more individual GPs 
almost doubled (from 15.8% in 2006–07 to 28.9% in 2015–16). Data were not available for  
2007–08 and 2008–09, as the question was altered to capture full-time equivalent GPs at the 
practice instead of number of individuals. However, from 2009–10 both data elements were 
captured. 
• Changes noted in regard to after-hours care are described below (multiple responses were 
allowed for this question). 
– The proportion of GPs working in practices that provided their own after-hours services (with 
no reliance on other arrangements) did not change over the decade (22.9% in 2006–07 and 
20.0% in 2015–16, results not tabled). The proportion in practices that provided all or some of 
their own after-hours care (for example, provide their own and in co-operation with other 
practices) decreased from 34.6% to 29.4% (Table 4.2).  
– The proportion providing after-hours services in cooperation with other practices (as their sole 
arrangement) decreased over the time period, from 11.3% in 2006–07 to 8.6% in 2015–16 
(results not tabled), and decreased from 15.5% to 9.8% when this option was combined with 
others (for example, provided some of their own and some in co-operation with other practices; 
or co-operatively with other practices and also using a deputising service).  
– However, the proportion of GPs working in practices that solely used deputising services for 
the provision of their after-hours care significantly increased from 35.9% in 2006–07 to 48.7% 
in 2015–16 (results not tabled). The proportion using deputising services in combination with 
other arrangements increased from 48.1% to 56.8%. 
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* Multiple responses were allowed. 
Note:  FRACGP – Fellows of the Royal Australian College of General Practitioners; Own A.H. – the practice provides its own after-hours 
service for their patients; Co-op A.H. – the practice provides after-hours services in a cooperative arrangement with other practices; 
Deputising A.H. – the practice uses deputising services for the provision of their after-hours care. 
Figure 4.1: Selected characteristics of participating GPs and their practices, 2006–07 and 2015–16 
Female < 45 years 55+ years Solo GP 10+ GPs FRACGP Own A.H.* Co-opA.H.*
Deputising
A.H.*
2006–07 34.1 29.4 35.0 8.2 15.8 46.3 34.6 15.5 48.1
2015–16 44.9 30.2 45.3 8.3 28.9 62.6 29.4 9.8 56.8
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 5 The encounters 
This chapter includes details about the GP encounters from each of the most recent 10 years of the 
BEACH study from 2006–07 to 2015–16. The direction and type of change from 2006–07 to 2015–16 
is indicated for each result in the far right column of the tables: / indicates a statistically significant 
change (increase or decrease) in 2015–16 compared with 2006–07; / indicates a marginally 
significant change in 2015–16 compared with 2006–07; — indicates there was no significant change in 
2015–16 compared with 2006–07; and § indicates a noteworthy change during the decade. 
Significant changes in rates per 100 encounters can be extrapolated to estimate the national increase 
or decrease in the measured event between 2006–07 and 2015–16. Some examples of extrapolated 
change are provided. The method used to extrapolate to national change estimates is described in 
Section 2.9. More detailed analyses of the GP–patient encounters in 2015–16 can be found in 
Chapter 5 of General practice activity in Australia 2015–16.1  
5.1 Content of the encounters 
Table 5.1 provides an overview of the changes that occurred between 2006–07 and 2015–16. The 
number of patient reasons for encounter (RFEs) recorded by the GP fluctuated over the decade, 
starting from 150.8 RFEs per 100 encounters in 2006–07, rising to a peak of 156.5 in 2008–09 and 
then falling to 153.1 per 100 encounters in 2015–16. Changes in types of RFEs are reported in 
Chapter 6. 
The number of problems managed increased from 148.5 per 100 encounters in 2006–07 to 154.3 per 
100 encounters in 2015–16. This represents 67.1 million more problems managed in general practice 
in 2015–16 than a decade earlier. Further details about changes in the types of problems managed 
are presented in Chapter 7. 
From 2014–15 onwards, data regarding the work-related nature of the problem under management 
was no longer collected and is therefore reported as not available in Table 5.1. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at encounters, it 
may be more informative to consider changes in GP management actions in terms of rates per 100 
problems managed as described in Chapters 8 to 12, inclusive. 
There was no change in the overall rate of medications recorded per 100 encounters although the rate 
of advised medications increased marginally. Specific changes in the types of medications recorded 
are detailed in Chapter 9. 
Between 2006–07 and 2015–16, there was a significant increase of 30% in the rate of clinical 
treatments (such as advice and counselling) provided, from 29.6 per 100 encounters in 2006–07 to 
38.6 per 100 in 2015–16. This represents an additional 24.6 million clinical treatments provided 
nationally in general practice in 2015–16 than a decade earlier. This pattern was reflected in the 
increase in the total other treatments (of which clinical treatments are the major component). These 
changes are described in further detail in Chapter 10.  
There was a significant increase in the number of procedural treatments performed in general practice 
between 2006–07 and 2015–16, from 15.1 per 100 encounters to 17.6 per 100 encounters. This 
increase represents an additional 9.6 million procedures performed nationally in 2015–16 compared 
with a decade earlier. More detail is provided in Chapter 10.  
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Referrals increased over the decade 2006–07 to 2015–16 by about 30%, from 12.2 to 16.1 per 100 
encounters. This represented 10.4 million more referrals nationally in 2015–16 than a decade earlier. 
The change was reflected in increased referrals to medical specialists and to allied health services 
and is described further in Chapter 11. 
Orders for pathology and imaging tests also increased significantly between 2006–07 and 2015–16. 
Orders for other investigations decreased marginally over the period. These changes are reported in 
greater detail in Chapter 12. 
5.2 Medicare/DVA-claimable encounters 
Table 5.2 provides a summary of encounters recorded in BEACH as claimable through the Medicare 
Benefits Schedule/Department of Veterans’ Affairs (MBS/DVA). These are expressed as a proportion 
of all MBS/DVA-claimable encounters.  
Only one MBS/DVA-claimable item per encounter is counted in Table 5.2. The selection of one item 
number per encounter was based on priority, whereby consultation item numbers overrode Practice 
Incentives Program payment item numbers, which overrode procedural item numbers, which overrode 
other Medicare item numbers. Table 5.2 includes only items claimed by GPs (excluding items claimed 
for practice nurses etc.) and the major changes are summarised below. 
• Short surgery consultations almost doubled, increasing significantly from 1.1% of MBS/DVA-
claimable encounters in 2006–07 to 2.0% in 2015–16. Previous research suggests that part of this 
increase is related to increasing practice nurse involvement in GP encounters.39 
• Standard consultations decreased significantly from 83.3% of MBS/DVA-claimable encounters in 
2006–07 to 77.2% in 2015–16. 
• Long surgery consultations accounted for 10.0% of MBS/DVA-claimable encounters in 2006–07. 
The proportion dropped significantly in 2008–09, then slowly rose, and in 2015–16 was not 
significantly different to 10 years earlier. 
• The proportion of encounters claimable under chronic disease management items, GP mental 
healthcare items and health assessments all significantly increased. 
In May 2010, changes were made to the MBS that combined the existing Medicare items for home 
visits, consultations at hospitals and consultations at other institutions.40 Unfortunately, this change 
prevented the discrete measurement of GP home visit frequency through MBS data. To allow the 
comparison of changes over time, we have applied this change to all previous years in the decade, 
and now report a single line for ‘home and institution visits’. There was no change in the proportion of 
home and institution visits (together) between 2006–07 and 2015–16. 
5.3 Consultation length 
In a subsample of consultations, start and finish times were recorded. There was a marginal increase 
in the mean length of consultation from 14.0 minutes to 14.5 minutes between 2006–07 and 2015–16 
for A1 MBS/DVA-claimable encounters. The mean length of consultation for all MBS/DVA-claimable 
encounters also increased significantly from 14.1 minutes to 14.9 minutes between 2006–07 and 
2015–16. The median consultation length for both of these groups was consistently 12 minutes from 
2006–07 to 2012–13. In 2013–14, it increased to 13 minutes, and then remained steady until  
2015–16 (Table 5.3). 
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f c
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; 
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ng
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 c
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6–
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gn
ifi
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 c
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 c
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pa
re
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w
ith
 2
00
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07
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N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
A
v 
– 
no
t a
va
ila
bl
e;
 O
T
C
 –
 o
ve
r-
th
e-
co
un
te
r.
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T
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ire
ct
io
n 
an
d 
ty
pe
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f c
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ng
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00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
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/
 in
di
ca
te
s 
a 
st
at
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tic
al
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 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
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 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; a
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 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
o
te
: I
nc
lu
de
s 
ite
m
s 
th
at
 w
er
e 
re
co
rd
ed
 a
s 
cl
ai
m
ab
le
 th
ro
ug
h 
th
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M
ed
ic
ar
e 
B
en
ef
its
 S
ch
ed
ul
e 
(M
B
S
)/D
ep
ar
tm
en
t o
f V
et
er
an
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ffa
irs
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D
V
A
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co
un
tin
g 
on
e 
ite
m
 p
er
 e
nc
ou
nt
er
 (
se
e 
C
ha
pt
er
 2
). 
C
I –
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on
fid
en
ce
 in
te
rv
al
. 
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f c
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 6 The patients 
This chapter includes data about the patients who participated in the BEACH study, including their 
characteristics and their reasons for encounter (RFEs), from each of the most recent 10 years of the 
BEACH study. The direction and type of change from 2006–07 to 2015–16 is shown for each result in 
the column on the far right of the tables: / indicates a statistically significant change (increase or 
decrease) in 2015–16 compared with 2006–07; / indicates a marginally significant change in 
2015–16 compared with 2006–07; — indicates there was no significant change in 2015–16 compared 
with 2006–07; and § indicates a noteworthy change during the decade. 
Detailed analyses of the patients at encounters in 2015–16 can be found in Chapter 6 of General 
practice activity in Australia 2015–16.1  
Significant changes in rates per 100 encounters can be extrapolated to estimate the national increase 
or decrease in the measured event between 2006–07 and 2015–16. There were 39.6 million more 
encounters claimed through Medicare in 2015–16 than in 2006–07 (143.0 million versus 
103.4 million). It should be noted that because of this increase, even a decrease in the rate of an 
event per 100 encounters can result in an increase in the estimated total number of events nationally. 
Examples of extrapolated change are provided. The method used to extrapolate to national change 
estimates is described in Section 2.9. 
6.1 Age and sex of patients at encounter 
Figure 6.1 and Table 6.1 show the age and sex distribution of patients at BEACH encounters from 
2006–07 to 2015–16. Over this period, there was no significant change in the proportion of encounters 
with male or female patients. The proportion of encounters with patients aged 15–24 years decreased 
from 9.1% to 7.9%, while the proportion with patients aged 65–74 years increased from 12.7% to 
14.7%. When extrapolated this suggests that nationally there were approximately 7.9 million more 
encounters with patients aged 65–74 years in 2015–16, than a decade earlier. This increase is likely 
to be due to the wave of baby boomers entering this age group over the decade, and the overall 
increase in average number of GP visits per head of population over this period. 
Readers interested in changes in the care of middle aged people (aged 45–64 years) in general 
practice, should see the feature (Chapter 14) in the companion report General practice activity in 
Australia 2015–16.1  
6.2 Other patient characteristics 
Over the decade, there was no significant change in the proportion of encounters that were with 
patients new to the practice. Between 2006–07 and 2015–16, the proportion of encounters with 
patients holding a Commonwealth concession card did not significantly change (45.4% to 46.2%) 
while those patients with a Repatriation Health Card nearly halved (3.4% to 1.8%). There was no 
significant change in the proportion of encounters that were with patients from a non-English-speaking 
background or with patients identifying themselves as Indigenous (Table 6.1). 
  
32
  
 
 
 Note: Missing data removed. 
Figure 6.1: Age and sex distribution of patients at encounters, 2006–07 and 2015–16 (95% confidence 
intervals) 
6.3 Patient reasons for encounter 
Patient RFEs reflect the patient’s demand for care and can provide an indication of service use 
patterns. Patient demand for care can be influenced by interventions aimed at the general population 
(for example, health awareness campaigns in popular media and print). 
Participating GPs were asked to record at least one, and up to three, patient RFEs in words as close 
as possible to those used by the patient, before the diagnostic or management process had begun. 
RFEs can be expressed in terms of one or more symptoms (for example, ‘itchy eyes’, ‘chest pain’), in 
diagnostic terms (for example, ‘about my diabetes’, ‘for my hypertension’), a request for a service  
(‘I need more scripts’, ‘I want a referral’), an expressed fear of disease, or a need for a check-up. 
The patient may describe a single RFE that relates to a single problem managed at the encounter, a 
single RFE that relates to multiple problems, multiple RFEs that relate to a single problem managed at 
the encounter, or multiple RFEs that relate to multiple problems managed at the encounter. GPs may 
also manage a problem that was unrelated to the patient’s RFE (for example, a patient presents about 
their diabetes but while they are there, the GP also provides a vaccination and manages their 
hypertension). 
Number of reasons for encounter 
Table 6.2 shows that the proportion of encounters with two patient RFEs significantly increased from 
27.9% in 2006–07 to 29.6% of all encounters in 2015–16. Extrapolation of this increase suggests 
there were about 13.5 million more encounters nationally where two RFEs were reported in 2015–16 
than in 2006–07.  
The overall rate of RFEs did not significantly change, with 150.8 reported per 100 encounters in  
2006–07 and 153.1 reported per 100 encounters in 2015–16 (Table 6.3).  
Male Female <1 year 1–4 years
5–14 
years
15–24 
years
25–44 
years
45–64 
years
65–74 
years
75+
years
2006–07 43.7 56.3 1.8 4.1 5.6 9.1 23.3 28.2 12.7 15.2
2015–16 43.4 56.6 1.7 4.3 5.3 7.9 22.8 27.2 14.7 16.0
0
10
20
30
40
50
60
Per cent of encounters 
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Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3. 
Symptoms and diagnoses 
• RFEs expressed in terms of a symptom or complaint (for example, ‘tired’, ‘feeling anxious’) were 
the most frequent in all years and their presentation rate did not significantly change across the 
decade. 
• With one exception, the rate of RFEs relating to specific diagnoses (including infections, injuries, 
neoplasms, congenital anomalies, and other diagnoses) did not significantly change across the 
decade. The exception was a significant decrease in the rate of RFEs related to infections, from 
8.0 to 6.6 per 100 encounters. 
Processes of care 
RFEs relating to three of the five processes of care groups significantly increased across the decade. 
• Patient requests for medications, treatments and therapeutics (such as repeat prescriptions) 
significantly increased from 14.2 to 16.1 per 100 encounters across the decade. 
• Presentations for test results increased by nearly 50%, from 6.9 to 10.2 per 100 encounters. When 
extrapolated, we estimate 7.5 million more encounters nationally with an RFE of this type in  
2015–16 than a decade earlier.  
• The rate of requests for an administrative procedure (such as a sickness certificate) doubled from 
1.9 to 3.8 per 100 encounters. This change equates to an estimated national increase of 
approximately 3.5 million more requests for an administrative procedure nationally in 2015–16 
than in 2006–07. 
Patient requests for ‘diagnostic and preventive procedures’ and ‘referrals and other RFEs’ did not 
significantly change across the decade. 
Reasons for encounter by ICPC-2 chapter 
• Table 6.4 shows that between 2006–07 and 2015–16, the rate at which patients described RFEs 
of a general and unspecified nature increased by over 20%. When extrapolated to national 
estimates, this equates to about 27.1 million more general and unspecified RFEs in 2015–16 than 
in 2006–07. 
• RFEs related to psychological problems increased by about 20% over the decade. This equates to 
approximately 5.2 million more RFEs related to psychological problems nationally in 2015–16 than 
in 2006–07. The increased role of GPs in the management of mental health was the focus of 
Chapter 14 in the book General practice activity in Australia, health priorities and policies 1998 to 
2008.41 
Table 6.4 also shows that between 2006–07 and 2015–16, there were significant decreases in: 
• the rate of RFEs relating to digestive problems, which decreased by about 8% 
• the rate of RFEs relating to the circulatory system, which decreased by about 25%. This may be 
linked to the decrease in the management rate of hypertension (as discussed in Chapter 7)  
• the rate of eye problem RFEs, which decreased by about 15% over the decade 
The rate of RFEs relating to neurological problems decreased marginally between 2006–07 and 
2015–16. 
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Proportion of encounters with at least one RFE by ICPC-2 chapter 
Table 6.5 shows that between 2006–07 and 2015–16, there were significant increases in the 
proportion of encounters: 
• where patients described at least one RFE of a general and unspecified nature (about 20% 
increase). When extrapolated to national estimates, this equates to about 22.7 million more 
encounters with at least one general and unspecified RFE in 2015–16 than in 2006–07 
• with at least one RFE of a psychological nature (an increase of about 20%). This equates to 
approximately 4.6 million more encounters with at least one RFE of a psychological nature 
nationally in 2015–16 than in 2006–07. 
Table 6.5 also shows that between 2006–07 and 2015–16, there were decreases in the proportion of 
encounters with at least one: 
• circulatory-related RFE (a significant increase of about 25%) 
• eye-related RFE (a significant increase of about 20%) 
• digestive related RFEs (a marginal decrease) 
• neurological RFE (a marginal decrease). 
Most frequent patient reasons for encounter 
The most frequent individual RFEs are shown in Table 6.6. As expected from results in Table 6.3, over 
the decade there were significant increases in RFEs related to specific processes of care: 
• requests for prescriptions (an increase of about 15%) 
• requests for test results (by nearly 50%) 
• patient requests for administrative procedures (such as sickness certificates, wellness certificates 
and care plans) (which doubled) 
• requests for other referrals (by over 50%). 
There was, however, a significant decrease in the requests for check-ups (about a 15% decrease). 
In terms of symptoms and diagnoses, from 2006–07 to 2015–16, there were significant increases in 
patient presentations of sneezing/nasal congestion (by over one-third) and anxiety (by 50%). 
From 2006–07 to 2015–16, there was a marginal increase in patient presentations of skin symptoms 
or complaints (by about 15%). 
From 2006–07 to 2015–16, there were significant decreases in the RFE rates for: 
• throat complaints (about 20%) 
• abdominal pain (about 15%) 
• upper respiratory tract infection (30%) 
• hypertension/high blood pressure (about 30%) 
• leg/thigh complaint (20%) 
• chest pain not otherwise specified (40%). 
Over the same period, there were marginally significant decreases in the rates of observation/health 
education/advice/diet (nearly 20%), ear pain/earache (15%), diarrhoea (15%), and vomiting (20%). 
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 7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health problem 
presented by the patient, family or community, and can be described in terms of a disease, symptom 
or complaint, social problem, or ill-defined condition. At each patient encounter, up to four problems 
could be recorded by the GP and a minimum of one problem was compulsory. GPs were instructed to 
record each problem at the most specific level possible from the information available. As such, the 
problem managed may be limited to the level of a presenting symptom rather than a diagnosis. 
The status of each problem to the patient – new (first presentation to a medical practitioner), or old 
(follow-up of previously managed problem) – was also indicated (see Glossary). The concept of a 
principal diagnosis, which is often used in hospital statistics, is not adopted in studies of general 
practice where multiple problem management is the norm rather than the exception. Further, the 
range of problems managed at the encounter often crosses multiple body systems and may include 
undiagnosed symptoms, psychosocial problems, chronic disease or preventive health, which makes 
the designation of a principal diagnosis difficult. Thus the order in which the problems were recorded 
by the GP is not significant. 
This chapter includes data about the problems managed in general practice from each of the most 
recent 10 years of the BEACH study: 2006–07 to 2015–16. The direction and type of change from 
2006–07 to 2015–16 is indicated for each result in the far right column of the tables: / indicates a 
statistically significant change (increase or decrease) in 2015–16 compared with 2006–07; / 
indicates a marginally significant change in 2015–16 compared with 2006–07; — indicates there was 
no significant change in 2015–16 compared with 2006–07; and § indicates a noteworthy change 
during the decade. 
Significant change in the rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the measured event between 2006–07 and 2015–16. Examples of 
extrapolated change are given. The method used to extrapolate to national change estimates is 
described in Section 2.9. The number of GP–patient encounters claimed through the MBS nationally 
increased by 39.6 million (38%) between 2006–07 (103.4 million encounters) and 2015–16 
(143.0 million encounters).6,9 As a result, a decreased rate of a particular ‘measured event’ per 100 
encounters may yield a national increase in the absolute number of those events. 
Detailed analyses of ‘problems managed’ by participating GPs in the 2015–16 BEACH year can be 
found in the companion report, General practice activity in Australia 2015–16.1 
There are two ways to describe the relative frequency of problems managed: as a percentage of all 
problems managed in the study, or as a rate of problems managed per 100 encounters. Where groups 
of problems are reported (for example, circulatory problems), it must be remembered that more than 
one of that type of problem (such as hypertension and heart failure) may have been managed at a 
single encounter.  
The reader must be mindful that a rate per 100 encounters for a single ungrouped problem, for 
example ‘asthma, 2.0 per 100 encounters,’ can be regarded as equivalent to ‘asthma is managed at 
2.0% of encounters’, and can be extrapolated (with the methods described in Section 2.9) to 
accurately estimate the number of national encounters involving management of the selected problem. 
This is not the case for grouped concepts (ICPC-2 chapters and those marked with asterisks in the 
tables) for which extrapolations represent the number of problem contacts involving the management 
of any of the problems within the group at general practice encounters nationally. In these cases, an 
extrapolated result may be an overestimate of the number of encounters involving management of 
these problems. This is because multiple problems (within the selected group) can be recorded within 
a single encounter. To estimate more precisely the number of encounters nationally that involve 
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management of the grouped concept, the extrapolation has to be based on the proportion of 
encounters involving at least one of the concepts within the group.  
Table 7.3b describes the proportion of encounters during which at least one problem has been 
managed within an ICPC-2 chapter, for each of the 10 years from 2006–07 to 2015–16. The table 
allows users to make the following kinds of statements: “in 2015–16 at least one respiratory problem 
was managed at 18.9% of encounters”, and then extrapolate this result (see Section 2.9). Such 
extrapolation suggests that at least one respiratory problem was managed at 27.0 million encounters 
nationally in 2015–16. 
Figure 7.1 shows a statistically significant increase in the rate at which all problems were managed per 
100 encounters over the 10 years to 2015–16. However, there was no change in the rate at which 
chronic problems were managed. This suggests that non-chronic problems were the major contributor 
to the increase in the number of problems managed. There was an increase over the decade in the 
rate at which new problems were managed. 
 
 
  
 
Note: Data are drawn from Tables 7.2, 7.5 and 7.6. 
Figure 7.1: Changes in the management rates of all problems, new problems and chronic 
problems, 2006–07 to 2015–16 (95% confidence intervals) 
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7.1 Number of problems managed 
GPs can record up to four problems at each encounter. Table 7.1 shows the number of problems 
managed at encounters over the decade. There were increases in the proportion of encounters at 
which two and four problems were managed, and a decrease in encounters where only one problem 
was managed. When extrapolated to all GP–patient encounters in Australia, this suggests there were 
about 12.5 million more occasions on which two problems were managed, and 2.0 million more 
occasions where four problems were managed by GPs in Australia in 2015–16 than in 2006–07. 
Despite the decrease in encounters where only one problem was managed, due to the overall 
increase in the number of encounters nationally, there were 20.5 million more occasions where one 
problem was managed in 2015–16 than in 2006–07.  
These results led to a significant increase in the average number of problems managed at encounter, 
from 148.5 per 100 encounters in 2006–07 to 154.3 in 2015–16 (Table 7.2). This suggests there were 
67.1 million more problems managed at GP–patient encounters in Australia in 2015–16 than in  
2006–07. 
7.2 Problems managed by ICPC-2 component 
To provide a better understanding of the types of problems managed during general practice 
encounters, problems may be examined using the components of the ICPC-2 classification. The 
component structure of ICPC-2 is described in detail in Section 2.10. 
Table 7.2 shows there were significant increases in the management rate of problems in a number of 
ICPC-2 components. Extrapolated to national general practice encounters, these increases represent 
about: 
• 15.0 million more contacts with problems described by GPs in terms of ‘symptoms and complaints’ 
in 2015–16 than in 2006–07 
• 2.8 million more contacts described in terms of ‘medications, treatments and therapeutics’ in 
2015–16 than in 2006–07 
• 1.6 million more contacts described as ‘test results’ in 2015–16 than in 2006–07 
• 1.5 million more contacts with problems classified as ‘administrative’. 
There was no change over the decade in the management of problems described as ‘diagnosis, 
diseases’. This component can be broken down into various subtypes (described in Section 2.10), 
many of which did not show change over the decade. There was a marginal decrease in the 
management rate of ‘infections’. However, due to the overall increase in the number of encounters in 
Australian general practice (as described in the introduction to this chapter), there were 7.6 million 
more contacts with problems classified as infections in 2015–16 than in 2006–07. 
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7.3 Problems managed by ICPC-2 chapter and
 individual problems managed 
Problems managed by ICPC-2 chapter 
Problems managed at general practice encounters classified by ICPC-2 chapter are described in 
Table 7.3a for all years from 2006–07 to 2015–16.  
General and unspecified problems were the most frequently managed type of problem in 2015–16, 
their management rate increased from 16.2 per 100 encounters in 2006–07 to 20.0 per 100 in  
2015–16, an increase of 23.5% over the decade. 
There were also significant increases in the management rates of the following problem types at 
general practice encounters between 2006–07 and 2015–16:  
• endocrine and metabolic problems, from 12.1 to 13.5 per 100 encounters 
• psychological problems, from 10.9 to 13.1 per 100 encounters 
• social problems, from 0.6 to 0.8 per 100 encounters. 
There were marginal increases in the management rate of digestive problems (increasing from 10.4 to 
11.1 per 100 encounters) and urological problems, from 3.1 to 3.5 per 100 encounters over the 
decade. 
There were significant decreases in the management rates of: 
• circulatory problems, from 17.4 to 15.1 per 100 encounters 
• problems classified in the ‘eye’ chapter, from 2.7 to 2.2 per 100 encounters (Table 7.3a). 
Comparing 2006–07 with 2015–16, there was no change in the management rate of respiratory 
problems. However, there was a statistically significant spike in the rate of respiratory problems in 
2009–10 which was probably due to concern regarding H1N1 influenza. 
Table 7.3b shows changes over time in the proportion of encounters during which at least one 
problem was managed per ICPC-2 chapter. The table shows that there were significant increases in 
the proportion of encounters at which at least one problem was managed. Examples include: 
• general and unspecified problems (from 15.4% of encounters in 2006–07 to 18.5% in 2015–16), 
representing an additional 10.5 million encounters during which at least one general and 
unspecified problem was managed in 2015–16 compared with 2006–07 
• psychological problems (from 10.4% to 12.4%), representing an additional 7.0 million encounters 
during which at least one psychological problem was managed in 2015–16 compared with  
2006–07 
• endocrine and metabolic problems (from 11.2% to 12.3%), representing an additional 6.0 million 
encounters in 2015–16 where at least one endocrine and metabolic problem was managed 
compared with 2006–07. 
In contrast, the proportion of encounters during which at least one circulatory problem was managed 
decreased from 16.3% to 14.1%. However, due to the overall increase in general practice encounters 
nationally, this equated to 3.3 million more encounters during which at least one circulatory problem 
was managed in 2015–16 than in 2006–07. Similarly, there was a decrease in the proportion of 
encounters at which at least one eye problem was managed, but there were 460,000 additional 
encounters during which at least one ear problem was managed in 2015–16 compared with 2006–07. 
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Individual problems managed 
The most frequently managed individual problems are described in Table 7.4. This demonstrates that 
in all years from 2006–07 to 2015–16, the most frequently managed problems were hypertension, 
check-up, upper respiratory tract infection (URTI) and immunisation/vaccination.  
Though remaining the most frequently managed problem across the decade, the management rate of 
hypertension decreased from 2006–07 to 2015–16, from 9.6 per 100 encounters to 7.5 per 100. 
However, due to the overall increase in the number of GP encounters nationally, this equated to 
800,000 more encounters at which hypertension was managed in 2015–16 than in 2006–07.  
There was no overall change in the management rate of URTI between 2006–07 and 2015–16. 
However, as reported in the 2014 report, General practice activity in Australia 2013–14,19 a significant 
decrease was observed in the management rate of URTI between 2012–13 (5.8 per 100 encounters) 
and 2013–14 (4.9 per 100 encounters). In the most recent 2 years of data (2014–15 and 2015–16), 
the management rate has bounced back to the rate seen in 2012–13. A similar pattern occurred in the 
management rate of acute bronchitis/bronchiolitis. It appears these decreases in 2013–14 were 
isolated to that single period. The reasons for the drop observed in 2013–14 are unclear. 
The management rate of immunisation/vaccination did not change significantly over the decade (4.7 
per 100 encounters in 2006–07 and 5.3 in 2015–16). However, there were numerous fluctuations in 
the management rate over the decade, with a significant spike in 2009–10 (7.3 per 100 encounters) 
that coincided with the H1N1 influenza pandemic, and a significant decrease in 2014–15 (3.6 per 100 
encounters) which may be explained by a delay in supply of the influenza vaccine in 2014–15, from 
early March to late April 2015.42 The BEACH data year runs from 1 April to 30 March, so fewer 
influenza vaccinations were given in the 2014–15 BEACH year than usual. The 2015–16 rate was 
similar to that recorded in 2013–14. 
Between 2006–07 and 2015–16, there were statistically significant increases in the management rates 
of a number of problem types, including depression, general check-up, back complaints, prescriptions, 
anxiety, test results, administrative procedure, vitamin/nutritional deficiency, abnormal test results and 
bursitis/tendonitis/ synovitis. When extrapolated to all GP–patient encounters across Australia, these 
changes represent: 
• 2.2 million more occasions of depression management 
• 1.7 million more general check-ups. It is likely that the introduction of MBS items for health 
assessments contributed to this increase. These health assessments are targeted towards 
particular groups of patients, including those aged 45–49 at risk of developing chronic disease,43 
those aged 75 years and over, and the ‘Healthy Kids Check’ for children of pre-school age 
(discontinued from 1 November 2015) 
• 1.7 million more occasions of management of back complaints 
• 1.6 million more contacts for test results and 1.1 million more contacts for abnormal test results. 
These increases may be explained by an increased rate of pathology test ordering over the 
decade, as described in Chapter 12 
• 1.9 million more contacts for prescriptions  
• 1.4 million more occasions of anxiety management 
• 1.5 million more contacts for problems regarded as administrative procedures 
• 1.5 million more occasions where vitamin/nutritional deficiency was managed 
• 830,000 more occasions where bursitis/tendonitis/synovitis was managed. 
In contrast, over the decade there was a significant decrease in the management rate of oral 
contraception. However, due to the overall increase in the number of general practice encounters, this 
equated to an additional 90,000 encounters involving management of oral contraception. There were 
also significant decreases in the management rate of ischaemic heart disease, cardiovascular check-
up and fracture. 
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7.4 Most common new problems 
There was a significant increase in the management rate of new problems from 56.5 per 100 
encounters in 2006–07 to 60.1 in 2015–16. This suggests there were an additional 27.5 million new 
problems managed at GP–patient encounters in Australia in 2015–16 compared with 2006–07. 
URTI was the most frequently managed new problem. Although there was no overall change in its 
management rate between 2006–07 and 2015–16, there was a marginal decrease in its management 
rate in 2013–14. This drop in new presentations was isolated to 2013–14. In 2014–15, the rate 
returned to the 2012–13 rate and was consistent in 2015–16. A similar pattern occurred in new 
presentations of acute bronchitis/bronchiolitis (Table 7.5).  
There was a marginal increase in the rate of new presentations for immunisation/vaccination over the 
decade. There were also fluctuations that occurred during the decade that reflect the management of 
all immunisation/vaccinations problems, discussed in Section 7.3.  
The management rate of new check-ups increased significantly (from 2.5 to 3.0 per 100 encounters). 
This is likely to be due to the ageing population and the introduction of MBS items specifically for 
check-ups (as discussed in Section 7.3). When extrapolated, this increase represents 1.7 million 
additional occasions where a check-up was managed as a new problem in Australia in 2015–16 
compared with 2006–07.  
7.5 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work undertaken in 
200432 and regularly updated by the lead author (see ‘Chronic conditions’ grouper G84 
<sydney.edu.au/medicine/fmrc/icpc-2-plus/demonstrator>), was applied to the BEACH data set. In 
other parts of this chapter, both chronic and non-chronic conditions (for example, diabetes and 
gestational diabetes) have been grouped together when reporting (for example, diabetes – all*, 
Table 7.4). In this section, only problems regarded as chronic have been included in the analysis. For 
this reason, the condition labels in Table 7.6 may differ from those in Table 7.4. Where the group used 
for the chronic analysis differs from that used in other analyses in this report, they are marked with a 
double asterisk (for example, Diabetes [non-gestational]**). Codes included in asterisked concepts are 
presented in Appendix 4, Table A4.2, available at <hdl.handle.net/2123/15482>. 
Table 7.6 shows the most frequently managed chronic problems between 2006–07 and 2015–16. The 
management rate of chronic conditions did not change overall between 2006–07 and 2015–16 
(53.3 per 100 encounters in both years). However, due to the increase in the number of GP visits 
nationally, we estimate that GPs managed 21.1 million more chronic problems in 2015–16, than they 
did a decade earlier. 
The most common chronic problems managed were non-gestational hypertension, depressive 
disorder, non-gestational diabetes, chronic arthritis and lipid disorder.  
From 2006–07 to 2015–16, there were significant increases in the management rates of: 
• depressive disorder (representing 2.2 million more occasions of management in 2015–16 than in 
2006–07) 
• hypothyroidism/myxoedema (representing 670,000 more occasions of management) 
• chronic back pain (400,000 more contacts for this problem) and unspecified chronic pain (also 
representing 400,000 more contacts for this problem in 2015–16 than in 2006–07). 
There were marginally significant increases in the management rates of atrial fibrillation/flutter, 
shoulder syndrome, and schizophrenia. 
There were significant decreases in the management rates of hypertension and ischaemic heart 
disease, and marginally significant decreases in the rates of asthma and heart failure (Table 7.6). 
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a
b
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.3
b
 (
c
o
n
ti
n
u
e
d
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s
e
n
c
e
 o
f 
a
t 
le
a
s
t 
o
n
e
 p
ro
b
le
m
 m
a
n
a
g
e
d
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e
r 
IC
P
C
-2
 c
h
a
p
te
r,
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0
0
6
–
0
7
 t
o
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0
1
5
–
1
6
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c
e
n
t 
o
f 
e
n
c
o
u
n
te
rs
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
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0
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0
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 c
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
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; I
C
P
C
-2
 –
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 P
rim
ar
y 
C
ar
e 
- V
er
si
on
 2
. 
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e
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ro
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
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 
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b
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 8 Overview of management 
Over the most recent 10 years of the BEACH program (2006–07 to 2015–16), there have been major 
changes in how GPs manage patient problems. This chapter provides an overview of the 
management of problems in general practice. More detailed analyses of the overview of management 
in 2015–16 can be found in Chapter 8 in General practice activity in Australia 2015–16.1 
As discussed in Chapter 2, we can consider changes in GP management actions over time in terms of 
the number of the selected actions per 100 GP–patient encounters, or in terms of the number of 
problems managed. If the number of problems managed on average at encounters did not alter, it 
would not matter which way change was measured. 
However, as reported in Chapter 7, there was a significant increase in the number of problems 
managed at GP–patient encounters over the decade of this study. If we simply compared 
management actions (for example, number of prescriptions) as a rate per 100 encounters, we would 
be ignoring the fact that more problems were managed in 2015–16 than in 2006–07. If more problems 
are managed, more management actions should result, without any change occurring in GP 
management behaviour. 
In this, and the following management chapters, changes over time are reported in two ways: 
• rate (of the selected action) per 100 problems managed 
• rate (of the selected action) per 100 encounters. 
The rate per 100 problems managed gives a clearer idea of how GP management actions have (or 
have not) changed. The rate per 100 encounters is used as the basis of extrapolation to national 
estimated change. 
The direction and type of change from 2006–07 to 2015–16 is indicated for each result in the far  
right column of the tables: / indicates a statistically significant change (increase or decrease) in 
2015–16 compared with 2006–07; / indicates a marginally significant change in 2015–16 
compared with 2006–07; — indicates there was no significant change in 2015–16 compared with 
2006–07; and § indicates a noteworthy change during the decade. 
Examples of extrapolations are provided in each of the specific management chapters (Chapters 9 to 
12, inclusive). The method used to extrapolate to national change estimates is described in 
Section 2.9. 
Between 2006–07 and 2015–16, some trends emerged in management actions per 100 problems 
managed (Table 8.1a), and per 100 encounters (Table 8.1b). The most noticeable changes (from 
Table 8.1a) are listed below. 
• There was a significant decrease in the rate of prescribed medications, from 56.1 per 100 
problems managed in 2006–07 to 53.1 per 100 problems in 2015–16. 
• The rate of ‘other treatments’, including clinical and procedural treatments, increased significantly, 
from 30.1 to 36.4 per 100 problems. Individually, both clinical and procedural treatments increased 
significantly. Clinical treatments increased from 19.9 to 25.0 per 100 problems, and the rate of  
GP-provided procedures increased from 10.2 to 11.4 per 100 problems over the decade. 
• The rate of referrals to other health providers significantly increased, from 8.2 to 10.4 per 100 
problems managed between 2006–07 and 2015–16, influenced by a 15% increase in referrals to 
medical specialists (from 5.4 to 6.2 per 100 problems managed) and a 71% increase in referrals to 
allied health services over the period (from 2.1 to 3.6 per 100 problems managed). It was further 
influenced by a marginal increase in referrals to emergency departments (from 0.1 to 0.2 per 100 
problems managed). 
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• The rate at which pathology tests/batteries were ordered significantly increased by 8%, from 28.6 
tests/batteries per 100 problems managed in 2006–07, to 30.8 per 100 in 2015–16.  
• The rate at which imaging was ordered increased significantly, from 6.0 imaging orders per 
100 problems managed in 2006–07, to 7.1 per 100 in 2015–16, a rise of 18%. 
Similar changes between 2006–07 and 2015–16 were apparent in the percentage of problems 
(Table 8.2a), and the percentage of encounters (Table 8.2b), where at least one management type 
was recorded. 
Table 8.2a shows that over the decade 2006–07 to 2015–16, the proportion of problems for which at 
least one: 
• medication was provided decreased significantly (from 54.5% of problems to 51.9%), mainly 
influenced by a significant decrease in the proportion of problems for which medication was 
prescribed, from 45.6% to 42.4% over this time  
• other treatment was provided increased significantly, from 27.0% to 32.2%, due to significant 
increases in both the proportion of problems for which at least one clinical treatment was provided 
(18.1% to 22.5%) and for which at least one procedure was undertaken (9.6% to 10.7%) 
• referral was given increased significantly (from 8.3% of problems to 10.3%), particularly to medical 
specialists (5.5% to 6.2%), and allied health services (2.1% to 3.6%). There was a marginal 
increase in referrals to emergency departments, from 0.1% to 0.2% of problems 
• imaging test was ordered increased from 5.5% to 6.4% 
• other investigation was ordered decreased marginally from 0.7% to 0.5%.  
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
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s 
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.7
) 
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) 
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.2
) 
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.8
) 
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.1
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.7
) 
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.5
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.1
) 
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.8
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.4
) 
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.3
) 
 
15
.9
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.5
) 
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.1
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) 
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M
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ic
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 s
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al
is
t*
 
8.
0 
(7
.7
–8
.4
) 
 
8.
0 
(7
.6
–8
.3
) 
 
9.
0 
(8
.7
–9
.3
) 
 
8.
4 
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.1
–8
.8
) 
 
8.
6 
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.2
–9
.0
) 
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.2
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.9
) 
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9 
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.5
–9
.3
) 
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–9
.9
) 
 
9.
6 
(9
.2
–1
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9.
5 
(9
.1
–9
.9
) 

 
 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s*
 
3.
1 
(2
.9
–3
.3
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
9 
(3
.6
–4
.1
) 
 
3.
9 
(3
.7
–4
.2
) 
 
4.
2 
(3
.9
–4
.5
) 
 
4.
7 
(4
.4
–5
.0
) 
 
4.
7 
(4
.4
–5
.0
) 
 
4.
9 
(4
.6
–5
.2
) 
 
5.
2 
(4
.9
–5
.5
) 
 
5.
6 
(5
.2
–6
.0
) 

 
 
H
os
pi
ta
l* 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
 
E
m
er
ge
nc
y 
de
pa
rtm
en
t*
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
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(0
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–0
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) 
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(0
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.6
) 
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) 
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—
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m
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m
a
n
a
g
e
m
e
n
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a
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 p
e
r 
1
0
0
 e
n
c
o
u
n
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0
0
6
–
0
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o
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0
1
5
–
1
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R
a
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 p
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1
0
0
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n
c
o
u
n
te
rs
 (
9
5
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0
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0
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0
1
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0
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2
0
1
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
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a
n
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g
e
m
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p
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1
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0
5
) 
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5
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9
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6
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8
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0
1
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4
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5
,8
3
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 =
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9
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3
0
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8
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6
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5
,8
7
9
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8
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2
8
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7
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9
8
) 
P
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0.
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.4
) 
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.0
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
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
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(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4 
<h
dl
.h
an
dl
e.
ne
t/2
12
3/
15
48
2>
).
 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; O
T
C
 –
 o
ve
r-
th
e-
co
un
te
r.
 
70
  
T
a
b
le
 8
.2
a
: 
P
ro
b
le
m
s
 f
o
r 
w
h
ic
h
 a
t 
le
a
s
t 
o
n
e
 m
a
n
a
g
e
m
e
n
t 
a
c
ti
o
n
 w
a
s
 r
e
c
o
rd
e
d
 (
p
e
r 
c
e
n
t 
o
f 
p
ro
b
le
m
s
),
 2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
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en
t t
yp
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6–
86
.9
) 
 
86
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(8
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6–
86
.9
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85
.8
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1–
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(8
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3–
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(8
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.9
) 
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85
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.0
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85
.7
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86
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—
 
 
M
ed
ic
at
io
n 
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 o
th
er
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at
m
en
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.8
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0.
9–
72
.6
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(7
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) 
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P
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n 
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.6
) 
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A
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5.
8 
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(4
.9
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.1
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(5
.4
–6
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6.
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.7
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) 
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1 
(4
.7
–5
.4
) 
 
5.
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(5
.1
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) 
 
6.
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(5
.8
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O
th
er
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t 
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(2
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8–
28
.2
) 
 
30
.2
 
(2
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.4
) 
 
29
.3
 
(2
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.4
) 
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.3
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.7
) 
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.4
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1–
31
.7
) 
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.9
) 
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9.
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.9
) 
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.6
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) 
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.4
 
(2
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) 
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.2
 
(3
0.
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.5
) 
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C
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ic
al
* 
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.1
 
(1
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0–
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.1
) 
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.7
 
(1
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.7
) 
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.0
 
(1
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0–
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) 
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.6
 
(1
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.8
) 
 
20
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) 
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.4
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) 
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.1
 
(1
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.3
) 
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.4
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0.
3–
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) 
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.9
 
(1
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8–
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) 
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.5
 
(2
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2–
23
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) 
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P
ro
ce
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ra
l* 
9.
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(9
.1
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0.
1)
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.3
 
(9
.8
–1
0.
8)
 
 
10
.1
 
(9
.7
–1
0.
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.6
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) 
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.3
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.9
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) 
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R
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er
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is
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3 
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) 
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) 
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(8
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8.
7 
(8
.4
–9
.0
) 
 
9.
2 
(8
.9
–9
.5
) 
 
9.
3 
(9
.0
–9
.7
) 
 
9.
5 
(9
.1
–9
.8
) 
 
9.
8 
(9
.5
–1
0.
2)
 
 
10
.2
 
(9
.8
–1
0.
5)
 
 
10
.3
 
(1
0.
0–
10
.7
) 

 
 
 
M
ed
ic
al
 s
pe
ci
al
is
t*
 
5.
5 
(5
.3
–5
.8
) 
 
5.
3 
(5
.1
–5
.5
) 
 
5.
9 
(5
.7
–6
.1
) 
 
5.
6 
(5
.4
–5
.8
) 
 
5.
7 
(5
.5
–5
.9
) 
 
5.
6 
(5
.4
–5
.9
) 
 
5.
8 
(5
.5
–6
.1
) 
 
6.
1 
(5
.9
–6
.3
) 
 
6.
3 
(6
.0
–6
.5
) 
 
6.
2 
(6
.0
–6
.5
) 

 
 
 
A
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 h
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–0
.1
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 

 
 
 
O
th
er
 re
fe
rr
al
s*
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 

 
 
In
ve
st
ig
at
io
n 
18
.2
 
(1
7.
7–
18
.7
) 
 
18
.1
 
(1
7.
6–
18
.6
) 
 
18
.5
 
(1
8.
0–
19
.0
) 
 
18
.1
 
(1
7.
6–
18
.6
) 
 
18
.2
 
(1
7.
7–
18
.7
) 
 
18
.6
 
(1
8.
1–
19
.2
) 
 
18
.6
 
(1
8.
1–
19
.2
) 
 
19
.1
 
(1
8.
6–
19
.6
) 
 
19
.0
 
(1
8.
5–
19
.5
) 
 
19
.2
 
(1
8.
6–
19
.7
) 
—
 
 
 
P
at
ho
lo
gy
 o
rd
er
 
13
.4
 
(1
3.
0–
13
.9
) 
 
13
.1
 
(1
2.
7–
13
.6
) 
 
13
.6
 
(1
3.
2–
14
.0
) 
 
13
.2
 
(1
2.
8–
13
.7
) 
 
13
.3
 
(1
2.
9–
13
.7
) 
 
13
.6
 
(1
3.
1–
14
.1
) 
 
13
.5
 
(1
3.
1–
14
.0
) 
 
13
.9
 
(1
3.
5–
14
.3
) 
 
13
.4
 
(1
3.
0–
13
.8
) 
 
13
.7
 
(1
3.
2–
14
.1
) 
—
 
 
 
Im
ag
in
g 
or
de
r 
5.
5 
(5
.3
–5
.7
) 
 
5.
7 
(5
.4
–5
.9
) 
 
5.
7 
(5
.4
–5
.9
) 
 
5.
7 
(5
.5
–6
.0
) 
 
5.
7 
(5
.5
–5
.9
) 
 
5.
8 
(5
.6
–6
.1
) 
 
5.
9 
(5
.7
–6
.2
) 
 
6.
1 
(5
.9
–6
.4
) 
 
6.
6 
(6
.3
–6
.8
) 
 
6.
4 
(6
.1
–6
.6
) 

 
 
 
O
th
er
 in
ve
st
ig
at
io
n 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4 
<h
dl
.h
an
dl
e.
ne
t/2
12
3/
15
48
2>
).
 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; O
T
C
 –
 o
ve
r-
th
e-
co
un
te
r.
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T
a
b
le
 8
.2
b
: 
P
ro
p
o
rt
io
n
 o
f 
to
ta
l 
e
n
c
o
u
n
te
rs
 a
t 
w
h
ic
h
 a
t 
le
a
s
t 
o
n
e
 m
a
n
a
g
e
m
e
n
t 
a
c
ti
o
n
 w
a
s
 r
e
c
o
rd
e
d
 (
p
e
r 
c
e
n
t 
o
f 
e
n
c
o
u
n
te
rs
),
 2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
o
f 
e
n
c
o
u
n
te
rs
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 

(a
)  
 
 
A
t 
le
a
s
t 
o
n
e
…
 
(n
 =
 9
1
,8
0
5
) 
 
(n
 =
 9
5
,8
9
8
) 
 
(n
 =
 9
6
,6
8
8
) 
 (
n
 =
 1
0
1
,3
4
9
) 
 
(n
 =
 9
5
,8
3
9
) 
 
(n
 =
 9
9
,0
3
0
) 
 
(n
 =
 9
8
,5
6
4
) 
 
(n
 =
 9
5
,8
7
9
) 
 
(n
 =
 9
8
,7
2
8
) 
 
(n
 =
 9
7
,3
9
8
) 
M
an
ag
em
en
t t
yp
e 
90
.4
 
(8
9.
8–
91
.0
) 
 
91
.9
 
(9
1.
3–
92
.4
) 
 
92
.2
 
(9
1.
7–
92
.7
) 
 
91
.3
 
(9
0.
7–
91
.9
) 
 
91
.5
 
(9
0.
8–
92
.1
) 
 
91
.9
 
(9
1.
3–
92
.5
) 
 
90
.7
 
(9
0.
1–
91
.3
) 
 
91
.3
 
(9
0.
7–
92
.0
) 
 
90
.8
 
(9
0.
2–
91
.4
) 
 
91
.6
 
(9
0.
9–
92
.2
) 
—
 
 
M
ed
ic
at
io
n 
or
 o
th
er
 
 
tre
at
m
en
t 
79
.9
 
(7
9.
1–
80
.8
) 
 
82
.2
 
(8
1.
4–
82
.9
) 
 
82
.4
 
(8
1.
7–
83
.1
) 
 
81
.6
 
(8
0.
8–
82
.4
) 
 
81
.4
 
(8
0.
5–
82
.3
) 
 
81
.9
 
(8
1.
1–
82
.8
) 
 
80
.5
 
(7
9.
6–
81
.3
) 
 
80
.9
 
(8
0.
1–
81
.8
) 
 
79
.8
 
(7
8.
8–
80
.7
) 
 
81
.0
 
(8
0.
1–
81
.9
) 
—
 
 
 
M
ed
ic
at
io
n 
 
63
.9
 
(6
3.
0–
64
.9
) 
 
64
.4
 
(6
3.
4–
65
.3
) 
 
65
.1
 
(6
4.
3–
65
.9
) 
 
64
.6
 
(6
3.
6–
65
.5
) 
 
64
.7
 
(6
3.
8–
65
.6
) 
 
65
.1
 
(6
4.
2–
66
.0
) 
 
62
.8
 
(6
1.
9–
63
.7
) 
 
62
.1
 
(6
1.
2–
63
.0
) 
 
62
.3
 
(6
1.
4–
63
.3
) 
 
62
.7
 
(6
1.
8–
63
.6
) 
—
 
 
 
 
P
re
sc
rip
tio
n 
54
.1
 
(5
3.
2–
55
.1
) 
 
53
.6
 
(5
2.
6–
54
.5
) 
 
54
.6
 
(5
3.
7–
55
.5
) 
 
52
.4
 
(5
1.
3–
53
.4
) 
 
54
.3
 
(5
3.
3–
55
.2
) 
 
54
.5
 
(5
3.
5–
55
.5
) 
 
52
.8
 
(5
1.
8–
53
.7
) 
 
52
.1
 
(5
1.
2–
53
.1
) 
 
53
.1
 
(5
2.
1–
54
.0
) 
 
51
.9
 
(5
1.
0–
52
.8
) 

 
 
 
 
G
P
-s
up
pl
ie
d 
6.
8 
(6
.3
–7
.3
) 
 
7.
9 
(7
.4
–8
.4
) 
 
8.
5 
(7
.9
–9
.1
) 
 
10
.5
 
(9
.8
–1
1.
2)
 
 
8.
0 
(7
.4
–8
.6
) 
 
7.
4 
(6
.9
–7
.9
) 
 
7.
7 
(7
.1
–8
.2
) 
 
8.
3 
(7
.6
–9
.0
) 
 
6.
1 
(5
.7
–6
.6
) 
 
7.
4 
(6
.7
–8
.0
) 
§ 
 
 
 
A
dv
is
ed
 O
TC
 
8.
4 
(7
.8
–8
.9
) 
 
8.
9 
(8
.3
–9
.6
) 
 
8.
0 
(7
.5
–8
.5
) 
 
8.
3 
(7
.6
–8
.9
) 
 
8.
6 
(8
.0
–9
.2
) 
 
9.
3 
(8
.9
–9
.9
) 
 
8.
2 
(7
.5
–9
.0
) 
 
7.
8 
(7
.2
–8
.4
) 
 
8.
3 
(7
.7
–8
.9
) 
 
9.
3 
(8
.7
–9
.9
) 
—
 
 
 
O
th
er
 tr
ea
tm
en
t 
35
.3
 
(3
3.
8–
36
.9
) 
 
39
.9
 
(3
8.
3–
41
.4
) 
 
39
.6
 
(3
8.
3–
41
.0
) 
 
40
.3
 
(3
8.
5–
42
.0
) 
 
40
.1
 
(3
8.
4–
41
.7
) 
 
40
.5
 
(3
8.
9–
42
.1
) 
 
40
.7
 
(3
9.
0–
42
.3
) 
 
42
.6
 
(4
1.
0–
44
.2
) 
 
39
.4
 
(3
7.
8–
41
.0
) 
 
42
.3
 
(4
0.
6–
43
.9
) 

 
 
 
 
C
lin
ic
al
* 
23
.9
 
(2
2.
5–
25
.3
) 
 
27
.6
 
(2
6.
1–
29
.0
) 
 
27
.4
 
(2
6.
0–
28
.7
) 
 
27
.7
 
(2
6.
1–
29
.3
) 
 
28
.0
 
(2
6.
4–
29
.6
) 
 
28
.5
 
(2
7.
0–
30
.1
) 
 
28
.4
 
(2
6.
8–
30
.0
) 
 
29
.4
 
(2
7.
9–
30
.9
) 
 
26
.9
 
(2
5.
4–
28
.3
) 
 
29
.9
 
(2
8.
3–
31
.5
) 

 
 
 
 
P
ro
ce
du
ra
l* 
13
.8
 
(1
3.
1–
14
.4
) 
 
15
.0
 
(1
4.
3–
15
.7
) 
 
15
.0
 
(1
4.
4–
15
.6
) 
 
15
.6
 
(1
4.
7–
16
.5
) 
 
15
.0
 
(1
4.
3–
15
.7
) 
 
15
.1
 
(1
4.
4–
15
.8
) 
 
15
.5
 
(1
4.
8–
16
.2
) 
 
16
.7
 
(1
6.
0–
17
.4
) 
 
15
.4
 
(1
4.
7–
16
.0
) 
 
15
.8
 
(1
5.
0–
16
.5
) 

 
 
R
ef
er
ra
ls
 &
 a
dm
is
si
on
s 
11
.5
 
(1
1.
0–
11
.9
) 
 
11
.8
 
(1
1.
3–
12
.2
) 
 
12
.8
 
(1
2.
3–
13
.2
) 
 
12
.4
 
(1
1.
9–
12
.9
) 
 
13
.0
 
(1
2.
5–
13
.5
) 
 
13
.3
 
(1
2.
8–
13
.8
) 
 
13
.5
 
(1
3.
0–
14
.1
) 
 
14
.4
 
(1
3.
9–
14
.9
) 
 
14
.5
 
(1
4.
0–
15
.1
) 
 
14
.7
 
(1
4.
1–
15
.3
) 

 
 
 
M
ed
ic
al
 s
pe
ci
al
is
t*
 
7.
7 
(7
.4
–8
.0
) 
 
7.
7 
(7
.4
–8
.0
) 
 
8.
6 
(8
.3
–8
.9
) 
 
8.
1 
(7
.7
–8
.5
) 
 
8.
2 
(7
.9
–8
.6
) 
 
8.
2 
(7
.9
–8
.5
) 
 
8.
5 
(8
.1
–8
.9
) 
 
9.
1 
(8
.7
–9
.4
) 
 
9.
1 
(8
.7
–9
.5
) 
 
9.
1 
(8
.7
–9
.4
) 

 
 
 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s*
 
3.
0 
(2
.8
–3
.1
) 
 
3.
3 
(3
.1
–3
.5
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
9 
(3
.7
–4
.2
) 
 
4.
3 
(4
.1
–4
.6
) 
 
4.
3 
(4
.1
–4
.6
) 
 
4.
6 
(4
.4
–4
.9
) 
 
4.
8 
(4
.5
–5
.1
) 
 
5.
2 
(4
.8
–5
.5
) 

 
 
 
H
os
pi
ta
l* 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
(c
o
n
ti
n
u
e
d
) 
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T
a
b
le
 8
.2
b
 (
c
o
n
ti
n
u
e
d
):
 P
ro
p
o
rt
io
n
 o
f 
to
ta
l 
e
n
c
o
u
n
te
rs
 a
t 
w
h
ic
h
 a
t 
le
a
s
t 
o
n
e
 m
a
n
a
g
e
m
e
n
t 
a
c
ti
o
n
 w
a
s
 r
e
c
o
rd
e
d
 (
p
e
r 
c
e
n
t 
o
f 
e
n
c
o
u
n
te
rs
),
 2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
o
f 
e
n
c
o
u
n
te
rs
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 

(a
)  
 
 
A
t 
le
a
s
t 
o
n
e
 …
 
(n
 =
 9
1
,8
0
5
) 
 
(n
 =
 9
5
,8
9
8
) 
 
(n
 =
 9
6
,6
8
8
) 
 (
n
 =
 1
0
1
,3
4
9
) 
 
(n
 =
 9
5
,8
3
9
) 
 
(n
 =
 9
9
,0
3
0
) 
 
(n
 =
 9
8
,5
6
4
) 
 
(n
 =
 9
5
,8
7
9
) 
 
(n
 =
 9
8
,7
2
8
) 
 
(n
 =
 9
7
,3
9
8
) 
 
 
E
m
er
ge
nc
y 
 
 
de
pa
rtm
en
t*
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 

 
 
 
O
th
er
 re
fe
rr
al
s*
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 

 
 
In
ve
st
ig
at
io
n 
23
.5
 
(2
2.
8–
24
.2
) 
 
23
.8
 
(2
3.
1–
24
.5
) 
 
24
.6
 
(2
3.
9–
25
.3
) 
 
24
.2
 
(2
3.
5–
24
.9
) 
 
24
.1
 
(2
3.
4–
24
.8
) 
 
24
.7
 
(2
4.
0–
25
.4
) 
 
24
.7
 
(2
4.
0–
25
.5
) 
 
26
.1
 
(2
5.
3–
26
.8
) 
 
25
.4
 
(2
4.
7–
26
.1
) 
 
25
.6
 
(2
4.
9–
26
.3
) 

 
 
 
P
at
ho
lo
gy
 o
rd
er
 
17
.4
 
(1
6.
8–
18
.0
) 
 
17
.4
 
(1
6.
7–
18
.0
) 
 
18
.2
 
(1
7.
6–
18
.8
) 
 
17
.7
 
(1
7.
1–
18
.3
) 
 
17
.8
 
(1
7.
2–
18
.4
) 
 
18
.1
 
(1
7.
4–
18
.7
) 
 
18
.1
 
(1
7.
4–
18
.7
) 
 
19
.1
 
(1
8.
4–
19
.7
) 
 
18
.1
 
(1
7.
5–
18
.7
) 
 
18
.4
 
(1
7.
8–
19
.0
) 
—
 
 
 
Im
ag
in
g 
or
de
r 
7.
9 
(7
.6
–8
.2
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
5 
(8
.1
–8
.8
) 
 
8.
5 
(8
.2
–8
.9
) 
 
8.
4 
(8
.0
–8
.7
) 
 
8.
6 
(8
.3
–9
.0
) 
 
8.
8 
(8
.4
–9
.2
) 
 
9.
3 
(9
.0
–9
.7
) 
 
9.
8 
(9
.4
–1
0.
1)
 
 
9.
4 
(9
.1
–9
.8
) 

 
 
 
O
th
er
 in
ve
st
ig
at
io
n 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
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 9 Medications 
This chapter summarises the medications prescribed, advised or supplied by general practitioners in 
each year of the BEACH study from 2006–07 to 2015–16. The direction and type of change over the 
study period is indicated for each result in the far right column of the tables: / indicates a 
statistically significant change (increase or decrease) in 2015–16 compared with 2006–07; / 
indicates a marginally significant change in 2015–16 compared with 2006–07; — indicates there was 
no significant change in 2015–16 compared with 2006–07; and § indicates a noteworthy change 
during the decade. 
Significant change in the rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the number of prescribed, supplied, or advised medications between the first 
and last years of the study period. Some examples of extrapolated changes are given in this chapter. 
The method used to extrapolate to national change estimates is described fully in Section 2.9. In 
2015–16, there were 39.6 million more encounters claimed through Medicare than there were in 
2006–07 (143.0 million versus 103.4 million). It should be noted that because of this increase, it is 
possible that a significant decrease in a medication rate per 100 encounters can still result in an 
increase in the extrapolated national estimates of that medication over time.  
GPs could record up to four medications for each of four problems – a maximum of 16 medications per 
encounter. Each medication could be recorded as prescribed (the default), supplied by the GP, or 
recommended for over-the-counter (OTC) purchase. More detailed analyses of medication recorded in 
BEACH in 2015–16 can be found in Chapter 9 of General practice activity in Australia 2015–16.1 
Medication data for the 10 years 2006–07 to 2015–16, are reported in two ways in this chapter: as 
rates per 100 problems managed and as rates per 100 encounters. In describing data over time, the 
rates per 100 problems are reported as the primary measure, because there was a significant 
increase in the number of problems managed per encounter over the decade (see Chapter 7).  
The tables with rates per 100 encounters are included to show the basis for the extrapolations 
discussed above. On the other hand, changes discussed in the examples below are per 100 problems 
managed and are taken from results shown in the ‘a’ tables (Tables 9.1a, 9.2a, 9.3a, 9.4a, 9.5a and 
9.6a). The extrapolations are based on rate per 100 encounters so that they are equivalent to the 
national encounter data from Medicare. They therefore rely on results shown in the ‘b’ tables (Tables 
9.1b, 9.2b, 9.3b, 9.4b, 9.5b and 9.6b). 
Overall, there was no significant change in the rate of total medications (prescribed, supplied or 
advised) per 100 problems managed or per 100 encounters between 2006–07 and 2015–16 (Tables 
9.1a and 9.1b). 
Figure 9.1 and Table 9.1a show that between 2006–07 and 2015–16, there was a significant decrease 
in prescribed medication rates per 100 problems managed. Table 9.1b shows this change was not 
significant per 100 encounters. 
GP-supplied medications showed no significant change per 100 problems managed or per 100 
encounters between the years 2006–07 and 2015–16, but there were fluctuations over the decade. A 
noteworthy increase was seen in 2008–09 and 2009–10, and a decrease was seen in 2014–15 
(Tables 9.1a and 9.1b).  
The rates at which GPs advised medications for OTC purchase remained stable over the decade as a 
rate per 100 problems managed, but a marginal increase was observed per 100 encounters (Tables 
9.1a and 9.1b). 
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Note: Data are drawn from Table 9.1a. 
Figure 9.1: All medications and prescribed medications: rates per 100 problems managed, 
2006–07 to 2015–16 (95% confidence intervals) 
9.1 Prescribed medications 
The rate at which medications were prescribed per 100 problems managed decreased significantly 
from 2006–07 (56.1 per 100 problems) to 2015–16 (53.1 per 100) (Table 9.1a). There was no 
significant change per 100 encounters (Table 9.1b). However, the extrapolated national effect of the 
increased number of encounters (described above) resulted in an estimated 31.1 million more 
prescriptions being given nationally by GPs in 2015–16 than in 2006–07. 
Tables 9.2a and 9.2b show prescribing rates of common drug groups over the 10-year period at ATC 
drug group Level 2, because this level is more consistent over time than the lower ATC levels. There 
were significant changes in GP prescribing rates per 100 problems managed for a wide range of drug 
groups (Table 9.2a). In particular, there were measured increases in the prescription rate of: 
• psychoanaleptics (the group includes antidepressants, psychostimulants and antidementia drugs), 
from 2.3 per 100 problems managed in 2006–07 to 2.8 in 2015–16. The extrapolated national 
effect of this change (calculated from the encounter rate from Table 9.2b) was about 2.7 million 
more prescriptions for drugs in this group given in 2015–16 than in 2006–07 
• drugs for acid-related digestive disorders, from 2.0 per 100 problems in 2006–07 to 2.4 in  
2015–16. The extrapolated national effect of this change was that about 2.2 million more 
prescriptions for drugs in this group were given in 2015–16 than in 2006–07 
• corticosteroids for systemic use, from 0.9 per 100 problems in 2006–07 to 1.2 in 2015–16, an 
estimated 1.4 million more prescriptions nationally in 2015–16 than in 2006–07 
• antiepileptics, from 0.4 per 100 problems in 2006–07 to 0.8 in 2015–16, with an extrapolated effect 
of 1.3 million more prescriptions nationally in 2015–16. 
0
10
20
30
40
50
60
70
80
2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15 2015–16
All medications
Prescribed medications
Rate per 100 problems managed 
 
BEACH data years  
76
  
There were also significant decreases in the prescribing rate per 100 problems managed for several 
drug groups. With the increase in number of Medicare encounters, the majority of estimates 
extrapolated from decreased medication rates represent a national increase in total prescriptions. As 
shown in Table 9.2a, significant decreases in the prescription rate per 100 problems were measured 
for:  
• antibacterials for systemic use, from 9.4 per 100 problems managed in 2006–07 to 8.3 in  
2015–16, but the extrapolated national effect of this change (calculated on the encounter rate from 
Table 9.2b) was that about 3.8 million more prescriptions for drugs in this group were given in 
2015–16 than in 2006–07, due to the increase in encounter numbers nationally 
• agents acting on the renin-angiotensin system, from 4.4 per 100 problems managed in 2006–07 to 
3.8 per 100 in 2015–16, but the estimated national effect of this change was 1.8 million more of 
these drugs prescribed over the decade due to the increase in encounter numbers 
• drugs for obstructive airway disease, from 2.5 per 100 problems managed in 2006–07 to 2.2 in 
2015–16, with an estimated national effect of about 940,000 more prescriptions for drugs in this 
group given in 2015–16 than in 2006–07  
• anti-inflammatory and antirheumatic products, from 2.4 per 100 problems in 2006–07 to 2.0 in 
2015–16, with an extrapolated national effect of about 570,000 more prescriptions for these 
products nationally in 2015–16 than in 2006–07 
• sex hormones and modulators of the genital system, from 2.0 per 100 problems in 2006–07 to 1.5 
in 2015–16, which led to an extrapolated national effect of about 190,000 more prescriptions for 
this drug group nationally in 2015–16 than in 2006–07 
• beta blocking agents, from 1.2 per 100 problems in 2006–07 to 1.0 in 2015–16, leading to an 
extrapolated national effect of about 280,000 more prescriptions for them nationally in 2015–16 
than in 2006–07 
• calcium channel blockers, from 1.4 per 100 problems in 2006–07 to 0.9 in 2015–16, leading to an 
extrapolated national effect of about 170,000 fewer prescriptions for them nationally in 2015–16 
than in 2006–07 
• ophthalmologicals, from 1.2 per 100 problems in 2006–07 to 0.8 in 2015–16, but resulted in an 
estimated increase of 100,000 prescriptions nationally in 2015–16 than in 2006–07 
• diuretics, from 0.9 per 100 problems in 2006–07 to 0.6 in 2015–16, an estimated decrease of 
160,000 fewer prescriptions given nationally in 2015–16 than in 2006–07. 
Some of the changes referred to here can be linked to changes in the patterns of morbidity managed. 
For example, the rise in psychoanaleptics coincides with the significant increase in management rates 
of depression. Other changes coincide with policy initiatives, such as the rise in rates of antiepileptic 
agents, which accelerated in 2013–14 when a new indication for subsidised access to one of these 
medications was added to the Pharmaceutical Benefits Scheme (PBS). 
Decreases in prescribing rates of drug groups can sometimes be linked to medications within the 
group becoming available over-the-counter (for example, salbutamol); becoming more likely to be 
supplied directly to the patient by the GP (for example, vaccines); or being included in combination 
medication products (for example, cardiovascular agents such as diuretics). The decrease in systemic 
antibacterials over the decade may be linked to improving public awareness of the negative effects of 
antibiotic overuse.  
When no statistically significant change occurs in a prescribing rate per 100 problems managed, or in 
rate per 100 encounters, there may still be a national increase due to the increased GP attendance 
rates. An example of this is the prescribing of analgesics, the rate of which did not change significantly 
over the study period. However, we estimate that due to the increase in GP attendances, about 
3.7 million more analgesics were prescribed in 2015–16 than in 2006–07.  
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Tables 9.3a and 9.3b show prescribed medication rates at the individual generic level. The same 
effect of the increased number of Medicare encounters over time applies to these individual drugs. 
There was a significant increase in the prescribing rate per 100 problems for a number of drugs, 
including:  
• the proton pump inhibitor esomeprazole, which rose from 0.7 per 100 problems in 2006–07 to 1.2 
per 100 in 2015–16, with an extrapolated national effect of 1.5 million more esomeprazole 
prescriptions given in 2015–16 than in 2006–07 (calculated from the encounter rate in Table 9.3b) 
• the opioid oxycodone, which increased from 0.6 per 100 problems managed in 2006–07 to 0.9 in 
2015–16, with an extrapolated national effect of about 1.2 million more prescriptions for 
oxycodone nationally in 2015–16 than 10 years earlier  
• the lipid modifying agent rosuvastatin, first listed on the PBS in December 2006, rose from less 
than 0.05 per 100 problems in 2006–07 to 0.9 per 100 in 2015–16, an estimated 1.8 million more 
prescriptions than in 2006–07 
• another proton pump inhibitor, pantoprazole, rose from 0.3 per 100 problems in 2006–07 to 0.5 in 
2015–16, an extrapolated increase of 620,000 more pantoprazole prescriptions between the two 
study points 
• oral tablets of the corticosteroid prednisolone, which rose significantly from 0.4 per 100 problems 
managed in 2006–07 to 0.5 in 2015–16, with an estimated increase of 520,000 nationally 
• the antiepileptic pregabalin, which was first listed in 2005 as an antiepileptic and in 2012 as a 
treatment for refractory neuropathic pain, rose from 0.0 to 0.5 per 100 problems, an estimated 
1.1 million more prescriptions in 2015–16 than 10 years earlier. There were an estimated 940,000 
more prescriptions for pregabalin in 2015–16 than in 2012–13. 
In 2015–16, a large number of medications were prescribed less frequently than in 2006–07, some 
decreases being associated with low-cost over-the-counter availability, particularly from supermarkets 
(for example, paracetamol); or becoming part of combination medications (for example, irbesartan). 
Some of the decreases observed in the prescription rate per 100 problems were for:  
• plain paracetamol, from 1.7 per 100 problems in 2006–07 to 1.1 per 100 problems in 2015–16, 
with an extrapolated national effect of about 260,000 fewer prescriptions for this medication 
nationally in 2015–16 than in 2006–07  
• paracetamol in combinations with codeine, from 1.3 per 100 problems in 2006–07 to 1.0 per 100 
problems in 2015–16, with this decrease showing an extrapolated national effect of about 77,000 
more prescriptions for these products nationally in 2015–16 than in 2006–07 (due to the increase 
in attendances) 
• the hypnotic drug, temazepam, from 0.7 per 100 problems to 0.6, giving an extrapolated national 
increase of 150,000 prescriptions between 2006–07 and 2015–16 
• the antibiotic macrolide, roxithromycin, from 0.9 to 0.5 per 100 problems, a decrease of 300,000 
prescriptions over the decade 
• the angiotensin II antagonist irbesartan, from 0.7 per 100 problems in 2006–07 to 0.4 in 2015–16, 
suggesting 30,000 fewer prescriptions nationally for irbesartan as a single agent in 2015–16 than 
in 2006–07.  
Number of repeats ordered 
The pattern of the number of repeat prescriptions recorded by GPs changed between 2006–07 and 
2015–16 (Table 9.4). There was a significant decrease in the proportion of prescribed medications 
with one, three or four repeats ordered. On the other hand, there was a significant increase in the 
proportion for which five repeats were recorded. The proportion of prescriptions given with five repeats 
increased from 33.0% in 2006–07 to 36.1% in 2015–16.  
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9.2 Medications supplied by GPs 
The rate of total GP-supplied medications per 100 problems managed showed no measurable change 
in 2015–16 compared with 2006–07 (Table 9.5a). The peak in 2009–10 and ebb in 2014–15 reflect: 
the high rate of influenza virus vaccine supplied in 2009–10 at the time of the H1N1 influenza 
pandemic, and the delay in availability of influenza vaccine in 2015. 
Table 9.5a shows rates per 100 problems managed of individual medications most frequently supplied 
by GPs between 2006–07 and 2015–16. Nine of the top 10 were vaccines, and rates of most 
childhood vaccines increased significantly. The peak in supply of influenza virus vaccine can be seen 
in 2009–10. There was also a significant decrease from 2013–14 to 2014–15 associated with the 
delay in supply of influenza vaccine in 2015 (late April instead of early March) causing the peak flu 
vaccination period to fall in the following study period. The significant decrease in immunisation as a 
problem managed in 2014–15 (Chapter 7) was also influenced by the change in influenza vaccination 
rate that year. The other change in GP-supplied medications was the rate of supply of vitamin B12, 
which increased significantly. 
9.3 Medications advised for over-the-counter 
purchase 
Table 9.6a shows the 10 medications most frequently advised for OTC purchase. There was no 
change in the rate per 100 problems managed for total advised OTC medications. However, 
significant increases were noted in advice for use of ibuprofen and vitamin D3 (cholecalciferol). 
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(8
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–1
0.
2)
 
 
10
.9
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
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e
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0
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9
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1
0
3
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1
0
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0
0
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1
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0
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0
0
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9
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(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; O
T
C
 –
 o
ve
r-
th
e-
co
un
te
r.
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y
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T
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 l
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b
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b
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0
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0
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2
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2
0
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0
1
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–
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0
1
5
–
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
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 =
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4
5
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o
n
ti
n
u
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s
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b
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y
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T
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 l
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v
e
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 p
e
r 
1
0
0
 p
ro
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 t
o
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R
a
te
 p
e
r 
1
0
0
 p
ro
b
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m
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9
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%
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T
C
 l
e
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0
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0
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
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 
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) 

 
O
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e 
N
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N
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N
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N
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N
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0.
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0.
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.1
–0
.2
) 
 
0.
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.2
–0
.3
) 
 
0.
4 
(0
.4
–0
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) 
 
0.
5 
(0
.4
–0
.6
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
 
Le
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no
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et
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–0
.7
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.6
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–0
.6
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.4
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.5
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.5
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.4
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.5
) 
 
0.
5 
(0
.4
–0
.5
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0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 

 
D
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lin
e 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
—
 
P
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ga
ba
lin
 
0.
0Ŧ
 
(0
.0
–0
.0
) 
 
0.
0Ŧ
 
(0
.0
–0
.0
) 
 
0.
1 
(0
.0
–0
.1
) 
 
0.
1 
(0
.0
–0
.1
) 
 
0.
1 
(0
.0
–0
.1
) 
 
0.
1 
(0
.1
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.1
) 
 
0.
1 
(0
.1
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0.
4 
(0
.3
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.4
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 

 
R
ox
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ro
m
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0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 

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ar
ta
n 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
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0.
6 
(0
.6
–0
.7
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0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
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.7
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0.
5 
(0
.5
–0
.6
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0.
5 
(0
.5
–0
.6
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0.
5 
(0
.4
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.5
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0.
4 
(0
.4
–0
.5
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
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(0
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0.
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(0
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0.
5 
(0
.4
–0
.5
) 
 
0.
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
 
(c
o
n
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n
u
e
d
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a
 (
c
o
n
ti
n
u
e
d
):
 M
o
s
t 
fr
e
q
u
e
n
tl
y
 p
re
s
c
ri
b
e
d
 m
e
d
ic
a
ti
o
n
s
 b
y
 C
A
P
S
 g
e
n
e
ri
c
 (
ra
te
 p
e
r 
1
0
0
 p
ro
b
le
m
s
),
 2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
R
a
te
 p
e
r 
1
0
0
 p
ro
b
le
m
s
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
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2
0
1
1
–
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2
0
1
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–
1
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2
0
1
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2
0
1
4
–
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2
0
1
5
–
1
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
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)  
 
 
G
e
n
e
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c
 d
ru
g
 
(n
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3
6
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3
3
) 
 
(n
 =
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4
5
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7
8
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 =
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4
9
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6
2
) 
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5
5
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7
3
) 
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4
6
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5
2
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8
6
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5
2
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5
1
,6
7
5
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5
3
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3
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 =
 1
5
0
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7
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G
e
n
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c
 m
e
d
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a
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o
n
s
 f
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q
u
e
n
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y
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s
c
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b
e
d
 i
n
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v
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u
s
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1 
(0
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) 

 
T
o
ta
l 
p
re
s
c
ri
b
e
d
  
m
e
d
ic
a
ti
o
n
s
 
5
6
.1
 
(5
4
.7
–
5
7
.4
) 
 
5
4
.5
 
(5
3
.2
–
5
5
.8
) 
 
5
5
.9
 
(5
4
.5
–
5
7
.2
) 
 
5
4
.4
 
(5
2
.8
–
5
6
.0
) 
 
5
5
.8
 
(5
4
.5
–
5
7
.1
) 
 
5
6
.5
 
(5
4
.9
–
5
8
.1
) 
 
5
3
.8
 
(5
2
.5
–
5
5
.1
) 
 
5
2
.8
 
(5
1
.5
–
5
4
.1
) 
 
5
5
.2
 
(5
3
.8
–
5
6
.5
) 
 
5
3
.1
 
(5
1
.9
–
5
4
.4
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
. 
(b
) 
D
oe
s 
no
t i
nc
lu
de
 p
re
dn
is
ol
on
e 
so
di
um
 p
ho
sp
ha
te
. 
Ŧ
 
R
at
es
 a
re
 r
ep
or
te
d 
to
 o
ne
 d
ec
im
al
 p
la
ce
. T
hi
s 
in
di
ca
te
s 
th
at
 th
e 
ra
te
 is
 le
ss
 th
an
 0
.0
5 
pe
r 
10
0 
pr
ob
le
m
s 
m
an
ag
ed
. 
N
o
te
: C
A
P
S
 –
 C
od
in
g 
A
tla
s 
fo
r 
P
ha
rm
ac
eu
tic
al
 S
ub
st
an
ce
s;
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
/A
 –
 n
ot
 a
pp
lic
ab
le
 (
th
at
 is
, d
ru
g 
w
as
 n
ot
 a
va
ila
bl
e 
at
 th
at
 ti
m
e)
. 
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b
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M
o
s
t 
fr
e
q
u
e
n
tl
y
 p
re
s
c
ri
b
e
d
 m
e
d
ic
a
ti
o
n
s
 b
y
 C
A
P
S
 g
e
n
e
ri
c
 (
ra
te
 p
e
r 
1
0
0
 e
n
c
o
u
n
te
rs
),
 2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
R
a
te
 p
e
r 
1
0
0
 e
n
c
o
u
n
te
rs
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
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0
9
–
1
0
 
 
2
0
1
0
–
1
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2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 

(a
)  
 
 
G
e
n
e
ri
c
 d
ru
g
 
(n
 =
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1
,8
0
5
) 
 
(n
 =
 9
5
,8
9
8
) 
 
(n
 =
 9
6
,6
8
8
) 
 (
n
 =
 1
0
1
,3
4
9
) 
 
(n
 =
 9
5
,8
3
9
) 
 
(n
 =
 9
9
,0
3
0
) 
 
(n
 =
 9
8
,5
6
4
) 
 
(n
 =
 9
5
,8
7
9
) 
 
(n
 =
 9
8
,7
2
8
) 
 
(n
 =
 9
7
,3
9
8
) 
A
m
ox
yc
ill
in
 
3.
3 
(3
.0
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) 
 
3.
5 
(3
.2
–3
.7
) 
 
3.
5 
(3
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.8
) 
 
3.
2 
(3
.0
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) 
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) 
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3.
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) 
 
2.
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3.
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) 
 
2.
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) 
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C
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at
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 d
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.0
5 
pe
r 
10
0 
pr
ob
le
m
s 
m
an
ag
ed
. 
N
o
te
: C
A
P
S
 –
 C
od
in
g 
A
tla
s 
fo
r 
P
ha
rm
ac
eu
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I –
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 10 Other treatments 
This chapter summarises other (non-pharmacological) treatments (including clinical and procedural 
treatments) provided at, or in conjunction with, recorded GP–patient encounters in each of the 10 
years of the BEACH study 2006–07 to 2015–16. Clinical and procedural treatments are defined in 
Appendix 4, Tables A4.3 and A4.4, available at <hdl.handle.net/2123/15482>. 
The survey form allowed GPs to record up to two other treatments for each problem managed at the 
encounter. Routine clinical measurements or observations, such as measurements of blood pressure 
and physical examinations, were not recorded if they were undertaken by the GP. However, GPs were 
instructed to record clinical measurements or observations if these were undertaken by the practice 
nurse (PN) or Aboriginal health worker (AHW) in conjunction with the GP at the encounter. 
All ‘other treatments’ are reported, irrespective of whether they were done by the GP or by the 
PN/AHW at the encounter. That is, all non-pharmacological management provided at general practice 
patient encounters is described, rather than management provided specifically by the GP. In the 
analysis of procedural treatments (Section 10.2), injections given in the provision of vaccines were 
removed, as this action has already been counted and reported in Section 9.2. 
Other treatments data for the 10 years from 2006–07 to 2015–16, are reported in two ways: as rates 
per 100 problems managed (for example, Table 10.1a) and as rates per 100 encounters (for example, 
Table 10.1b). In describing changes over time, the rates per 100 problems are reported as the primary 
measure, because there was a significant increase in the number of problems managed per encounter 
over the study period – this increases the chance one or more other treatments would be given at the 
encounter. 
The direction and type of change from 2006–07 to 2015–16 is indicated for each result in the far right 
column of the tables: / indicates a statistically significant change (increase or decrease) comparing 
2015–16 with 2006–07; / indicates a marginally significant change comparing 2015–16 with  
2006–07; — indicates there was no significant change across the decade; and § indicates no change 
comparing 2015–16 with 2006–07 but a noteworthy change within the decade. 
Changes in the rate per 100 encounters are extrapolated to estimate the national increase or 
decrease in the other treatments provided between 2006–07 and 2015–16. Examples of extrapolated 
change are given. The method used to extrapolate to national change estimates is described in 
Section 2.9. Readers interested in the national impact of a specific measured change can apply this 
extrapolation method to any reported change. 
More detailed analyses of other treatments recorded in BEACH in 2015–16 can be found in 
Chapter 10 of General practice activity in Australia 2015–16.1 
Figure 10.1 shows there was a significant increase in the rate at which clinical treatments were 
provided per 100 problems managed from 2006–07 to 2007–08. The rate then remained relatively 
steady, but again rose significantly in 2015–16.  
Comparing 2015–16 with 2006–07, there was no significant change in the rate at which procedural 
treatments were performed over the decade, peaking in 2013–14, but remaining steady in other years.  
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Note: Data are drawn from Tables 10.1a and 10.3a. 
Figure 10.1: Clinical and procedural treatments per 100 problems, 2006–07 to 2015–16 
(95% confidence intervals) 
10.1 Clinical treatments  
From 2006–07 to 2015–16, there was a significant increase in the rate at which clinical treatments 
were provided at GP–patient encounters, from 19.9 per 100 problems managed to 25.0 per 100 
problems managed. However, this increase largely occurred between 2006–07 and 2007–08, and in 
the final BEACH year of 2015–16 (Table 10.1a).  
• General advice and education was the most frequently recorded clinical treatment throughout the 
decade. There was no significant change in the rate between 2006–07 (3.9 per 100 problems 
managed) and 2015–16 (4.1 per 100). The rates at which GPs provided counselling about the 
problem, and psychological counselling did not change over the study period. 
• The rates at which both advice/education about treatment, and about medication were provided, 
significantly increased over the decade.  
• While the provision of sickness certificates remained steady over the decade, other administrative 
procedures/documentations almost doubled, from 0.9 per 100 problems to 1.7 per 100.  
• Counselling/advice about nutrition/weight remained steady at around 2 per 100 problems 
managed, but occasions of counselling about lifestyle almost tripled (from 0.3 per 100 problems 
managed to 0.8 per 100), as did counselling about health/body (0.1 to 0.4 per 100). 
• Over the decade, there was no change in the rate of counselling/advice about smoking, but there 
was a significant rise in such advice in the middle of the decade. 
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When these results are considered in terms of content of GP encounters, there was a 30% growth in 
provision of clinical treatments from 29.6 to 38.6 per 100 encounters (Table 10.1b). Extrapolation of 
this result to all Medicare-claimed encounters suggests that nationally in 2015–16, there were 
24.6 million more occasions of clinical treatments given by GPs than 10 years earlier. This was due to 
the increase in provision of clinical treatments + the increased number of problems managed per 
encounter over the decade (see Section 7.1) + the massive increase in the number of GP visits 
claimed through Medicare due to an increase in visit rate (see Table 2.1). 
In 2006–07, for every 100 GP–patient encounters in 2006–07, one or more clinical treatments were 
provided in the management of 26.8 problems. In 2015–16, this had significantly increased to 34.7 
problems per 100 encounters (Table 10.2). 
• In 2015–16, URTI was the most common problem managed with clinical treatment(s) and the 
frequency of clinical treatment management of URTI rose from 1.4 per 100 encounters in  
2006–07 to 1.9 per 100 in 2015–16.  
• There were significant increases in the rates at which clinical treatments were provided in 
management of: diabetes, back complaint, test results, general check-up, and sleep disturbance. 
Extrapolation of the diabetes result to all Medicare-claimed GP consultation items suggests that 
there were about 890,000 more occasions nationally where clinical treatment was provided in 
management of diabetes in 2015–16 than in 2006–07. 
• There was no change in the frequency of GP provision of clinical treatments at management 
occasions of: depression, hypertension, lipid disorders, gastroenteritis or obesity. 
10.2 Procedures undertaken  
There was a significant increase in the rate at which procedures were performed, from 10.2 per 100 
problems managed in 2006–07 to 11.4 per 100 in 2015–16 (Table 10.3a), and from 15.1 procedures 
per 100 encounters in 2006–07 to 17.6 per 100 in 2015–16 (Table 10.3b). The extrapolated effect of 
this increase is that nationally in 2015–16 there were an estimated 9.6 million more procedures 
undertaken at GP–patient encounters than there were a decade earlier. 
• The most frequently recorded group of procedures throughout the decade was excision/removal 
tissue/biopsy/destruction/debridement/cauterisation. In 2015–16, procedures in this group were 
provided at a rate of 2.0 per 100 problems managed. There was no significant change in this rate 
between 2006–07 and 2015–16. 
• There was a four-fold increase in the rate at which GPs recorded international normalised ratio 
(INR) tests (rising from 0.1 per 100 problems managed to 0.4 per 100 problems managed). When 
extrapolated on the basis of its increased rate per 100 encounters (Table 10.3b), we estimate 
there were approximately 900,000 more INR tests performed at GP encounters nationally in 
2015–16, than in 2006–07. 
• Significant increases were also apparent in rates of other preventive procedures/high risk 
medication, and local injection/infiltrations, per 100 problems managed. 
• In 2006–07, one or more procedures were used in the management of 14.3 problems per 100 
GP–patient encounters. By 2015–16, this had significantly increased to 16.5 problems per 100 
encounters (Table 10.4). Extrapolation of this result suggests that across Australia in 2015–16, 
there were about 8.8 million more occasions where one or more procedures were used than a 
decade earlier. 
• In 2015–16, laceration/cut was the most common problem managed with a procedural treatment 
(0.9 per 100 encounters) compared with 0.7 per 100 encounters 10 years earlier, though this 
change was only marginally significant.  
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T
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 d
ire
ct
io
n 
an
d 
ty
pe
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f c
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e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
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ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
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In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4,
 T
ab
le
 A
4.
3,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
15
48
2>
).
 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
.; 
N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
; e
xc
l –
 e
xc
lu
di
ng
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 r
at
e 
of
 m
or
e 
th
an
 o
r 
eq
ua
l t
o 
0.
5 
pe
r 
10
0 
en
co
un
te
rs
 in
 a
ny
 
ye
ar
, a
nd
 a
ny
 o
th
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
. 
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
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o
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(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
15
48
2>
).
 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
O
S
 –
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
; B
M
I –
 b
od
y 
m
as
s 
in
de
x.
 T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 ra
te
 o
f m
or
e 
th
an
 o
r 
eq
ua
l t
o 
0.
5 
pe
r 
10
0 
en
co
un
te
rs
 in
 
an
y 
ye
ar
, a
nd
 a
ny
 o
th
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
. 
104
  
T
a
b
le
 1
0
.3
a
: 
T
h
e
 m
o
s
t 
fr
e
q
u
e
n
t 
p
ro
c
e
d
u
ra
l 
tr
e
a
tm
e
n
ts
 (
ra
te
 p
e
r 
1
0
0
 p
ro
b
le
m
s
),
 2
0
0
6
–
0
7
 t
o
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0
1
5
–
1
6
 
 
R
a
te
 p
e
r 
1
0
0
 p
ro
b
le
m
s
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 

(a
)  
 
 
T
re
a
tm
e
n
t 
(n
 =
 1
3
6
,3
3
3
) 
 
(n
 =
 1
4
5
,0
7
8
) 
 
(n
 =
 1
4
9
,4
6
2
) 
 
(n
 =
 1
5
5
,3
7
3
) 
 
(n
 =
 1
4
6
,1
4
1
) 
 
(n
 =
 1
5
2
,2
8
6
) 
 
(n
 =
 1
5
2
,5
1
7
) 
 
(n
 =
 1
5
1
,6
7
5
) 
 
(n
 =
 1
5
3
,1
3
3
) 
 
(n
 =
 1
5
0
,2
7
9
) 
E
xc
is
io
n/
re
m
ov
al
 ti
ss
ue
/ 
bi
op
sy
/d
es
tru
ct
io
n/
 
de
br
id
em
en
t/c
au
te
ris
at
io
n*
 
2.
1 
(1
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.4
) 
 
2.
2 
(2
.0
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) 
 
2.
0 
(1
.8
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) 
 
1.
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(1
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) 
 
1.
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(1
.7
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) 
 
1.
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(1
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–1
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) 
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(1
.7
–2
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) 
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0 
(1
.8
–2
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) 
 
1.
9 
(1
.7
–2
.1
) 
 
2.
0 
(1
.8
–2
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) 
—
 
Lo
ca
l i
nj
ec
tio
n/
 
in
fil
tra
tio
n*
(b
)  
1.
3 
(1
.2
–1
.4
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
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(1
.5
–1
.8
) 
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(1
.4
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) 
 
1.
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(1
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(1
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–1
.7
) 
 
1.
6 
(1
.5
–1
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) 
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5 
(1
.4
–1
.6
) 
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7 
(1
.5
–1
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) 

 
D
re
ss
in
g/
pr
es
su
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/ 
co
m
pr
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si
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/ta
m
po
na
de
* 
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–1
.6
) 
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(1
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–1
.6
) 
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.5
–1
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.7
–1
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(1
.5
–1
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) 
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6 
(1
.5
–1
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) 
—
 
P
hy
si
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l m
ed
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e/
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io
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l* 
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) 

 
C
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– 
P
N
/A
H
W
* 
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) 
 
0.
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) 
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–0
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) 
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) 
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(0
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–0
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) 
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) 
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P
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 s
m
ea
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–0
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) 
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) 
 
0.
7 
(0
.6
–0
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) 
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) 
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.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/re
m
ov
e)
* 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 

 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/h
ig
h-
ris
k 
m
ed
ic
at
io
n*
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 

 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.3
–1
.1
) 
 
0.
5 
(0
.4
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
—
 
IN
R
 te
st
 
0.
1 
(0
.0
–0
.1
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
* 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
—
 
(c
o
n
ti
n
u
e
d
) 
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T
a
b
le
 1
0
.3
a
 (
c
o
n
ti
n
u
e
d
):
 T
h
e
 m
o
s
t 
fr
e
q
u
e
n
t 
p
ro
c
e
d
u
ra
l 
tr
e
a
tm
e
n
ts
 (
ra
te
 p
e
r 
1
0
0
 p
ro
b
le
m
s
),
 2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
R
a
te
 p
e
r 
1
0
0
 p
ro
b
le
m
s
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 

(a
)  
 
 
T
re
a
tm
e
n
t 
(n
 =
 1
3
6
,3
3
3
) 
 
(n
 =
 1
4
5
,0
7
8
) 
 
(n
 =
 1
4
9
,4
6
2
) 
 
(n
 =
 1
5
5
,3
7
3
) 
 
(n
 =
 1
4
6
,1
4
1
) 
 
(n
 =
 1
5
2
,2
8
6
) 
 
(n
 =
 1
5
2
,5
1
7
) 
 
(n
 =
 1
5
1
,6
7
5
) 
 
(n
 =
 1
5
3
,1
3
3
) 
 
(n
 =
 1
5
0
,2
7
9
) 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 

 
T
o
ta
l 
p
ro
c
e
d
u
ra
l 
tr
e
a
tm
e
n
ts
 
1
0
.2
 
(9
.7
–
1
0
.7
) 
 
1
1
.0
 
(1
0
.4
–
1
1
.5
) 
 
1
0
.8
 
(1
0
.3
–
1
1
.2
) 
 
1
1
.4
 
(1
0
.7
–
1
2
.1
) 
 
1
1
.0
 
(1
0
.5
–
1
1
.5
) 
 
1
1
.0
 
(1
0
.5
–
1
1
.5
) 
 
1
1
.2
 
(1
0
.6
–
1
1
.7
) 
 
1
1
.8
 
(1
1
.3
–
1
2
.4
) 
 
1
0
.9
 
(1
0
.5
–
1
1
.4
) 
 
1
1
.4
 
(1
0
.8
–
1
2
.1
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
. 
(b
) 
E
xc
lu
de
s 
al
l l
oc
al
 in
je
ct
io
n/
in
fil
tr
at
io
ns
 p
er
fo
rm
ed
 fo
r i
m
m
un
is
at
io
ns
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4,
 T
ab
le
s 
A
4.
4 
an
d 
A
4.
5,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
15
48
2>
).
 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; I
N
R
 –
 in
te
rn
at
io
na
l n
or
m
al
is
ed
 r
at
io
; P
N
 –
 p
ra
ct
ic
e 
nu
rs
e;
 A
H
W
 –
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 ra
te
 o
f m
or
e 
th
an
 o
r 
eq
ua
l t
o 
0.
5 
pe
r 
10
0 
en
co
un
te
rs
 in
 a
ny
 y
ea
r,
 a
nd
 a
ny
 o
th
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
. 
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0
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h
e
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o
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e
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u
e
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n
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2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
9 
(2
.6
–3
.1
) 
 
2.
5 
(2
.3
–2
.6
) 
 
2.
5 
(2
.4
–2
.7
) 

 
P
hy
si
ca
l m
ed
ic
in
e/
 
re
ha
bi
lit
at
io
n 
– 
al
l* 
1.
1 
(0
.9
–1
.3
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.5
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
4 
(1
.2
–1
.6
) 
 
1.
4 
(1
.2
–1
.7
) 
 
1.
4 
(1
.2
–1
.6
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
4 
(1
.2
–1
.6
) 
—
 
In
ci
si
on
/d
ra
in
ag
e/
flu
sh
in
g/
 
as
pi
ra
tio
n/
re
m
ov
al
 b
od
y 
flu
id
* 
1.
3 
(1
.1
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 

 
(c
o
n
ti
n
u
e
d
) 
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T
a
b
le
 1
0
.3
b
 (
c
o
n
ti
n
u
e
d
):
 T
h
e
 m
o
s
t 
fr
e
q
u
e
n
t 
p
ro
c
e
d
u
ra
l 
tr
e
a
tm
e
n
ts
 (
ra
te
 p
e
r 
1
0
0
 e
n
c
o
u
n
te
rs
),
 2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
R
a
te
 p
e
r 
1
0
0
 e
n
c
o
u
n
te
rs
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 

(a
)  
 
 
T
re
a
tm
e
n
t 
(n
 =
 9
1
,8
0
5
) 
 
(n
 =
 9
5
,8
9
8
) 
 
(n
 =
 9
6
,6
8
8
) 
 
(n
 =
 1
0
1
,3
4
9
) 
 
(n
 =
 9
5
,8
3
9
) 
 
(n
 =
 9
9
,0
3
0
) 
 
(n
 =
 9
8
,5
6
4
) 
 
(n
 =
 9
5
,8
7
9
) 
 
(n
 =
 9
8
,7
2
8
) 
 
(n
 =
 9
7
,3
9
8
) 
C
he
ck
-u
p 
– 
P
N
/A
H
W
* 
0.
2 
(0
.1
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.2
–0
.5
) 
 
0.
7 
(0
.3
–1
.0
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
6 
(0
.5
–0
.8
) 
 
0.
6 
(0
.5
–0
.8
) 
 
1.
0 
(0
.3
–1
.6
) 

 
P
ap
 s
m
ea
r*
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
0 
(0
.9
–1
.2
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/re
m
ov
e)
* 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/h
ig
h-
ris
k 
m
ed
ic
at
io
n*
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 

 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
0.
9 
(0
.7
–1
.0
) 
 
0.
9 
(0
.7
–1
.1
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
1 
(0
.5
–1
.7
) 
 
0.
8 
(0
.6
–1
.0
) 
 
0.
9 
(0
.7
–1
.1
) 
 
1.
0 
(0
.8
–1
.2
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
8 
(0
.6
–1
.0
) 
 
0.
7 
(0
.6
–0
.9
) 
—
 
IN
R
 te
st
 
0.
1 
(0
.1
–0
.2
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
* 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 

 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
0.
6 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
—
 
T
o
ta
l 
p
ro
c
e
d
u
ra
l 
tr
e
a
tm
e
n
ts
 
1
5
.1
 
(1
4
.3
–
1
5
.9
) 
 
1
6
.6
 
(1
5
.8
–
1
7
.5
) 
 
1
6
.7
 
(1
6
.0
–
1
7
.4
) 
 
1
7
.5
 
(1
6
.4
–
1
8
.5
) 
 
1
6
.8
 
(1
6
.0
–
1
7
.7
) 
 
1
6
.8
 
(1
6
.0
–
1
7
.7
) 
 
1
7
.3
 
(1
6
.4
–
1
8
.2
) 
 
1
8
.7
 
(1
7
.9
–
1
9
.6
) 
 
1
7
.0
 
(1
6
.2
–
1
7
.8
) 
 
1
7
.6
 
(1
6
.6
–
1
8
.7
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
. 
(b
) 
E
xc
lu
de
s 
al
l l
oc
al
 in
je
ct
io
n/
in
fil
tr
at
io
ns
 p
er
fo
rm
ed
 fo
r i
m
m
un
is
at
io
ns
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4,
 T
ab
le
s 
A
4.
4 
an
d 
A
4.
5,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
15
48
2>
).
 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
; I
N
R
 –
 in
te
rn
at
io
na
l n
or
m
al
is
ed
 r
at
io
; P
N
 –
 p
ra
ct
ic
e 
nu
rs
e;
 A
H
W
 –
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 ra
te
 o
f m
or
e 
th
an
 o
r 
eq
ua
l t
o 
0.
5 
pe
r 
10
0 
en
co
un
te
rs
 in
 a
ny
 y
ea
r,
 a
nd
 a
ny
 o
th
er
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
. 
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T
a
b
le
 1
0
.4
: 
T
h
e
 m
o
s
t 
c
o
m
m
o
n
 p
ro
b
le
m
s
 m
a
n
a
g
e
d
 w
it
h
 p
ro
c
e
d
u
ra
l 
tr
e
a
tm
e
n
ts
, 
2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
R
a
te
 a
t 
w
h
ic
h
 a
 s
e
le
c
te
d
 p
ro
b
le
m
 w
a
s
 m
a
n
a
g
e
d
 w
it
h
 o
n
e
 o
r 
m
o
re
 p
ro
c
e
d
u
ra
l 
tr
e
a
tm
e
n
ts
, 
p
e
r 
1
0
0
 e
n
c
o
u
n
te
rs
 (
9
5
%
 C
I)
 
 
 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 

(a
)  
 
 
P
ro
b
le
m
 m
a
n
a
g
e
d
 
(n
 =
 9
1
,8
0
5
) 
 
(n
 =
 9
5
,8
9
8
) 
 
(n
 =
 9
6
,6
8
8
) 
 
(n
 =
 1
0
1
,3
4
9
) 
 
(n
 =
 9
5
,8
3
9
) 
 
(n
 =
 9
9
,0
3
0
) 
 
(n
 =
 9
8
,5
6
4
) 
 
(n
 =
 9
5
,8
7
9
) 
 
(n
 =
 9
8
,7
2
8
) 
 
(n
 =
 9
7
,3
9
8
) 
La
ce
ra
tio
n/
cu
t 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 

 
Fe
m
al
e 
ge
ni
ta
l c
he
ck
-u
p/
 
P
ap
 s
m
ea
r*
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(0
.9
–1
.2
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
S
ol
ar
 k
er
at
os
is
/s
un
bu
rn
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
7 
(0
.6
–0
.8
) 

 
E
xc
es
si
ve
 e
ar
 w
ax
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
—
 
W
ar
ts
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
—
 
G
en
er
al
 c
he
ck
-u
p*
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 

 
M
al
ig
na
nt
 n
eo
pl
as
m
 o
f s
ki
n 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
—
 
C
hr
on
ic
 u
lc
er
 s
ki
n 
(in
cl
ud
in
g 
va
ric
os
e 
ul
ce
r)
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
—
 
A
tri
al
 fi
br
ill
at
io
n/
flu
tte
r 
0.
1 
(0
.1
–0
.1
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 

 
T
o
ta
l 
p
ro
b
le
m
s
 w
it
h
 
p
ro
c
e
d
u
re
s
 
1
4
.3
 
(1
3
.5
–
1
5
.0
) 
 
1
5
.6
 
(1
4
.8
–
1
6
.3
) 
 
1
5
.6
 
(1
4
.9
–
1
6
.2
) 
 
1
6
.3
 
(1
5
.4
–
1
7
.2
) 
 
1
5
.8
 
(1
5
.0
–
1
6
.5
) 
 
1
5
.7
 
(1
5
.0
–
1
6
.4
) 
 
1
6
.2
 
(1
5
.4
–
1
7
.0
) 
 
1
7
.6
 
(1
6
.8
–
1
8
.3
) 
 
1
6
.0
 
(1
5
.3
–
1
6
.8
) 
 
1
6
.5
 
(1
5
.6
–
1
7
.4
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
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 11 Referrals and admissions  
A referral is defined as the process by which the responsibility for part, or all, of the care of a patient is 
temporarily transferred to another health care provider. GPs were instructed only to record new 
referrals arising at the encounter (that is, not to record continuations). For each encounter, GPs could 
record up to two referrals, and each referral was linked by the GP to the problem(s) for which the 
patient was referred. Referrals included those to medical specialists, allied health services, hospitals 
for admission, emergency departments, and to other services (including outpatient clinics and other 
GPs). 
Referral data for the 10 years from 2006–07 to 2015–16, are reported in two ways: as rates per 100 
problems managed (Table 11.1a); and as rates per 100 encounters (Table 11.1b). In describing 
changes over time, the rates per 100 problems are reported as the primary measure, because there 
was a significant increase in the average number of problems managed per encounter over the study 
period reported here.  
The direction and type of change from 2006–07 to 2015–16 is indicated for each result in the far right 
column of the tables: / indicates a statistically significant change (increase or decrease) in  
2015–16 compared with 2006–07; / indicates a marginally significant change in 2015–16 
compared with 2006–07; — indicates there was no significant change in 2015–16 compared with 
2006–07; and § indicates a noteworthy change during the decade. Significant changes in the rate per 
100 encounters can be extrapolated to estimate the national increase or decrease in the measured 
event between 2006–07 and 2015–16. Examples of extrapolated change are given. The method used 
to extrapolate is described in Section 2.9. 
The number of GP–patient encounters claimed through the Medicare Benefits Schedule nationally 
increased by 38.3% between 2006–07 (103.4 million encounters) and 2015–16 (143.0 million 
encounters).6,9 As a result, a decreased rate of a particular ‘measured event’ per 100 encounters may 
occasionally yield a national increase in the estimated number of events. 
More specific analyses of referrals recorded by participating GPs in the 2015–16 BEACH year can be 
found in the companion report, General practice activity in Australia 2015–16.1 
11.1 Results 
Figure 11.1 illustrates the proportion of encounters and problems managed where one or more 
referrals were made, and referral rates per 100 encounters and per 100 problems, over the decade. 
As described in detail below, there was an increase in the likelihood that GP–patient encounters would 
involve one or more referrals, and that a problem being managed at encounter would be referred. 
There were also significant increases in the overall rates of referrals per 100 encounters and per 100 
problems managed.  
The likelihood that a problem being managed at encounter would be referred, increased significantly 
over the study period, with 8.3% of problems referred in 2006–07 and 10.3% in 2015–16. There was a 
significant increase in the overall rate of referrals, from 8.2 per 100 problems managed in 2006–07 to 
10.4 per 100 in 2015–16, largely due to increased referral rates to medical specialists and to allied 
health professionals (Table 11.1a).  
The rate of referral to medical specialists per 100 problems managed increased from 5.4 in 2006–07 
to 6.2 per 100 in 2015–16. There was a significant decrease in the rate of referrals to 
ophthalmologists, and marginally significant increases in referrals to dermatologists, cardiologists and 
psychiatrists. The significant increase in the overall referral rate to specialists reflects a slight increase 
across many specialist types.  
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The rate of referral to allied health services per 100 problems managed increased from 2.1 in 2006–07 
to 3.6 per 100 in 2015–16 (an increase of 71%). Strong contributions to the overall rate arose from a 
two and a half-fold increase in referrals to psychologists (from 0.3 to 0.8 per 100 problems) and a 
doubling of the rate of referrals to podiatrists/chiropodists (from 0.2 to 0.4). Referrals to 
physiotherapists and dietitians/nutritionists also increased (Table 11.1a). 
Table 11.1b also shows that over time there was an increased likelihood that GP–patient encounters 
would involve one or more referrals (11.5% involving a referral in 2006–07 and 14.7% in 2015–16). 
Overall, referrals increased significantly from 12.2 per 100 encounters in 2006–07, to 16.1 per 100 in 
2015–16. Extrapolation of this change suggests there were about 10.4 million more GP referrals 
nationally in 2015–16 than in 2006–07. These referrals included about 5.2 million more referrals to 
medical specialists and about 4.8 million more to allied health services. Of these 4.8 million additional 
allied health referrals, 1.4 million were to psychologists, probably largely due to the government’s 
introduction of the Better Outcomes44 and later the Better Access45 mental health programs. There 
were also about 1.2 million more referrals to physiotherapists, which may be due to more patients with 
chronic disease or due to government policy, such as the introduction of MBS item numbers for a 
limited number of physiotherapy services for selected patients referred by a GP.43 
 
 
 
 
 Note: Data are drawn from Tables 11.1a and 11.1b. 
Figure 11.1: Proportion of encounters and problems managed where referrals were made, 
and referral rates per 100 encounters and per 100 problems, 2006–07 to 2015–16 
(95% confidence intervals) 
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t c
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 c
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 c
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3/
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 12 Investigations 
Investigations ordered by GPs or undertaken in the practice for each of the 10 years from 2006–07 to 
2015–16, are reported in two ways: as rates per 100 problems managed (for example, Table 12.2a) 
and as rates per 100 encounters (for example, Table 12.2b). In the text describing changes over time, 
the rates per 100 problems are reported as the primary measure, because there was a significant 
increase over the decade in the number of problems managed per encounter.  
The direction and type of change from 2006–07 to 2015–16 is indicated for each result in the far right 
column of the tables: / indicates a statistically significant change (increase or decrease) in  
2015–16 compared with 2006–07; / indicates a marginally significant change in 2015–16 
compared with 2006–07; — indicates there was no significant change in 2015–16 compared with 
2006–07; and § indicates a noteworthy change during the decade. 
Significant changes in the rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the number of investigations ordered between 2006–07 and 2015–16. 
Examples of extrapolated change are given, and the method used is described in Section 2.9. 
The GPs participating in BEACH were asked to record (in free text) any pathology, imaging or other 
tests ordered or done at the encounter, and to nominate the patient problem(s) associated with each 
test order. This allows a test order to be linked to a single problem or multiple problems. Up to five 
orders for pathology and two for imaging and other tests could be recorded at each encounter. A 
single test may have been ordered for the management of multiple problems, and multiple tests may 
have been used in the management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a battery of 
tests (for example, lipids, full blood count). Where a battery of tests was ordered, the battery name 
was recorded rather than each individual test. GPs also recorded the body site for any imaging 
ordered (for example, x-ray chest, computerised tomography head). 
More detailed analyses of investigations ordered by GPs in 2015–16 can be found in Chapter 12 of 
General practice activity in Australia 2015–16.1 
Comprehensive investigation of GPs’ pathology and imaging ordering using BEACH data has been 
published in several reports. Interested readers may wish to consult: 
• a comprehensive report on pathology ordering by GPs in Australia in 1998, published on the 
internet by the then Department of Health and Aged Care46 
• a report on imaging orders by GPs in Australia in 1999–2000, published as an AIHW–University of 
Sydney book in the GP series in 200147 
• a report on changes in pathology ordering by GPs from 1998 to 2001, published as an AIHW–
University of Sydney book in the GP series in 200348 
• a review of pathology ordering in the National Health Priority Areas and other selected problems 
from 2000 to 2008, in General practice in Australia, health priorities and policies 1998 to 200849 
• the report Evidence-practice gap in GP pathology test ordering: a comparison of BEACH 
pathology data and recommended testing, prepared for the Australian Government Quality Use of 
Pathology Program in June 200950 
• a 2013 PhD thesis, Evaluation of pathology ordering by general practitioners in Australia51 
• the 2014 report, Evaluation of imaging ordering by general practitioners in Australia 2002–03 to 
2011–12, which described changes in GPs’ imaging ordering over time and evaluated the 
alignment between guidelines and GP test ordering for selected problems.52 This was funded by a 
grant from the Diagnostic Imaging Quality Program, Australian Government Department of Health. 
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12.1 Pathology ordering 
There was no change in the proportion of problems for which GPs ordered pathology, with at least one 
pathology test ordered for 13.4% of all problems managed in 2006–07 and 13.7% in 2015–16 (Table 
12.1a). Similarly, there was no change in the proportion of encounters involving at least one pathology 
test over the decade (17.4% of encounters in 2006–07 and 18.4% in 2015–16) (Table 12.1b).  
Readers should be aware that even with no change in GPs’ likelihood of ordering pathology tests, 
there was growth in the number of encounters involving pathology as the number of GP–patient 
encounters in Australia has increased from 103.4 to 143.0 million over the decade.6,9 The effect of this 
increase can be demonstrated by extrapolating the likelihood of pathology being ordered at 
encounters: in 2015–16 we estimate 26.3 million encounters involved pathology orders compared with 
18.0 million in 2006–07, an increase of 8.3 million over the decade. 
Figure 12.1 shows graphically the likelihood of ordering pathology at encounters and for problems, 
and the increased numbers of total pathology orders per 100 problems and per 100 encounters, over 
the 10 years to 2015–16. 
The number of pathology tests (or batteries of tests) ordered, increased from 28.6 per 100 problems 
managed in 2006–07 to 30.8 per 100 problems in 2015–16 (Table 12.2a). The number of tests 
ordered per 100 encounters increased from 42.4 tests (or batteries of tests) per 100 encounters in 
2006–07 to 47.6 in 2015–16 (Table 12.2b), which, when combined with the increase in GP attendance 
rate, extrapolates to approximately 24.2 million more tests (or batteries of tests) ordered in 2015–16 
than in 2006–07 nationally.  
Readers should consider the impact of the changes in the number and types of problems managed on 
the rates of pathology tests ordered by GPs. For example, the number of problems managed rose 
from 148.5 to 154.3 per 100 encounters (reported in Chapter 5), and has contributed to the increased 
testing rate per 100 encounters. 
In summary, the national increase in number of pathology tests ordered by GPs in Australia is not due 
to any change in the likelihood of GPs’ ordering pathology for a problem or at an encounter. Rather, it 
is due to the combined effect of: 
• the increased number of tests ordered when the decision to test was made, rising from an average 
2.21 tests/batteries per tested problem in 2006–0712 to 2.35 in 2015–161 
• the increased number of problems managed per encounter, rising from 148.5 to 154.3 per 100 
encounters over the decade (see Chapter 5) 
• the increased GP attendance rate in Australia.6,9  
Pathology test orders by MBS groups 
Tables 12.2a and 12.2b show the changes in the distribution of tests ordered by MBS pathology 
groups.53 
There were marginal increases in the rate of chemistry, immunology and ‘simple’ tests per 100 
problems managed. Order rates in all other test groups did not change over the decade (Table 12.2a). 
Orders for chemistry tests increased from 24.5 to 27.9 per 100 encounters, an increase of 14%. This 
extrapolates to an estimated 14.6 million more chemistry test orders nationally in 2015–16 than 10 
years earlier. Immunology tests increased from 0.7 to 0.9 per 100 encounters, extrapolating to an 
increase of about 560,000 additional test orders nationally in 2015–16 compared with a decade 
earlier. There were also marginal increases in tissue pathology and simple tests, and no changes in 
the other test groups (Table 12.2b). 
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 Note: Data are drawn from Tables 12.1a, 12.1b, 12.2a, and 12.2b. 
Figure 12.1: Proportion of encounters and problems where pathology was ordered, and pathology test 
order rates per 100 encounters and per 100 problems, 2006–07 to 2015–16 (95% confidence intervals) 
 
12.2 Imaging ordering 
Table 12.1a shows there was a significant increase in the proportion of problems for which imaging 
was ordered, from 5.5% in 2006–07 to 6.4% in 2015–16. Between 2006–07 and 2015–16, the number 
of problems managed per 100 encounters rose from 148.5 to 154.3 (Table 5.1). Both the rise in the 
proportion of problems generating imaging orders and the rise in the number of problems managed 
per encounter contributed to an overall increase in the proportion of encounters involving an imaging 
test (Table 12.1b). This increased from 7.9% in 2006–07 to 9.4% in 2015–16, resulting in an estimated 
5.3 million more encounters nationally at which imaging was ordered in 2015–16 than in 2006–07. 
Total imaging test orders increased significantly from 6.0 per 100 problems managed in 2006–07 to 
7.1 per 100 in 2015–16. The rate of imaging test orders per 100 encounters also increased 
significantly from 9.0 in 2006–07 to 11.0 in 2015–16 (Table 12.3b), an increase of 22%, equating to 
approximately 6.4 million more imaging orders nationally in 2015–16 than 10 years earlier. 
Figure 12.2 provides a graphical view of the change in the likelihood of GPs ordering imaging and the 
increases in the rates of imaging tests ordered per 100 problems and per 100 encounters over the 
10 years to 2015–16. 
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Imaging test orders by MBS group 
Tables 12.3a and 12.3b show the changes in imaging orders by MBS imaging group from 2006–07 to 
2015–16. There were changes in the types of imaging tests ordered, with a move away from 
diagnostic radiology toward ultrasound imaging. The rate of ultrasound orders increased by 52% over 
the decade, from 2.1 tests per 100 problems in 2006–07 to 3.2 per 100 in 2015–16. In contrast, the 
rate of diagnostic radiology marginally decreased (from 3.1 to 2.8 per 100 problems).  
There was also a significant increase in the order rate of magnetic resonance imaging (from less than 
0.05 per 100 problems in 2006–07 to 0.3 in 2015–16), and a marginal increase in the rate of 
computerised tomography (from 0.7 to 0.8 per 100 problems). The order rate of nuclear medicine 
decreased marginally over the decade (Table 12.3a). 
Ultrasound imaging orders increased from 3.2 tests per 100 encounters in 2006–07 to 4.9 per 100 in 
2015–16, a national increase of about 3.7 million ultrasound orders in 2015–16 than a decade earlier. 
Magnetic resonance imaging orders increased from less than 0.05 per 100 encounters in 2006–07 to 
0.5 in 2015–16. The order rate of computerised tomography increased marginally. Order rates of 
diagnostic radiology and nuclear medicine did not change over this period (Table 12.3b). 
 
 
 
Note: Data are drawn from Tables 12.1a, 12.1b, 12.3a, and 12.3b. 
Figure 12.2: Proportion of encounters and problems where imaging was ordered, and imaging test 
order rates per 100 encounters and per 100 problems, 2006–07 to 2015–16 (95% confidence intervals) 
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f c
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; 
/
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 c
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 13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of the 
population visit a GP at least once per year — in 2015–16, 86.8% of Australians visited a GP at least 
once (personal communication, DoH, May 2016). GPs have substantial knowledge of population 
health and screening programs. They are in an ideal position to advise patients about the benefits of 
health screening, and to individually counsel patients about their lifestyle choices. 
Since the beginning of the BEACH program (1998), a section on the bottom of each encounter form 
has been used to investigate aspects of patient health or healthcare delivery not covered by general 
practice encounter-based information. These additional substudies are referred to as Supplementary 
Analysis of Nominated Data (SAND). The SAND methods are described in Section 2.6. 
• In brief, measured patient risk factors included self-reported height and weight (to calculate body 
mass index or BMI), alcohol consumption and smoking status. Each GP completed risk factor 
questions for patients at a subsample of 40 encounters. An example of the encounter form with 
the patient risk factor SAND questions is provided in Appendix 1. The methods used to investigate 
each risk factor are summarised in this chapter. Further detail is provided in Chapter 13 of the 
companion report, General practice activity in Australia 2015–16.1 
This chapter includes unweighted data about the risk behaviours of general practice patients from 
each of the most recent 10 years of the BEACH study from 2006–07 to 2015–16 (Tables 13.1a, 13.2a, 
13.3a). Unweighted data are presented for comparability over time as this was reported in all annual 
reports. Medicare claims data (from DoH), were used to calculate more precise estimates of 
prevalence, after adjusting results to the general practice attending population. These data were only 
provided from 2007–08 onwards, so risk factor prevalence after adjustment for general practice 
attendance patterns by age–sex are presented for each of the 9 most recent years (Tables 13.1b, 
13.2b, 13.3b).  
The direction and type of change from 2006–07 to 2015–16 is indicated for each result in the far  
right column of the tables: / indicates a statistically significant change (increase or decrease) in 
2015–16 compared with 2006–07; / indicates a marginally significant change in 2015–16 
compared with 2006–07; — indicates there was no significant change in 2015–16 compared with 
2006–07; and § indicates a noteworthy change during the decade.  
13.1 Body mass index 
Patient BMI was investigated for a subsample of 40 patients per GP. Each GP was instructed to ask 
the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (feet and inches; stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) squared. 
The WHO recommendations54 for BMI groups were used, which specify that an adult (18 years and 
over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
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The BEACH data on BMI are presented separately for adults (aged 18 years and over) and children 
(aged 2–17 years). The standard BMI cut-offs described above were applied for the adult sample, and 
the method described by Cole et al. (2000 & 2007) was used for children (aged 2–17 years).55,56 
Adults 
Overall prevalence of overweight/obesity in adults sampled at general practice encounters increased 
significantly from 58.5% in 2006–07 (95% CI: 57.6–59.3) to 63.2% in 2015–16 (95% CI: 62.3–64.1) 
(results not tabulated). 
• The prevalence of obesity in adults rose from 23.5% in 2006–07 to 28.8% in 2015–16 
(Table 13.1a), and this significant increase was apparent among both male and female patients 
(Tables 13.2a and 13.3a). An increase in obesity was evident between 2006–07 and 2010–11 
(from 23.5% to 26.7%), prevalence was then static at about 27% for the 3 years 2010–11 to 
2012–13. Between 2012–13 and 2015–16, there was another significant increase noted (from 
26.6% to 28.8%). 
• In contrast, prevalence of overweight remained steady over the decade at about 35% of surveyed 
adult patients. 
• The proportion of adults who were in the normal weight range decreased significantly from 39.0% 
in 2006–07 to 34.6% in 2015–16 (Table 13.1a). This significant decrease was apparent among 
both males and females (Tables 13.2a and 13.3a). A decrease in normal weight was evident 
between 2006–07 and 2010–11 (from 39.0% to 35.8%), prevalence was then static at about 36% 
for the 3 years from 2010–11 to 2012–13. A further decrease occurred from 2012–13 to 2015–16 
(36.2% to 34.6%), corresponding with the increase in obesity. 
• There was a marginal decrease in the proportion of patients who were underweight, from 2.6% to 
2.2% over the decade (Table 13.1a). This marginal decrease was only apparent among female 
patients (Tables 13.2a and 13.3a).  
• In summary, for both male and female sampled patients between 2006–07 and 2015–16, there 
was a significant increase in the prevalence of obesity for both sexes and a corresponding 
decrease in normal weight. Effectively a significant proportion of patients moved from the normal 
weight range into the overweight range, and a similar proportion of those who were overweight 
moved into the obese weight range.  
• The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed an increase in prevalence of obesity between 2007–08 and 
2015–16, from 23.4% to 27.9%, and a corresponding decrease in the prevalence of normal 
weight, from 38.9% to 35.8% (Table 13.1b). This pattern was noted among both male and female 
patients (Tables 13.2b and 13.3b). Effectively a significant proportion of attending patients moved 
from the normal weight range into the overweight range, and a similar proportion of those who 
were overweight moved into the obese weight range.  
Children 
The prevalence of overweight and obesity among sampled children aged 2–17 years remained 
effectively static for the 10 years from 2006–07 to 2015–16 (around 18% and 10% respectively) 
(Table 13.1a). Similar patterns were present among both male and female children (Tables 13.2a and 
13.3a). 
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13.2 Smoking 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
Results 
There was a significant decrease in the rates of current daily smoking and occasional smoking among 
sampled adults aged 18 years and over attending general practice, from 16.1% and 3.2% respectively 
in 2006–07 to 13.3% and 2.1% in 2015–16 (Table 13.1a). These decreases occurred among both 
sexes (Tables 13.2a and 13.3a). There was also a significant increase in the proportion who had 
never smoked, from 51.9% in 2006–07 to 56.8% in 2015–16, also apparent among both male and 
female patients. 
Rates of daily smoking were significantly higher among male patients than among female patients in 
all years. In 2015–16, prevalence was 16.1% of males and 11.5% of females. 
The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed a significant decrease in prevalence of daily smoking and 
occasional smoking from 19.3% and 3.5% respectively in 2006–07 to 15.8% and 2.8% in 2015–16. A 
corresponding increase in prevalence was noted for patients who had never smoked from 51.5% to 
56.4% (Table 13.1b). The pattern noted for male patients was a significant decrease in daily smoking 
and corresponding increase in never smoking, and among female patients there was a significant 
decrease in occasional smoking and corresponding increase in never smoking (Tables 13.2b 
and 13.3b).  
13.3 Alcohol consumption 
To measure alcohol consumption, BEACH uses AUDIT-C,57 which is the first three items from the 
WHO Alcohol Use Disorders Identification Test (AUDIT),58 with scoring for an Australian setting.59 The 
AUDIT-C has demonstrated validity and internal consistency and performs as well as the full AUDIT 
tool.60 The three–AUDIT-C tool is practical and valid in a primary care setting to assess ‘at-risk’ alcohol 
consumption (heavy drinking and/or active alcohol dependence).57 The scores for each question range 
from zero to four. A total (sum of all three questions) score of five or more for males, or four or more 
for females, suggests that the person’s drinking level is placing him or her at risk.59 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion? 
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
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A standard drinks chart was provided to each GP to help the patient identify the number of standard 
drinks consumed. 
Results 
Rates of at-risk levels of alcohol consumption among sampled adults declined from about 27% in 
2006–07 to 23% in 2015–16. There was a corresponding increase in the proportion who were non-
drinkers, from about 28% in 2006–07 to 33% in 2015–16 (Table 13.1a). The significant decrease in at-
risk levels of alcohol consumption and increase in non-drinking was apparent among both male and 
female patients (Tables 13.2a and 13.3a). 
The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed a significant decrease in prevalence of at-risk levels of alcohol 
consumption between 2007–08 and 2015–16 from 29.3% to 25.3%, and a corresponding increase in 
the proportion of non-drinkers, from 26.5% to 30.7% (Table 13.1b). This pattern in adults applied to 
both male and female patients (Tables 13.2b and 13.3b). 
13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the same 
subsample of adult patients. This allows us to build a risk profile for this sample for the three risk 
elements: overweight or obese weight status; daily smoking; and at-risk drinking. Each adult can have 
between zero and three of these risk factors. 
Results 
There was no significant change over the 10 years in the proportion of sampled adults who had no risk 
factors, remaining between about 25 to 26% in all years. There was a significant increase in the 
proportion of sampled adults with one risk factor, from 49.8% in 2006–07 to 53.7% in 2015–16 (Table 
13.1a). The increase was apparent among both male and female adult patients (Tables 13.2a and 
13.3a). There was a significant decrease in the proportion of patients with two (20.4% to 18.5%) or 
three (3.7% to 2.9%) risk factors — corresponding with the increase in the proportion with one risk 
factor. This pattern applied among both male and female patients. 
The estimates for the adult GP–patient attending population (after adjusting for age–sex general 
practice attendance patterns) showed an increase in prevalence of one risk factor between 2007–08 
and 2015–16 from 48.2% to 51.7%, and a corresponding decrease in prevalence of both two (21.9% 
to 20.4%) and three (5.1% to 3.6%) risk factors from (Table 13.1b). This pattern in adults applied 
among male patients, but among female patients the prevalence of only one risk factor increased and 
three risk factors decreased (Tables 13.2b and 13.3b). 
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.1
 
(3
4.
4–
35
.7
) 
 
35
.0
 
(3
4.
4–
35
.6
) 
 
34
.6
 
(3
4.
0–
35
.2
) 
 
34
.9
 
(3
4.
3–
35
.5
) 
 
34
.1
 
(3
3.
5–
34
.7
) 
 
34
.5
 
(3
3.
9–
35
.1
) 
—
 
 
N
or
m
al
 
39
.0
 
(3
8.
1–
39
.8
) 
 
38
.3
 
(3
7.
4–
39
.2
) 
 
36
.1
 
(3
5.
3–
36
.8
) 
 
37
.3
 
(3
6.
5–
38
.2
) 
 
35
.8
 
(3
5.
0–
36
.7
) 
 
36
.2
 
(3
5.
3–
37
.0
) 
 
36
.2
 
(3
5.
4–
37
.0
) 
 
35
.1
 
(3
4.
3–
35
.9
) 
 
35
.5
 
(3
4.
7–
36
.3
) 
 
34
.6
 
(3
3.
7–
35
.4
) 

 
 
U
nd
er
w
ei
gh
t 
2.
6 
(2
.4
–2
.8
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
6 
(2
.4
–2
.8
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
2 
(2
.0
–2
.4
) 

 
S
m
o
k
in
g
 s
ta
tu
s
 (
n
) 
3
1
,1
7
6
 
 
3
1
,6
5
2
 
 
3
4
,1
9
4
 
 
3
2
,7
4
4
 
 
3
2
,1
6
0
 
 
3
3
,0
8
6
 
 
3
2
,4
9
9
 
 
3
2
,1
6
6
 
 
3
3
,6
8
5
 
 
3
2
,6
6
4
 
 
 
D
ai
ly
 
16
.1
 
(1
5.
4–
16
.9
) 
 
16
.5
 
(1
5.
8–
17
.3
) 
 
15
.3
 
(1
4.
6–
15
.9
) 
 
15
.1
 
(1
4.
4–
15
.8
) 
 
14
.8
 
(1
4.
2–
15
.5
) 
 
14
.7
 
(1
4.
0–
15
.3
) 
 
14
.4
 
(1
3.
7–
15
.1
) 
 
13
.5
 
(1
2.
9–
14
.2
) 
 
14
.1
 
(1
3.
4–
14
.7
) 
 
13
.3
 
(1
2.
7–
14
.0
) 

 
 
O
cc
as
io
na
l 
3.
2 
(2
.9
–3
.4
) 
 
2.
9 
(2
.7
–3
.2
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
7 
(2
.5
–2
.9
) 
 
2.
7 
(2
.4
–2
.9
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
6 
(2
.3
–2
.8
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
1 
(1
.9
–2
.4
) 

 
 
P
re
vi
ou
s 
28
.8
 
(2
8.
0–
29
.6
) 
 
27
.9
 
(2
7.
1–
28
.6
) 
 
28
.8
 
(2
8.
1–
29
.6
) 
 
28
.2
 
(2
7.
4–
29
.0
) 
 
28
.3
 
(2
7.
5–
29
.1
) 
 
27
.9
 
(2
7.
2–
28
.7
) 
 
27
.7
 
(2
7.
0–
28
.5
) 
 
28
.6
 
(2
7.
8–
29
.4
) 
 
27
.8
 
(2
7.
0–
28
.6
) 
 
27
.7
 
(2
6.
9–
28
.5
) 
—
 
 
N
ev
er
 
51
.9
 
(5
0.
9–
52
.9
) 
 
52
.7
 
(5
1.
7–
53
.6
) 
 
53
.3
 
(5
2.
4–
54
.2
) 
 
54
.0
 
(5
3.
1–
55
.0
) 
 
54
.2
 
(5
3.
3–
55
.2
) 
 
54
.9
 
(5
3.
9–
55
.8
) 
 
55
.3
 
(5
4.
4–
56
.3
) 
 
55
.6
 
(5
4.
6–
56
.6
) 
 
55
.9
 
(5
4.
9–
56
.9
) 
 
56
.8
 
(5
5.
8–
57
.7
) 

 
A
lc
o
h
o
l 
c
o
n
s
u
m
p
ti
o
n
 (
n
) 
3
0
,3
4
7
 
 
3
0
,7
9
6
 
 
3
3
,3
4
7
 
 
3
1
,7
7
1
 
 
3
1
,1
9
0
 
 
3
3
,2
5
7
 
 
3
1
,6
4
0
 
 
3
1
,3
6
9
 
 
3
2
,8
3
5
 
 
3
1
,7
2
0
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
27
.0
 
(2
6.
1–
28
.0
) 
 
26
.2
 
(2
5.
3–
27
.1
) 
 
25
.2
 
(2
4.
3–
26
.0
) 
 
26
.5
 
(2
5.
7–
27
.4
) 
 
24
.8
 
(2
3.
9–
25
.7
) 
 
24
.5
 
(2
3.
7–
25
.4
) 
 
24
.1
 
(2
3.
3–
24
.9
) 
 
23
.0
 
(2
2.
2–
23
.8
) 
 
23
.3
 
(2
2.
5–
24
.2
) 
 
22
.7
 
(2
1.
9–
23
.6
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
44
.6
 
(4
3.
7–
45
.5
) 
 
44
.6
 
(4
3.
7–
45
.5
) 
 
45
.2
 
(4
4.
3–
46
.1
) 
 
44
.4
 
(4
3.
5–
45
.3
) 
 
44
.0
 
(4
3.
0–
44
.9
) 
 
43
.7
 
(4
2.
9–
44
.6
) 
 
44
.2
 
(4
3.
3–
45
.1
) 
 
43
.9
 
(4
3.
0–
44
.8
) 
 
42
.9
 
(4
2.
0–
43
.8
) 
 
43
.9
 
(4
3.
0–
44
.9
) 
—
 
 
N
on
-d
rin
ke
r 
28
.3
 
(2
7.
3–
29
.4
) 
 
29
.3
 
(2
8.
2–
30
.3
) 
 
29
.6
 
(2
8.
6–
30
.7
) 
 
29
.1
 
(2
8.
0–
30
.1
) 
 
31
.3
 
(3
0.
2–
32
.4
) 
 
31
.7
 
(3
0.
6–
32
.8
) 
 
31
.7
 
(3
0.
6–
32
.8
) 
 
33
.1
 
(3
2.
0–
34
.2
) 
 
33
.8
 
(3
2.
7–
34
.9
) 
 
33
.3
 
(3
2.
2–
34
.5
) 

 
 (
c
o
n
ti
n
u
e
d
) 
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T
a
b
le
 1
3
.1
a
 (
c
o
n
ti
n
u
e
d
):
 P
a
ti
e
n
t 
ri
s
k
 f
a
c
to
rs
, 
2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
(9
5
%
 C
I)
 

(a
)  
 
 
R
is
k
 f
a
c
to
r 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 
A
d
u
lt
s
 (
a
g
e
d
 1
8
 y
e
a
rs
 a
n
d
 o
v
e
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
u
m
b
e
r 
o
f 
ri
s
k
 f
a
c
to
rs
(c
)  
(n
) 
2
9
,3
8
6
 
 
3
0
,0
0
2
 
 
3
2
,4
3
2
 
 
3
0
,7
9
5
 
 
3
0
,1
7
7
 
 
3
1
,4
0
1
 
 
3
0
,3
4
5
 
 
3
0
,2
5
0
 
 
3
1
,9
5
2
 
 
3
0
,6
7
2
 
 
 
Ze
ro
 
26
.0
 
(2
5.
2–
26
.8
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
25
.0
 
(2
4.
2–
25
.7
) 
 
25
.8
 
(2
5.
0–
26
.5
) 
 
25
.0
 
(2
4.
3–
25
.7
) 
 
25
.4
 
(2
4.
6–
26
.2
) 
 
25
.8
 
(2
5.
0–
26
.6
) 
 
25
.4
 
(2
4.
7–
26
.2
) 
 
25
.6
 
(2
4.
8–
26
.4
) 
 
24
.9
 
(2
4.
1–
25
.6
) 
—
 
 
O
ne
 
49
.8
 
(4
9.
1–
50
.6
) 
 
50
.1
 
(4
9.
4–
50
.8
) 
 
51
.8
 
(5
1.
1–
52
.5
) 
 
50
.3
 
(4
9.
6–
51
.0
) 
 
52
.2
 
(5
1.
5–
52
.9
) 
 
52
.1
 
(5
1.
4–
52
.8
) 
 
52
.0
 
(5
1.
3–
52
.7
) 
 
53
.0
 
(5
2.
3–
53
.7
) 
 
52
.2
 
(5
1.
5–
53
.0
) 
 
53
.7
 
(5
3.
0–
54
.5
) 

 
 
Tw
o 
20
.4
 
(1
9.
8–
21
.1
) 
 
19
.8
 
(1
9.
1–
20
.4
) 
 
19
.5
 
(1
8.
9–
20
.0
) 
 
20
.1
 
(1
9.
5–
20
.7
) 
 
19
.1
 
(1
8.
5–
19
.8
) 
 
18
.9
 
(1
8.
3–
19
.5
) 
 
18
.8
 
(1
8.
1–
19
.4
) 
 
18
.4
 
(1
7.
8–
19
.0
) 
 
19
.0
 
(1
8.
3–
19
.6
) 
 
18
.5
 
(1
7.
9–
19
.2
) 

 
 
Th
re
e 
3.
7 
(3
.5
–4
.0
) 
 
4.
1 
(3
.8
–4
.4
) 
 
3.
8 
(3
.5
–4
.1
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
7 
(3
.4
–4
.0
) 
 
3.
6 
(3
.3
–3
.9
) 
 
3.
4 
(3
.1
–3
.7
) 
 
3.
2 
(2
.9
–3
.4
) 
 
3.
2 
(3
.0
–3
.4
) 
 
2.
9 
(2
.6
–3
.1
) 

 
C
h
il
d
re
n
 
(a
g
e
d
 2
–
1
7
 y
e
a
rs
)(
d
) (
n
) 
3
,0
8
7
 
 
3
,0
4
6
 
 
2
,9
7
0
 
 
3
,1
8
3
 
 
3
,0
0
8
 
 
3
,0
9
3
 
 
3
,0
6
9
 
 
2
,5
3
6
 
 
3
,1
1
2
 
 
3
,0
7
7
 
 
 
O
be
se
 
10
.6
 
(9
.3
–1
1.
9)
 
 
11
.2
 
(1
0.
0–
12
.5
) 
 
10
.5
 
(9
.3
–1
1.
7)
 
 
9.
6 
(8
.4
–1
0.
8)
 
 
10
.6
 
(9
.3
–1
2.
0)
 
 
11
.1
 
(9
.8
–1
2.
5)
 
 
9.
0 
(7
.9
–1
0.
2)
 
 
9.
6 
(8
.3
–1
0.
8)
 
 
8.
6 
(7
.5
–9
.7
) 
 
9.
9 
(8
.7
–1
1.
1)
 
—
 
 
O
ve
rw
ei
gh
t 
18
.6
 
(1
7.
2–
20
.0
) 
 
17
.1
 
(1
5.
7–
18
.5
) 
 
16
.7
 
(1
5.
3–
18
.2
) 
 
18
.0
 
(1
6.
7–
19
.4
) 
 
17
.7
 
(1
6.
2–
19
.1
) 
 
17
.6
 
(1
6.
2–
19
.0
) 
 
17
.3
 
(1
5.
9–
18
.7
) 
 
18
.7
 
(1
7.
1–
20
.4
) 
 
18
.4
 
(1
7.
0–
19
.9
) 
 
18
.1
 
(1
6.
7–
19
.5
) 
—
 
 
N
or
m
al
 
61
.2
 
(5
9.
3–
63
.0
) 
 
61
.7
 
(5
9.
7–
63
.6
) 
 
62
.9
 
(6
1.
0–
64
.8
) 
 
62
.3
 
(6
0.
4–
64
.1
) 
 
61
.8
 
(5
9.
9–
63
.8
) 
 
60
.3
 
(5
8.
4–
62
.3
) 
 
62
.5
 
(6
0.
6–
64
.5
) 
 
62
.1
 
(6
0.
1–
64
.2
) 
 
62
.1
 
(6
0.
3–
64
.0
) 
 
62
.1
 
(6
0.
3–
63
.9
) 
—
 
 
U
nd
er
w
ei
gh
t 
9.
7 
(8
.6
–1
0.
8)
 
 
10
.1
 
(8
.9
–1
1.
2)
 
 
9.
9 
(8
.8
–1
1.
1)
 
 
10
.1
 
(9
.0
–1
1.
3)
 
 
9.
9 
(8
.7
–1
1.
0)
 
 
11
.0
 
(9
.7
–1
2.
2)
 
 
11
.1
 
(9
.9
–1
2.
4)
 
 
9.
6 
(8
.3
–1
0.
8)
 
 
10
.8
 
(9
.6
–1
2.
0)
 
 
9.
9 
(8
.8
–1
1.
1)
 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
(c
) 
A
du
lt 
ris
k 
fa
ct
or
s 
ar
e:
 o
ve
rw
ei
gh
t o
r 
ob
es
ity
; d
ai
ly
 s
m
ok
in
g;
 o
r 
at
-r
is
k 
al
co
ho
l c
on
su
m
pt
io
n.
  
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) 
w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tr
es
 fo
r 
D
is
ea
se
 C
on
tro
l h
ei
gh
t r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
.
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T
a
b
le
 1
3
.1
b
: 
P
re
v
a
le
n
c
e
 o
f 
p
a
ti
e
n
t 
ri
s
k
 f
a
c
to
rs
 a
m
o
n
g
 a
d
u
lt
s
 1
8
+
 a
tt
e
n
d
in
g
 g
e
n
e
ra
l 
p
ra
c
ti
c
e
 a
t 
le
a
s
t 
o
n
c
e
, 
2
0
0
7
–
0
8
 t
o
 2
0
1
5
–
1
6
 
 
 
 
P
e
r 
c
e
n
t 
(9
5
%
 C
I)
 

(a
)  
 
 
R
is
k
 f
a
c
to
r 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
2
0
1
5
–
1
6
 
A
d
u
lt
s
 (
a
g
e
d
 1
8
 y
e
a
rs
 a
n
d
 o
v
e
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
o
d
y
 m
a
s
s
 i
n
d
e
x
 c
la
s
s
(b
)  
(n
) 
 
3
1
,2
9
2
 
 
3
3
,5
1
6
 
 
3
1
,9
2
4
 
 
3
1
,3
1
7
 
 
3
2
,3
7
3
 
 
3
1
,4
4
9
 
 
3
1
,3
6
3
 
 
3
2
,9
5
6
 
3
1
,6
6
7
 
 
 
O
be
se
 
 
23
.4
 
(2
2.
7–
24
.2
) 
 
24
.5
 
(2
3.
8–
25
.2
) 
 
25
.4
 
(2
4.
6–
26
.1
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
26
.0
 
(2
5.
2–
26
.9
) 
 
26
.9
 
(2
6.
1–
27
.8
) 
 
27
.2
 
(2
6.
4–
28
.0
) 
27
.9
 
(2
7.
1–
28
.8
) 

 
 
O
ve
rw
ei
gh
t 
 
35
.3
 
(3
4.
6–
36
.0
) 
 
35
.4
 
(3
4.
7–
36
.0
) 
 
34
.4
 
(3
3.
8–
35
.1
) 
 
34
.6
 
(3
3.
9–
35
.3
) 
 
34
.9
 
(3
4.
2–
35
.5
) 
 
34
.4
 
(3
3.
7–
35
.1
) 
 
34
.6
 
(3
3.
9–
35
.2
) 
 
33
.9
 
(3
3.
3–
34
.6
) 
34
.0
 
(3
3.
4–
34
.7
) 
—
 
 
N
or
m
al
 
 
38
.9
 
(3
8.
0–
39
.9
) 
 
37
.7
 
(3
6.
8–
38
.6
) 
 
38
.0
 
(3
7.
1–
38
.9
) 
 
37
.0
 
(3
6.
2–
37
.9
) 
 
36
.9
 
(3
6.
0–
37
.8
) 
 
37
.0
 
(3
6.
1–
37
.9
) 
 
36
.3
 
(3
5.
4–
37
.2
) 
 
36
.6
 
(3
5.
7–
37
.5
) 
35
.8
 
(3
4.
9–
36
.7
) 

 
 
U
nd
er
w
ei
gh
t 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
2 
(2
.0
–2
.3
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
3 
(2
.1
–2
.5
) 
2.
2 
(2
.0
–2
.4
) 
—
 
S
m
o
k
in
g
 s
ta
tu
s
 (
n
) 
 
3
1
,8
8
4
 
 
3
4
,1
8
9
 
 
3
2
,7
3
4
 
 
3
2
,1
6
1
 
 
3
3
,0
8
5
 
 
3
2
,4
9
7
 
 
3
2
,1
5
6
 
 
3
3
,6
8
5
 
3
2
,6
6
8
 
 
 
D
ai
ly
 
 
19
.3
 
(1
8.
5–
20
.1
) 
 
18
.8
 
(1
8.
0–
19
.6
) 
 
17
.7
 
(1
6.
9–
18
.5
) 
 
17
.8
 
(1
7.
0–
18
.6
) 
 
17
.4
 
(1
6.
6–
18
.2
) 
 
17
.3
 
(1
6.
4–
18
.1
) 
 
16
.9
 
(1
5.
9–
17
.8
) 
 
16
.5
 
(1
5.
7–
17
.3
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 re
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20
.4
) 
 
19
.2
 
(1
8.
3–
20
.1
) 
 
19
.0
 
(1
8.
1–
20
.0
) 
—
 
 
O
ne
 
48
.0
 
(4
7.
0–
49
.1
) 
 
48
.0
 
(4
7.
0–
49
.0
) 
 
50
.5
 
(4
9.
6–
51
.5
) 
 
49
.0
 
(4
8.
0–
50
.0
) 
 
50
.9
 
(4
9.
8–
51
.9
) 
 
51
.5
 
(5
0.
4–
52
.5
) 
 
51
.3
 
(5
0.
2–
52
.3
) 
 
51
.9
 
(5
0.
8–
52
.9
) 
 
51
.0
 
(4
9.
9–
52
.0
) 
 
53
.0
 
(5
1.
9–
54
.1
) 

 
 
Tw
o 
26
.2
 
(2
5.
2–
27
.2
) 
 
25
.9
 
(2
4.
9–
26
.9
) 
 
25
.0
 
(2
4.
1–
25
.9
) 
 
25
.8
 
(2
4.
9–
26
.8
) 
 
24
.7
 
(2
3.
7–
25
.6
) 
 
24
.3
 
(2
3.
3–
25
.2
) 
 
24
.5
 
(2
3.
5–
25
.4
) 
 
23
.9
 
(2
2.
9–
24
.9
) 
 
25
.1
 
(2
4.
2–
26
.1
) 
 
23
.9
 
(2
3.
0–
24
.9
) 

 
 
Th
re
e 
5.
5 
(5
.0
–6
.0
) 
 
5.
9 
(5
.4
–6
.4
) 
 
5.
5 
(5
.0
–5
.9
) 
 
5.
6 
(5
.1
–6
.1
) 
 
5.
3 
(4
.9
–5
.8
) 
 
5.
4 
(4
.9
–5
.8
) 
 
5.
3 
(4
.9
–5
.8
) 
 
4.
7 
(4
.2
–5
.1
) 
 
4.
7 
(4
.3
–5
.1
) 
 
4.
1 
(3
.7
–4
.5
) 

 
M
a
le
 c
h
il
d
re
n
 
(a
g
e
d
 2
–
1
7
 y
e
a
rs
)(
d
)  
(n
) 
1
,5
0
9
 
 
1
,4
8
4
 
 
1
,4
1
5
 
 
1
,4
9
9
 
 
1
,4
5
0
 
 
1
,4
8
7
 
 
1
,4
5
1
 
 
1
,2
2
6
 
 
1
,4
9
5
 
 
1
,5
4
1
 
 
 
O
be
se
 
11
.6
 
(9
.8
–1
3.
4)
 
 
11
.9
 
(1
0.
1–
13
.7
) 
 
10
.3
 
(8
.6
–1
1.
9)
 
 
10
.5
 
(8
.9
–1
2.
2)
 
 
11
.2
 
(9
.4
–1
2.
9)
 
 
11
.8
 
(1
0.
0–
13
.7
) 
 
10
.1
 
(8
.4
–1
1.
7)
 
 
10
.7
 
(8
.8
–1
2.
6)
 
 
9.
0 
(7
.5
–1
0.
5)
 
 
10
.1
 
(8
.6
–1
1.
7)
 
—
 
 
O
ve
rw
ei
gh
t 
19
.7
 
(1
7.
7–
21
.7
) 
 
17
.3
 
(1
5.
4–
19
.3
) 
 
18
.2
 
(1
6.
1–
20
.4
) 
 
17
.4
 
(1
5.
3–
19
.5
) 
 
17
.4
 
(1
5.
4–
19
.5
) 
 
17
.8
 
(1
5.
7–
19
.8
) 
 
17
.4
 
(1
5.
4–
19
.4
) 
 
17
.8
 
(1
5.
6–
20
.0
) 
 
17
.6
 
(1
5.
6–
19
.6
) 
 
18
.3
 
(1
6.
4–
20
.2
) 
—
 
 
N
or
m
al
 
58
.8
 
(5
6.
2–
61
.4
) 
 
61
.1
 
(5
8.
5–
63
.5
) 
 
62
.0
 
(5
9.
3–
64
.7
) 
 
62
.2
 
(5
9.
6–
64
.9
) 
 
62
.4
 
(5
9.
7–
65
.2
) 
 
60
.1
 
(5
7.
4–
62
.9
) 
 
61
.8
 
(5
9.
2–
64
.4
) 
 
62
.8
 
(5
9.
9–
65
.7
) 
 
63
.2
 
(6
0.
8–
65
.7
) 
 
62
.4
 
(5
9.
9–
64
.9
) 
—
 
 
U
nd
er
w
ei
gh
t 
9.
9 
(8
.4
–1
1.
5)
 
 
9.
6 
(8
.0
–1
1.
3)
 
 
9.
5 
(8
.0
–1
1.
1)
 
 
9.
8 
(8
.2
–1
1.
4)
 
 
9.
0 
(7
.4
–1
0.
6)
 
 
10
.3
 
(8
.6
–1
2.
0)
 
 
10
.7
 
(8
.9
–1
2.
4)
 
 
8.
7 
(7
.1
–1
0.
4)
 
 
10
.2
 
(8
.6
–1
1.
8)
 
 
9.
1 
(7
.6
–1
0.
7)
 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; a
nd
 —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
(c
) 
A
du
lt 
ris
k 
fa
ct
or
s 
ar
e:
 o
ve
rw
ei
gh
t o
r 
ob
es
ity
; d
ai
ly
 s
m
ok
in
g;
 o
r 
at
-r
is
k 
al
co
ho
l c
on
su
m
pt
io
n.
  
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) 
w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tr
es
 fo
r 
D
is
ea
se
 C
on
tro
l h
ei
gh
t r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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T
a
b
le
 1
3
.2
b
: 
P
re
v
a
le
n
c
e
 o
f 
p
a
ti
e
n
t 
ri
s
k
 f
a
c
to
rs
 a
m
o
n
g
 a
d
u
lt
 m
a
le
s
 1
8
+
 a
tt
e
n
d
in
g
 g
e
n
e
ra
l 
p
ra
c
ti
c
e
 a
t 
le
a
s
t 
o
n
c
e
, 
2
0
0
7
–
0
8
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
(9
5
%
 C
I)
 

(a
)  
 
 
R
is
k
 f
a
c
to
r 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
2
0
1
5
–
1
6
 
A
d
u
lt
 m
a
le
s
 (
a
g
e
d
 1
8
 y
e
a
rs
 a
n
d
 o
v
e
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
o
d
y
 m
a
s
s
 i
n
d
e
x
 c
la
s
s
(b
)  
(n
) 
1
2
,1
2
6
 
 
1
3
,5
9
5
 
 
1
1
,9
4
5
 
 
1
2
,3
2
2
 
 
1
2
,5
3
1
 
 
1
2
,1
7
1
 
 
1
2
,0
2
2
 
 
1
2
,9
4
7
 
1
2
,4
9
9
 
 
 
O
be
se
 
22
.8
 
(2
1.
8–
23
.8
) 
 
24
.2
 
(2
3.
3–
25
.2
) 
 
25
.1
 
(2
4.
1–
26
.1
) 
 
25
.4
 
(2
4.
4–
26
.4
) 
 
25
.7
 
(2
4.
6–
26
.8
) 
 
26
.1
 
(2
5.
0–
27
.2
) 
 
26
.2
 
(2
5.
1–
27
.4
) 
 
27
.1
 
(2
6.
0–
28
.1
) 
27
.7
 
(2
6.
6–
28
.8
) 

 
 
O
ve
rw
ei
gh
t 
42
.1
 
(4
1.
0–
43
.2
) 
 
42
.4
 
(4
1.
4–
43
.5
) 
 
40
.9
 
(3
9.
9–
41
.9
) 
 
41
.0
 
(3
9.
9–
42
.0
) 
 
41
.5
 
(4
0.
4–
42
.5
) 
 
41
.4
 
(4
0.
3–
42
.5
) 
 
41
.1
 
(4
0.
0–
42
.1
) 
 
40
.2
 
(3
9.
2–
41
.3
) 
40
.5
 
(3
9.
4–
41
.5
) 
—
 
 
N
or
m
al
 
34
.0
 
(3
2.
7–
35
.2
) 
 
32
.3
 
(3
1.
1–
33
.5
) 
 
32
.9
 
(3
1.
7–
34
.0
) 
 
32
.5
 
(3
1.
3–
33
.6
) 
 
31
.5
 
(3
0.
4–
32
.7
) 
 
31
.4
 
(3
0.
2–
32
.5
) 
 
31
.4
 
(3
0.
2–
32
.6
) 
 
31
.7
 
(3
0.
5–
32
.9
) 
30
.7
 
(2
9.
5–
31
.9
) 

 
 
U
nd
er
w
ei
gh
t 
1.
1 
(0
.9
–1
.4
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
1 
(0
.9
–1
.4
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
3 
(1
.0
–1
.5
) 
 
1.
0 
(0
.8
–1
.2
) 
1.
2 
(1
.0
–1
.4
) 
—
 
S
m
o
k
in
g
 s
ta
tu
s
 (
n
) 
1
2
,3
3
5
 
 
1
3
,8
4
1
 
 
1
2
,2
6
0
 
 
1
2
,6
0
0
 
 
1
2
,7
7
7
 
 
1
2
,5
1
8
 
 
1
2
,2
9
4
 
 
1
3
,1
8
0
 
1
2
,8
8
1
 
 
 
D
ai
ly
 
23
.4
 
(2
2.
2–
24
.5
) 
 
22
.8
 
(2
1.
7–
24
.0
) 
 
21
.4
 
(2
0.
2–
22
.6
) 
 
21
.6
 
(2
0.
6–
22
.7
) 
 
21
.4
 
(2
0.
3–
22
.5
) 
 
21
.3
 
(2
0.
1–
22
.4
) 
 
20
.9
 
(1
9.
6–
22
.2
) 
 
20
.5
 
(1
9.
4–
21
.7
) 
19
.3
 
(1
8.
2–
20
.3
) 

 
 
O
cc
as
io
na
l 
4.
1 
(3
.6
–4
.6
) 
 
4.
1 
(3
.5
–4
.6
) 
 
3.
9 
(3
.4
–4
.3
) 
 
4.
1 
(3
.5
–4
.6
) 
 
3.
8 
(3
.3
–4
.2
) 
 
4.
2 
(3
.6
–4
.7
) 
 
3.
9 
(3
.3
–4
.4
) 
 
3.
5 
(3
.1
–3
.9
) 
3.
5 
(3
.0
–4
.0
) 
—
 
 
P
re
vi
ou
s 
30
.5
 
(2
9.
4–
31
.6
) 
 
29
.9
 
(2
8.
8–
31
.0
) 
 
30
.6
 
(2
9.
5–
31
.7
) 
 
30
.0
 
(2
8.
9–
31
.1
) 
 
30
.4
 
(2
9.
3–
31
.5
) 
 
30
.5
 
(2
9.
4–
31
.6
) 
 
29
.8
 
(2
8.
7–
30
.9
) 
 
29
.5
 
(2
8.
3–
30
.6
) 
29
.5
 
(2
8.
3–
30
.6
) 
—
 
 
N
ev
er
 
42
.0
 
(4
0.
7–
43
.3
) 
 
43
.2
 
(4
1.
9–
44
.5
) 
 
44
.1
 
(4
2.
8–
45
.4
) 
 
44
.3
 
(4
3.
0–
45
.7
) 
 
44
.4
 
(4
3.
2–
45
.7
) 
 
44
.1
 
(4
2.
8–
45
.4
) 
 
45
.4
 
(4
4.
0–
46
.9
) 
 
46
.5
 
(4
5.
2–
47
.8
) 
47
.8
 
(4
6.
4–
49
.1
) 

 
A
lc
o
h
o
l 
c
o
n
s
u
m
p
ti
o
n
 (
n
) 
1
2
,0
7
1
 
 
1
3
,5
8
3
 
 
1
1
,9
7
4
 
 
1
2
,3
2
1
 
 
1
2
,5
7
2
 
 
1
2
,2
7
4
 
 
1
2
,0
7
9
 
 
1
2
,9
6
9
 
1
2
,5
8
8
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
35
.7
 
(3
4.
3–
37
.1
) 
 
35
.7
 
(3
4.
4–
37
.0
) 
 
35
.2
 
(3
3.
9–
36
.6
) 
 
34
.5
 
(3
3.
1–
35
.9
) 
 
33
.3
 
(3
2.
0–
34
.7
) 
 
33
.1
 
(3
1.
8–
34
.4
) 
 
31
.6
 
(3
0.
2–
32
.9
) 
 
31
.7
 
(3
0.
3–
33
.0
) 
29
.6
 
(2
8.
2–
30
.9
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
45
.0
 
(4
3.
8–
46
.3
) 
 
45
.1
 
(4
3.
9–
46
.4
) 
 
45
.3
 
(4
4.
0–
46
.6
) 
 
44
.7
 
(4
3.
4–
45
.9
) 
 
44
.3
 
(4
3.
1–
45
.6
) 
 
45
.3
 
(4
4.
0–
46
.5
) 
 
46
.5
 
(4
5.
2–
47
.8
) 
 
45
.3
 
(4
4.
2–
46
.5
) 
46
.6
 
(4
5.
3–
47
.9
) 
—
 
 
N
on
-d
rin
ke
r 
19
.3
 
(1
8.
2–
20
.4
) 
 
19
.2
 
(1
8.
1–
20
.3
) 
 
19
.5
 
(1
8.
3–
20
.7
) 
 
20
.9
 
(1
9.
6–
22
.1
) 
 
22
.3
 
(2
1.
1–
32
.6
) 
 
21
.7
 
(2
0.
5–
22
.8
) 
 
22
.0
 
(2
0.
7–
23
.2
) 
 
23
.0
 
(2
1.
8–
24
.2
) 
23
.8
 
(2
2.
5–
25
.1
) 

 
 (
c
o
n
ti
n
u
e
d
) 
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T
a
b
le
 1
3
.2
b
 (
c
o
n
ti
n
u
e
d
):
 P
re
v
a
le
n
c
e
 o
f 
p
a
ti
e
n
t 
ri
s
k
 f
a
c
to
rs
 a
m
o
n
g
 a
d
u
lt
 m
a
le
s
 1
8
+
 a
tt
e
n
d
in
g
 g
e
n
e
ra
l 
p
ra
c
ti
c
e
 a
t 
le
a
s
t 
o
n
c
e
, 
2
0
0
7
–
0
8
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
(9
5
%
 C
I)
 

(a
)  
 
 
R
is
k
 f
a
c
to
r 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
2
0
1
5
–
1
6
 
A
d
u
lt
 m
a
le
s
 (
a
g
e
d
 1
8
 y
e
a
rs
 a
n
d
 o
v
e
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
u
m
b
e
r 
o
f 
ri
s
k
 f
a
c
to
rs
(c
)  
(n
) 
1
1
,7
8
4
 
 
1
3
,2
2
8
 
 
1
1
,6
1
3
 
 
1
1
,9
5
4
 
 
1
2
,2
5
2
 
 
1
1
,8
2
7
 
 
1
1
,6
8
7
 
 
1
2
,6
6
5
 
1
2
,1
9
4
 
 
 
Ze
ro
 
18
.8
 
(1
7.
8–
19
.8
) 
 
17
.5
 
(1
6.
6–
18
.4
) 
 
18
.7
 
(1
7.
7–
19
.7
) 
 
18
.2
 
(1
7.
2–
19
.1
) 
 
17
.9
 
(1
7.
0–
18
.9
) 
 
18
.0
 
(1
7.
0–
19
.0
) 
 
18
.4
 
(1
7.
5–
19
.4
) 
 
18
.8
 
(1
7.
8–
19
.8
) 
18
.6
 
(1
7.
6–
19
.6
) 
—
 
 
O
ne
 
45
.8
 
(4
4.
7–
46
.9
) 
 
47
.0
 
(4
6.
0–
48
.1
) 
 
46
.8
 
(4
5.
7–
47
.8
) 
 
47
.9
 
(4
6.
8–
49
.1
) 
 
48
.8
 
(4
7.
7–
49
.9
) 
 
48
.8
 
(4
7.
7–
50
.0
) 
 
49
.1
 
(4
8.
0–
50
.3
) 
 
48
.1
 
(4
7.
0–
49
.3
) 
50
.6
 
(4
9.
4–
51
.7
) 

 
 
Tw
o 
28
.2
 
(2
7.
1–
29
.3
) 
 
28
.2
 
(2
7.
1–
29
.2
) 
 
27
.8
 
(2
6.
8–
28
.9
) 
 
27
.3
 
(2
6.
2–
28
.4
) 
 
26
.7
 
(2
5.
7–
27
.8
) 
 
26
.7
 
(2
5.
6–
27
.7
) 
 
26
.6
 
(2
5.
5–
27
.7
) 
 
27
.4
 
(2
6.
4–
28
.5
) 
25
.9
 
(2
4.
8–
27
.0
) 

 
 
Th
re
e 
7.
2 
(6
.6
–7
.8
) 
 
7.
3 
(6
.7
–7
.9
) 
 
6.
7 
(6
.1
–7
.3
) 
 
6.
6 
(6
.0
–7
.2
) 
 
6.
5 
(5
.9
–7
.1
) 
 
6.
5 
(5
.9
–7
.1
) 
 
5.
8 
(5
.3
–6
.4
) 
 
5.
6 
(5
.1
–6
.1
) 
4.
9 
(4
.5
–5
.4
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
7–
08
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
7–
08
; a
nd
 —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
7–
08
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
(c
) 
A
du
lt 
ris
k 
fa
ct
or
s 
ar
e:
 o
ve
rw
ei
gh
t o
r 
ob
es
ity
; d
ai
ly
 s
m
ok
in
g;
 o
r 
at
-r
is
k 
al
co
ho
l c
on
su
m
pt
io
n.
  
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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T
a
b
le
 1
3
.3
a
: 
P
a
ti
e
n
t 
ri
s
k
 f
a
c
to
rs
 a
m
o
n
g
 f
e
m
a
le
 p
a
ti
e
n
ts
, 
2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
(9
5
%
 C
I)
 

(a
)  
 
 
R
is
k
 f
a
c
to
r 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 
A
d
u
lt
 f
e
m
a
le
s
 (
a
g
e
d
 1
8
 y
e
a
rs
 a
n
d
 o
v
e
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
o
d
y
 m
a
s
s
 i
n
d
e
x
 c
la
s
s
(b
)  
(n
) 
1
9
,4
1
0
 
 
1
8
,7
0
3
 
 
1
9
,6
7
1
 
 
1
9
,7
3
5
 
 
1
8
,7
4
1
 
 
1
9
,6
0
5
 
 
1
9
,0
6
4
 
 
1
9
,1
1
2
 
 
1
9
,7
6
5
 
 
1
8
,9
3
2
 
 
 
O
be
se
 
24
.2
 
(2
3.
3–
25
.1
) 
 
24
.3
 
(2
3.
5–
25
.2
) 
 
25
.6
 
(2
4.
8–
26
.4
) 
 
26
.2
 
(2
5.
3–
27
.0
) 
 
27
.2
 
(2
6.
3–
28
.1
) 
 
26
.7
 
(2
5.
8–
27
.5
) 
 
26
.6
 
(2
5.
7–
27
.5
) 
 
28
.1
 
(2
7.
2–
29
.0
) 
 
27
.9
 
(2
7.
0–
28
.8
) 
 
28
.9
 
(2
8.
0–
29
.8
) 

 
 
O
ve
rw
ei
gh
t 
30
.1
 
(2
9.
4–
30
.9
) 
 
30
.4
 
(2
9.
7–
31
.2
) 
 
30
.9
 
(3
0.
2–
31
.6
) 
 
29
.6
 
(2
8.
9–
30
.3
) 
 
30
.3
 
(2
9.
6–
31
.0
) 
 
30
.2
 
(2
9.
5–
30
.9
) 
 
29
.5
 
(2
8.
8–
30
.2
) 
 
30
.4
 
(2
9.
7–
31
.2
) 
 
29
.3
 
(2
8.
6–
30
.1
) 
 
29
.7
 
(2
9.
0–
30
.4
) 
—
 
 
N
or
m
al
 
42
.2
 
(4
1.
2–
43
.2
) 
 
41
.9
 
(4
0.
9–
43
.0
) 
 
40
.0
 
(3
9.
1–
41
.0
) 
 
41
.1
 
(4
0.
1–
42
.0
) 
 
39
.3
 
(3
8.
3–
40
.3
) 
 
40
.2
 
(3
9.
3–
41
.2
) 
 
40
.4
 
(3
9.
4–
41
.4
) 
 
38
.5
 
(3
7.
5–
39
.5
) 
 
39
.5
 
(3
8.
4–
40
.5
) 
 
38
.5
 
(3
7.
5–
39
.5
) 

 
 
U
nd
er
w
ei
gh
t 
3.
5 
(3
.2
–3
.8
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
2 
(2
.9
–3
.5
) 
 
2.
9 
(2
.6
–3
.1
) 
 
3.
5 
(3
.2
–3
.8
) 
 
2.
9 
(2
.7
–3
.2
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
0 
(2
.7
–3
.2
) 

 
S
m
o
k
in
g
 s
ta
tu
s
 (
n
) 
1
8
,7
1
8
 
 
1
9
,0
8
1
 
 
2
0
,0
7
9
 
 
2
0
,2
2
4
 
 
1
9
,3
0
1
 
 
2
0
,0
6
0
 
 
1
9
,7
5
8
 
 
1
9
,6
2
5
 
 
2
0
,2
5
2
 
 
1
9
,5
4
6
 
 
 
D
ai
ly
 
14
.0
 
(1
3.
3–
14
.8
) 
 
14
.4
 
(1
3.
7–
15
.2
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
12
.9
 
(1
2.
2–
13
.6
) 
 
12
.6
 
(1
1.
8–
13
.3
) 
 
12
.4
 
(1
1.
7–
13
.0
) 
 
11
.6
 
(1
0.
9–
12
.3
) 
 
11
.9
 
(1
1.
3–
12
.6
) 
 
11
.5
 
(1
0.
9–
12
.2
) 

 
 
O
cc
as
io
na
l 
2.
7 
(2
.5
–3
.0
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
1 
(1
.9
–2
.4
) 
 
1.
9 
(1
.7
–2
.2
) 
 
2.
0 
(1
.7
–2
.2
) 
 
1.
8 
(1
.5
–2
.0
) 

 
 
P
re
vi
ou
s 
23
.3
 
(2
2.
5–
24
.2
) 
 
22
.3
 
(2
1.
4–
23
.1
) 
 
22
.5
 
(2
1.
7–
23
.3
) 
 
22
.8
 
(2
2.
0–
23
.7
) 
 
22
.7
 
(2
1.
8–
23
.5
) 
 
22
.6
 
(2
1.
8–
23
.5
) 
 
22
.1
 
(2
1.
3–
22
.9
) 
 
23
.3
 
(2
2.
4–
24
.1
) 
 
22
.4
 
(2
1.
6–
23
.3
) 
 
22
.4
 
(2
1.
5–
23
.2
) 
—
 
 
N
ev
er
 
59
.9
 
(5
8.
8–
61
.0
) 
 
60
.7
 
(5
9.
6–
61
.7
) 
 
61
.7
 
(6
0.
7–
62
.7
) 
 
61
.5
 
(6
0.
4–
62
.5
) 
 
62
.1
 
(6
1.
0–
63
.1
) 
 
62
.6
 
(6
1.
6–
63
.7
) 
 
63
.4
 
(6
2.
4–
64
.5
) 
 
63
.2
 
(6
2.
2–
64
.2
) 
 
63
.7
 
(6
2.
6–
64
.8
) 
 
64
.3
 
(6
3.
3–
65
.4
) 

 
A
lc
o
h
o
l 
c
o
n
s
u
m
p
ti
o
n
 (
n
) 
1
8
,3
4
2
 
 
1
8
,7
1
5
 
 
1
9
,7
6
4
 
 
1
9
,9
7
9
 
 
1
8
,8
6
9
 
 
1
9
,6
8
5
 
 
1
9
,3
6
6
 
 
1
9
,2
9
0
 
 
1
9
,8
6
6
 
 
1
9
,1
3
2
 
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
23
.5
 
(2
2.
5–
24
.5
) 
 
22
.6
 
(2
1.
6–
23
.6
) 
 
21
.8
 
(2
0.
8–
22
.7
) 
 
23
.4
 
(2
2.
5–
24
.4
) 
 
21
.4
 
(2
0.
5–
22
.3
) 
 
21
.5
 
(2
0.
6–
22
.5
) 
 
20
.8
 
(1
9.
9–
21
.7
) 
 
20
.1
 
(1
9.
2–
20
.9
) 
 
20
.1
 
(1
9.
2–
21
.0
) 
 
20
.3
 
(1
9.
3–
21
.2
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
42
.4
 
(4
1.
3–
43
.5
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.5
 
(4
1.
5–
43
.6
) 
 
41
.5
 
(4
0.
4–
42
.6
) 
 
41
.8
 
(4
0.
8–
42
.8
) 
 
42
.1
 
(4
1.
0–
43
.1
) 
 
40
.8
 
(3
9.
8–
41
.9
) 
 
40
.2
 
(3
9.
2–
41
.3
) 
 
41
.0
 
(3
9.
9–
42
.1
) 
—
 
 
N
on
-d
rin
ke
r 
34
.1
 
(3
2.
8–
35
.4
) 
 
34
.8
 
(3
3.
5–
36
.1
) 
 
35
.6
 
(3
4.
3–
36
.9
) 
 
34
.0
 
(3
2.
8–
35
.3
) 
 
37
.1
 
(3
5.
7–
38
.5
) 
 
36
.7
 
(3
5.
3–
38
.0
) 
 
37
.2
 
(3
5.
9–
38
.5
) 
 
39
.1
 
(3
7.
8–
40
.4
) 
 
39
.7
 
(3
8.
3–
41
.0
) 
 
38
.7
 
(3
7.
4–
40
.1
) 

 
(c
o
n
ti
n
u
e
d
) 
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T
a
b
le
 1
3
.3
a
 (
c
o
n
ti
n
u
e
d
):
 P
a
ti
e
n
t 
ri
s
k
 f
a
c
to
rs
 a
m
o
n
g
 f
e
m
a
le
 p
a
ti
e
n
ts
, 
2
0
0
6
–
0
7
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
(9
5
%
 C
I)
 

(a
)  
 
 
R
is
k
 f
a
c
to
r 
2
0
0
6
–
0
7
 
 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
 
2
0
1
5
–
1
6
 
A
d
u
lt
 f
e
m
a
le
s
 (
a
g
e
d
 1
8
 y
e
a
rs
 a
n
d
 o
v
e
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
u
m
b
e
r 
o
f 
ri
s
k
 f
a
c
to
rs
(c
)  
(n
) 
1
7
,7
2
4
 
 
1
8
,2
1
8
 
 
1
9
,2
0
4
 
 
1
9
,1
8
2
 
 
1
8
,2
2
2
 
 
1
9
,1
4
9
 
 
1
8
,5
1
8
 
 
1
8
,5
6
3
 
 
1
9
,2
8
7
 
 
1
8
,4
7
8
 
 
 
Ze
ro
 
29
.8
 
(2
8.
8–
30
.7
) 
 
29
.9
 
(2
8.
9–
30
.8
) 
 
29
.1
 
(2
8.
1–
30
.0
) 
 
29
.5
 
(2
8.
6–
30
.4
) 
 
28
.8
 
(2
7.
9–
29
.7
) 
 
29
.5
 
(2
8.
6–
30
.5
) 
 
30
.2
 
(2
9.
3–
31
.2
) 
 
29
.1
 
(2
8.
2–
30
.1
) 
 
29
.8
 
(2
8.
8–
30
.8
) 
 
28
.7
 
(2
7.
8–
29
.6
) 
—
 
 
O
ne
 
51
.0
 
(5
0.
1–
51
.9
) 
 
51
.4
 
(5
0.
6–
52
.3
) 
 
52
.7
 
(5
1.
8–
53
.5
) 
 
51
.2
 
(5
0.
3–
52
.0
) 
 
53
.1
 
(5
2.
2–
53
.9
) 
 
52
.5
 
(5
1.
7–
53
.4
) 
 
52
.5
 
(5
1.
6–
53
.3
) 
 
53
.7
 
(5
2.
8–
54
.5
) 
 
53
.1
 
(5
2.
2–
53
.9
) 
 
54
.2
 
(5
3.
4–
55
.1
) 

 
 
Tw
o 
16
.6
 
(1
5.
9–
17
.3
) 
 
15
.8
 
(1
5.
2–
16
.5
) 
 
15
.6
 
(1
5.
0–
16
.3
) 
 
16
.6
 
(1
5.
9–
17
.2
) 
 
15
.5
 
(1
4.
8–
16
.2
) 
 
15
.5
 
(1
4.
8–
16
.1
) 
 
15
.1
 
(1
4.
5–
15
.8
) 
 
15
.0
 
(1
4.
3–
15
.6
) 
 
14
.9
 
(1
4.
3–
15
.6
) 
 
15
.0
 
(1
4.
3–
15
.6
) 

 
 
Th
re
e 
2.
6 
(2
.3
–2
.9
) 
 
2.
9 
(2
.6
–3
.2
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
8 
(2
.5
–3
.0
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
5 
(2
.2
–2
.8
) 
 
2.
2 
(1
.9
–2
.4
) 
 
2.
2 
(2
.0
–2
.5
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
1 
(1
.8
–2
.3
) 

 
F
e
m
a
le
 c
h
il
d
re
n
 
(a
g
e
d
 2
–
1
7
 y
e
a
rs
)(
d
)  
(n
) 
1
,5
7
8
 
 
1
,5
6
2
 
 
1
,5
5
5
 
 
1
,6
8
4
 
 
1
,5
5
8
 
 
1
,6
0
6
 
 
1
,6
1
8
 
 
1
,3
1
0
 
 
1
,6
1
7
 
 
1
,5
3
6
 
 
 
O
be
se
 
9.
6 
(8
.1
–1
1.
2)
 
 
10
.6
 
(8
.9
–1
2.
2)
 
 
10
.7
 
(9
.1
–1
2.
3)
 
 
8.
7 
(7
.3
–1
0.
2)
 
 
10
.1
 
(8
.4
–1
1.
8)
 
 
10
.5
 
(8
.8
–1
2.
1)
 
 
8.
1 
(6
.7
–9
.5
) 
 
8.
5 
(7
.0
–1
0.
1)
 
 
8.
2 
(6
.9
–9
.6
) 
 
9.
6 
(8
.0
–1
1.
3)
 
—
 
 
O
ve
rw
ei
gh
t 
17
.5
 
(1
5.
6–
19
.4
) 
 
16
.8
 
(1
4.
9–
18
.8
) 
 
15
.4
 
(1
3.
5–
17
.2
) 
 
18
.6
 
(1
6.
6–
20
.5
) 
 
17
.8
 
(1
5.
9–
19
.7
) 
 
17
.4
 
(1
5.
6–
19
.3
) 
 
17
.2
 
(1
5.
3–
19
.2
) 
 
19
.6
 
(1
7.
3–
21
.9
) 
 
19
.2
 
(1
7.
2–
21
.3
) 
 
17
.9
 
(1
5.
9–
19
.9
) 
—
 
 
N
or
m
al
 
63
.4
 
(6
0.
9–
66
.0
) 
 
62
.2
 
(5
9.
6–
64
.7
) 
 
63
.7
 
(6
1.
1–
66
.2
) 
 
62
.3
 
(5
9.
8–
64
.8
) 
 
61
.3
 
(5
8.
8–
63
.8
) 
 
60
.5
 
(5
8.
0–
63
.1
) 
 
63
.2
 
(6
0.
6–
65
.7
) 
 
61
.5
 
(5
8.
7–
64
.2
) 
 
61
.2
 
(5
8.
6–
63
.7
) 
 
61
.7
 
(5
9.
1–
64
.3
) 
—
 
 
U
nd
er
w
ei
gh
t 
9.
4 
(7
.9
–1
1.
0)
 
 
10
.4
 
(8
.8
–1
2.
1)
 
 
10
.3
 
(8
.7
–1
1.
9)
 
 
10
.4
 
(8
.7
–1
2.
0)
 
 
10
.7
 
(9
.1
–1
2.
3)
 
 
11
.6
 
(9
.9
–1
3.
3)
 
 
11
.5
 
(9
.9
–1
3.
1)
 
 
10
.4
 
(8
.6
–1
2.
1)
 
 
11
.4
 
(9
.7
–1
3.
1)
 
 
10
.7
 
(9
.1
–1
2.
3)
 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
6–
07
 to
 2
01
5–
16
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
15
–1
6 
co
m
pa
re
d 
w
ith
 2
00
6–
07
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
5–
16
 c
om
pa
re
d 
w
ith
 2
00
6–
07
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
(c
) 
A
du
lt 
ris
k 
fa
ct
or
s 
ar
e:
 o
ve
rw
ei
gh
t o
r 
ob
es
ity
; d
ai
ly
 s
m
ok
in
g;
 o
r 
at
-r
is
k 
al
co
ho
l c
on
su
m
pt
io
n.
  
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) 
w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tr
es
 fo
r 
D
is
ea
se
 C
on
tro
l h
ei
gh
t r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
.  
N
o
te
: C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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T
a
b
le
 1
3
.3
b
: 
P
re
v
a
le
n
c
e
 o
f 
p
a
ti
e
n
t 
ri
s
k
 f
a
c
to
rs
 a
m
o
n
g
 a
d
u
lt
 f
e
m
a
le
s
 1
8
+
 a
tt
e
n
d
in
g
 g
e
n
e
ra
l 
p
ra
c
ti
c
e
 a
t 
le
a
s
t 
o
n
c
e
, 
2
0
0
7
–
0
8
 t
o
 2
0
1
5
–
1
6
 
 
P
e
r 
c
e
n
t 
(9
5
%
 C
I)
 

(a
)  
 
 
R
is
k
 f
a
c
to
r 
2
0
0
7
–
0
8
 
 
2
0
0
8
–
0
9
 
 
2
0
0
9
–
1
0
 
 
2
0
1
0
–
1
1
 
 
2
0
1
1
–
1
2
 
 
2
0
1
2
–
1
3
 
 
2
0
1
3
–
1
4
 
 
2
0
1
4
–
1
5
 
2
0
1
5
–
1
6
 
A
d
u
lt
 f
e
m
a
le
s
 (
a
g
e
d
 1
8
 y
e
a
rs
 a
n
d
 o
v
e
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
o
d
y
 m
a
s
s
 i
n
d
e
x
 c
la
s
s
(b
)  
(n
) 
1
8
,7
0
3
 
 
1
9
,6
7
1
 
 
1
9
,7
3
5
 
 
1
8
,7
4
1
 
 
1
9
,6
0
5
 
 
1
9
,0
6
4
 
 
1
9
,1
1
2
 
 
1
9
,7
6
5
 
1
8
,9
3
2
 
 
 
O
be
se
 
23
.9
 
(2
3.
0–
24
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 Abbreviations 
ACRRM Australian College of Rural and Remote Medicine 
AHW Aboriginal health worker 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
DoH Australian Government Department of Health 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
FACRRM Fellow of the Australian College of Rural and Remote Medicine 
FMRC Family Medicine Research Centre 
FRACGP Fellow of the Royal Australian College of General Practitioners 
FTE full-time equivalent 
GP general practitioner 
HbA1c haemoglobin, type A1c 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
MBS Medicare Benefits Schedule 
OTC over-the-counter (medications advised for over-the-counter purchase) 
Pap Papanicolaou test 
PBS Pharmaceutical Benefits Scheme 
PN practice nurse 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
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UCL upper confidence limit 
URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
 Symbols 
. . intentionally left blank 
< less than 
> more than 
n number 
N/A not applicable 
NAv not available 
2 chi-square 
 indicates a statistically significant increase in 2015–16 when compared with the 
first year of data reported 
 indicates a statistically significant decrease in 2015–16 when compared with the 
first year of data reported 
 indicates a marginally significant increase in 2015–16 when compared with the 
first year of data reported 
 indicates a marginally significant decrease in 2015–16 when compared with the 
first year of data reported 
§ indicates a noteworthy change during the data reporting period 
— indicates no significant change in 2015–16 when compared with the first year of 
data reported 
Ŧ rate is less than 0.05 per 100 encounters 
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 Glossary 
A1 Medicare items: See MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 3 
months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the management of 
patients by allied and other health professionals including physiotherapists, occupational therapists, 
dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily representing 
the body systems. 
Chronic problem: See Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, which 
entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits Scheme and some 
other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Co-located health service: a health service (for example, physiotherapist, psychologist etc) located in 
the practice building or within 50 metres of the practice building, available on a daily or regular basis. 
Co-operative after-hours arrangements: the normal after-hours arrangements for patient care 
provision is undertaken in co-operation with another practice(s). 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem presented by a 
patient, family or community. GPs are instructed to record at the most specific level possible from the 
information available at the time. It may be limited to the level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a recurrence 
of a previously resolved problem, but excluding the presentation of a problem first assessed by 
another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including follow-up for a 
problem or an initial presentation of a problem previously assessed by another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted, or is expected to last, 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that impact on an 
individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. Defining chronic 
conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely in the 
GP’s view that the problem has resulted from work-related activity or workplace exposure, or that 
a pre-existing condition has been significantly exacerbated by work activity or workplace 
exposure. 
Encounter: Any professional interchange between a patient and a GP. 
Indirect: Encounter where there is no face-to-face meeting between the patient and the GP but a 
service is provided (for example, prescription, referral). 
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Direct: Encounter where there is a face-to-face meeting of the patient and the GP. Direct encounters 
can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS item number 
as claimable, where the conditions of use of the item require that the patient be present at the 
encounter.  
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
Full-time equivalent (FTE): A GP working 35–45 hours per week. 
General practitioner (GP): A medical practitioner who provides primary comprehensive and continuing 
care to patients and their families within the community (Source: Royal Australian College of General 
Practitioners). 
Generic medication: See Medication: Generic 
GP consultation service items: See MBS/DVA items: GP consultation service items.  
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs and staff 
under the supervision of GPs. In BEACH, an MBS item number may be funded by Medicare or by the 
Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, A20, 
A22, A23, A27, A30 and selected items provided by GPs classified in A11 and A15. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years which are no 
longer valid are mapped to the current MBS groups). 
– Surgery consultations: Identified by any of the following item numbers: short 3, 52, 5000, 5200; 
standard 23, 53, 5020, 5203; long 36, 54, 2143, 5040; prolonged 44, 57, 2195, 5060, 5208. 
– Residential aged care facility: Identified by any of the following item numbers: 20, 35, 43, 51, 
92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): Identified by any of the 
following item numbers: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 503, 507, 
5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: Identified by any of the following item numbers: 2700, 2701, 2702, 
2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: Identified by any of the following item numbers: 720, 721, 
722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: Identified by any of the following item numbers: 700, 702, 703, 704, 705, 
706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: Identified by any of the following item numbers: 139, 734, 735, 736, 738, 
739, 740, 742, 743, 744, 747, 750, 762, 765, 771, 773, 775, 778. 
– Attendances associated with Practice Incentives Program payments: Identified by any of the 
following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 2522, 
2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 2606, 
2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 2673, 2675, 2677, 
2704, 2705. 
– Practice nurse/Aboriginal health worker/allied health worker services: Identified by any of the 
following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 10988, 
10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: Identified by any of the following item numbers: 173, 193, 195, 197, 199. 
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– Diagnostic procedures and investigations: Identified by item numbers: 11000–12533. 
– Therapeutic procedures: Identified by item numbers: 13206–23042 (excluding 16400). 
– Surgical operations: Identified by item numbers: 30001–52036. 
– Diagnostic imaging services: Identified by item numbers: 55037–63000. 
– Pathology services: Identified by item numbers: 65120–74991. 
Medication:  
• Generic: The generic name of a medication is its non-proprietary name, which describes the 
pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
• GP-supplied: The medication is provided directly to the patient by the GP at the encounter. 
• Over-the-counter (OTC): Medication that the GP advises the patient to purchase OTC (a 
prescription is not required for the patient to obtain an OTC medication). 
• Prescribed: Medications that are prescribed by the GP (that is, does not include medications that 
were GP-supplied or advised for over-the-counter purchase). 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for the 
management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a continuation or 
repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. In this sense, 
sickness, illness and morbid conditions are synonymous. 
Non-English speaking background: The patient reported that the primary language spoken at home is 
not English. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or contacting 
the general practitioner. These can be expressed in terms of symptoms, diagnoses or the need for a 
service. 
Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing medical 
education as defined in the Royal Australian College of General Practitioners (RACGP) Quality 
Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for general 
practice leading to the award of the Fellowship of the Royal Australian College of General 
Practitioners, or undertaking an approved placement in general practice as part of some other 
training program recognised by the RACGP as being of equivalent standard. (Source: 
Commonwealth Department of Health and Aged Care (DHAC) 2001. Medicare Benefits Schedule 
book. Canberra: DHAC).  
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Referral: The process by which the responsibility for part, or all, of the care of a patient is temporarily 
transferred to another health care provider. Only new referrals to specialists and allied health services, 
and for hospital and residential aged care facility admissions arising at a recorded encounter are 
included. Continuation referrals are not included. Multiple referrals can be recorded at any one 
encounter. 
Repatriation Health Card: An entitlement card provided by the Department of Veterans’ Affairs that 
entitles the holder to access a range of repatriation health care benefits, including access to 
prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance is 
measured at the 95% confidence level in this report.  
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander person. 
Work-related problem: See Diagnosis/problem.  
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 Appendices 
Appendix 1: Example of a 2015–16 recording form 
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Appendix 2: GP characteristics questionnaire, 
2015–16 
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Appendix 3: Patient information card, 2015–16 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <hdl.handle.net/2123/15482>. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.7:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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